US20020002152A1 - Hydrazide and alkoxyamide angiogenesis inhibitors - Google Patents

Hydrazide and alkoxyamide angiogenesis inhibitors Download PDF

Info

Publication number
US20020002152A1
US20020002152A1 US09/833,917 US83391701A US2002002152A1 US 20020002152 A1 US20020002152 A1 US 20020002152A1 US 83391701 A US83391701 A US 83391701A US 2002002152 A1 US2002002152 A1 US 2002002152A1
Authority
US
United States
Prior art keywords
amino
hydroxy
cyclohexyl
ethylsulfanyl
isopropylsulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/833,917
Inventor
Richard Craig
Megumi Kawai
Linda Lynch
Jyoti Patel
George Sheppard
Jieyi Wang
Fan Yang
Nwe Ba-Maung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US09/833,917 priority Critical patent/US20020002152A1/en
Assigned to ABBOTT LABORATORIES reassignment ABBOTT LABORATORIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAWAI, MAGUMI, YANG, FAN, BA-MAUNG, NWE, PATEL, JYOTI R., LYNCH, LINDA M., WANG, JIEYI, CRAIG, RICHARD A., SHEPPARD, GEORGE S.
Publication of US20020002152A1 publication Critical patent/US20020002152A1/en
Priority to US10/782,502 priority patent/US6887863B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Definitions

  • the present invention relates to substituted hydrazides and N-alkoxyamides which are useful for preventing angiogenesis, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
  • Angiogenesis the fundamental process by which new blood vessels are formed, is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state (i.e., one of no capillary growth) for prolonged periods which may last for as long as weeks or in some cases, decades. When necessary, however, (such as during wound repair), these same cells undergo rapid proliferation and turnover within a 5 day period. ( The Journal of Biological Chemistry, 267:10931-10934 (1987), Science, 235:442-447 (1987)).
  • angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as “angiogenic diseases”) are driven by persistent unregulated angiogenesis.
  • ocular angiogenesis has been implicated as the most common cause of blindness and dominates approximately 20 eye diseases.
  • ocular angiogenesis has been implicated as the most common cause of blindness and dominates approximately 20 eye diseases.
  • new capillary blood vessels invade the joints and destroy cartilage.
  • new capillaries formed in the retina invade the vitreous, bleed, and cause blindness.
  • Growth and metastasis of solid tumors are also angiogenesis-dependent (Cancer Research, 46:467-473 (1986), Journal of the National Cancer Institute, 82:4-6 (1989).
  • cystic Research 46:467-473 (1986)
  • agents which inhibit angiogenesis have been the subject of active current research for their clinical potential.
  • the present invention provides a compound of formula (I),
  • R 1 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, and R 5 S-(alkylene)-;
  • each group is drawn with its right-hand end being the end that is attached to the parent molecular moiety
  • R 3 is selected from the group consisting of hydrogen, alkyl, and arylalkyl
  • R 4 is selected from the group consisting of -NR 6 R 7 , and —OR 8 ;
  • each group is drawn with its left-hand end being the end that is attached to the parent molecular moiety
  • R 5 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;
  • R 6 and R 7 are independently selected from the group consisting of hydrogen, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl, aryl, arylalkanoyl, arylalkoxyalkyl, arylalkoxycarbonyl, arylalkyl, aryloxyalkyl, (aryl)oyl, arylsulfonyl, carboxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (cycloalkyl)alkanoyl, (cycloalkyl)oyl, haloalkanoyl, haloalkyl, heterocycle, (heterocycle)alkanoyl, (heterocycle)oyl, hydroxyalkyl, a nitrogen protecting group, and —C(O)NR 9 R 10 ; or R
  • R 6 and R 7 together with the nitrogen atom to which they are attached, form a heterocycle
  • R 8 is selected from the group consisting of hydrogen, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, arylalkoxycarbonylalkyl, (aryl)oylalkyl, carboxyalkyl, and (cycloalkyl)alkyl; and
  • R 9 and R 10 are independently selected from the group consisting of hydrogen, alkyl and aryl.
  • the present invention provides a compound of formula (II)
  • the present invention provides a compound of formula (II) wherein R 1 is R 5 S-(alkylene)-, R 3 is hydrogen, one of R 6 and R 7 is hydrogen, and the other is (aryl)oyl.
  • the present invention provides a compound of formula (III)
  • R 1 and R 3 are as previously defined and R A is selected from the group consisting of aryl, alkyl, and arylalkyl.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a therapeutically acceptable salt or prodrug thereof, in combination with a therapeutically acceptable carrier.
  • the present invention provides a method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising adminstering to the mammal a therapeutically acceptable amount of a compound of formula (I).
  • Compounds of the present invention comprise hydrazines and hydroxylamines substituted with substituted 2-hydroxy-3-amino alkanoic acids.
  • Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers are designated (RS).
  • Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art.
  • the invention contemplates various geometric isomers and mixtures thereof resulting from the arrangement of substituents around these carbon-carbon double bonds. These substituents are designated as being in the E or Z configuration wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon double bond, and the term “Z” represents higher order substituents on the same side of the carbon-carbon double bond.
  • alkanoyl refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.
  • the alkanoyl groups of this invention can be unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of alkoxycarbonyl, alkylsulfanyl, amino, and hydroxy.
  • alkanoylalkyl refers to an alkanoyl group attached to the parent molecular moiety through an alkyl group.
  • alkenyl refers to a monovalent straight or branched chain groups having from two to fourteen carbon atoms containing at least one carbon-carbon double bond.
  • alkenyloxy refers to an alkenyl group attached to the parent molecular moiety through an oxygen atom.
  • alkenyloxyalkyl refers to an alkenyloxy group attached to the parent molecular moiety through an alkyl group.
  • alkoxy refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.
  • alkoxyalkyl refers to an alkoxy group attached to the parent molecular moiety through an alkyl group.
  • alkoxycarbonyl refers to an alkoxy group attached to the parent molecular moiety through a carbonyl group.
  • alkoxycarbonylalkyl refers to an alkoxycarbonyl group attached to the parent molecular moiety through an alkyl group.
  • alkyl refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon having from one to fourteen carbons by the removal of a single hydrogen atom.
  • alkylene refers to a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon having from one to fourteen carbons by the removal of two hydrogen atoms.
  • alkylsulfanyl refers to an alkyl group attached to the parent molecular moiety through a sulfur atom.
  • alkylsulfanylalkyl refers to an alkylsulfanyl group attached to the parent molecular moiety through an alkyl group.
  • alkylsulfonyl refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group.
  • amido refers to an amino group attached to the parent molecular moiety through a carbonyl group.
  • amidoalkyl refers to an amido group attached to the parent molecular moiety through an alkyl group.
  • amino refers to —NR a R b , wherein R a and R b are independently selected from the group consisting of hydrogen, unsubstituted alkanoyl, alkoxycarbonylalkyl, alkyl, aryl, arylalkyl, (aryl)oyl, cycloalkyl, and (cycloalkyl)alkyl.
  • the aryl and the aryl part of the arylalkyl and the (aryl)oyl can be unsubstituted or substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxycarbonyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.
  • aminoalkoxy refers to an amino group attached to the parent molecular moiety through an alkoxy group.
  • aminoalkyl refers to an amino group attached to the parent molecular moiety through an alkyl group.
  • aminosulfonyl refers to an amino group attached to the parent molecular moiety through a sulfonyl group.
  • aryl refers to phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, and indenyl.
  • Aryl groups having an unsaturated or partially saturated ring fused to an aromatic ring can be attached through either the saturated or unsaturated part of the group.
  • the aryl groups of this invention can be unsubstituted or substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylsulfanyl, alkylsulfanylalkyl, amino, aminoalkoxy, aminoalkyl, aminosulfonyl, carboxy, cyano, (cycloalkyl)alkylsulfanyl, cycloalkylsulfanyl, halo, haloalkoxy, haloalkyl, haloalkylsulfanyl, (heterocycle)alkenyl, hydroxy, hydroxyalkoxy, nitro, oxo, and thioxo.
  • substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbon
  • the aryl groups of this invention can be further substituted with an additional aryl group or an arylalkyl, arylalkylsulfanyl, aryloxy, aryloxyalkyl, heterocycle, or (heterocycle)alkenyl group, wherein the aryl, the aryl part of the arylalkyl, the arylalkylsulfanyl, the aryloxy, and the aryloxyalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkenyl can be further substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, haloalkoxy, haloalkyl, and nitro.
  • arylalkanoyl refers to an aryl group attached to the parent molecular moiety through an alkanoyl group.
  • arylalkoxy refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
  • arylalkoxyalkyl refers to an arylalkoxy group attached to the parent molecular moiety through an alkyl group.
  • arylalkoxycarbonyl refers to an arylalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • arylalkoxycarbonylalkyl refers to an arylalkoxycarbonyl group attached to the parent molecular moiety through an alkyl group.
  • arylalkyl refers to an aryl group attached to the parent group through an alkyl group.
  • the alkyl part of the arylalkyl can be unsubstituted or substituted with a cyano group.
  • arylalkylsulfanyl refers to an arylalkyl group attached to the parent molecular moiety through a sulfur atom.
  • aryloxy refers to an aryl group attached to the parent molecular moiety through an oxygen atom.
  • aryloxyalkyl refers to an aryloxy group attached to the parent molecular moiety through an alkyl group.
  • the alkyl part of the aryloxyalkyl can be unsubstituted or substituted with a hydroxy group.
  • (aryl)oyl refers to an aryl group attached to the parent molecular moiety through a carbonyl group.
  • (aryl)oylalkyl represnts an (aryl)oyl group attached to the parent molecular moiety through an alkyl group.
  • arylsulfonyl refers to an aryl group attached to the parent molecular moiety through a sulfonyl group.
  • carbonyl refers to —C(O)—.
  • carboxyalkyl refers to a carboxy group attached to the parent molecular moiety through an alkyl group.
  • cyano refers to —CN.
  • cycloalkyl refers to a monovalent saturated cyclic hydrocarbon having from three to ten carbon atoms.
  • cycloalkylalkanoyl refers to a cycloalkyl group attached to the parent molecular moiety through an alkanoyl group.
  • (cycloalkyl)alkyl refers to a cycloalkyl group attached to the parent molecular moiety through an alkyl group.
  • (cycloalkyl)alkylsulfanyl refers to a (cycloalkyl)alkyl group attached to the parent molecular moiety through a sulfur atom.
  • (cycloalkyl)oyl refers to a cycloalkyl group attached to the parent molecular moiety through a carbonyl group.
  • cycloalkylsulfanyl refers to a cycloalkyl group attached to the parent molecular moiety through a sulfur atom.
  • halo or halogen refers to F, Cl, Br, or I.
  • haloalkanoyl refers to a haloalkyl group attached to the parent molecular moiety through a carbonyl group.
  • haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
  • haloalkyl refers to an alkyl group substituted by one, two, three, or four halogen atoms.
  • haloalkylsulfanyl refers to a haloalkyl group attached to the parent molecular moiety through a sulfur atom.
  • heterocycle refers to a five-, six- or seven-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the five-membered ring has zero to two double bonds and the six- and seven-membered rings have zero to three double bonds.
  • heterocycle also includes bicyclic groups in which the heterocycle ring is fused to a phenyl group or a cycloalkyl group.
  • the heterocycle groups of the present invention can be attached through a carbon atom or a nitrogen atom in the group.
  • heterocycles include, but are not limited to, benzodioxolyl, benzothiazolyl, benzothienyl, chromenyl, dihydropyridazinyl, furyl, isoxazolyl, morpholinyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinolinyl, quinoxolinyl, tetrahydrobenzothienyl, tetrahydrofuryl, thiazolidinyl, thiazolyl, thienyl, and the like.
  • heterocycle groups of this invention can be unsubstituted or substituted with one, two, three, or four, substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfanylalkyl, amino, aminosulfonyl, carboxy, halo, haloalkoxy, haloalkyl, hydroxy, nitro, oxo, and thioxo.
  • heterocycle groups of this invention can be further substituted with an aryl, arylalkyl, aryloxy, aryloxycarbonyl, or (heterocycle)alkenyl group, wherein the aryl, the aryl portion of the aryloxy, the arylalkyl, and the aryloxycarbonyl, and the heterocycle portion of the (heterocycle)alkenyl can be further substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, haloalkoxy, haloalkyl, and nitro.
  • (heterocycle)alkanoyl refers to a heterocycle group attached to the parent molecular moiety through an alkanoyl group.
  • (heterocycle)alkenyl refers to a heterocycle group attached to the parent molecular moiety through an alkenyl group.
  • (heterocycle)alkyl refers to a heterocycle group attached to the parent molecular moiety through an alkyl group.
  • (heterocycle)oyl refers to a heterocycle group attached to the parent molecular moiety through a carbonyl group.
  • hydroxy refers to —OH.
  • hydroxyalkoxy refers to a hydroxyalkyl group attached to the parent molecular moiety through an oxygen atom.
  • hydroxyalkyl refers to an alkyl group substituted with one, two, or three hydroxy groups.
  • nitro refers to —NO 2 .
  • nitrogen protecting group refers to groups intended to protect an amino group against undersirable reactions during synthetic procedures.
  • Common N-protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, ortho-nitrophenoxyacetyl, ⁇ -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, and 4-nitrobenzoyl; sulfonyl groups such as benzenesulfonyl, and para-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, para-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, tert-
  • sulfonyl refers to —SO 2 —.
  • the compounds of the present invention can exist as therapeutically acceptable salts.
  • therapeutically acceptable salt represents salts or zwitterionic forms of the compounds of the instant invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate,
  • amino groups in the compounds of the present invention can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • the present compounds can also exist as therapeutically acceptable prodrugs.
  • therapeutically acceptable prodrug refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • prodrug refers to compounds which are rapidly transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood.
  • the compounds can be administered alone or in combination with other anti-angiogenesis agents.
  • the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used.
  • the compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • parenteral includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.
  • Parenterally adminstered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents.
  • the injectable preparation can also be an injectable solution or suspension in a diluent or solvent.
  • acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.
  • the anti-angiogenesis effect of parenterally administered compounds can be prolonged by slowing their absorption.
  • One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound.
  • the rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state.
  • Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension.
  • injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides.
  • biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides.
  • the rate of drug release can be controlled.
  • Transdermal patches can also provide controlled delivery of the compounds.
  • the rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel.
  • absorption enhancers can be used to increase absorption.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose.
  • Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings.
  • Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefor.
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches.
  • the compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers.
  • These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight.
  • Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.
  • Assays for the inhibition of catalytic activities of MetAP2 were performed in 96-well microtiter plates. Compounds to be tested were dissolved in dimethyl-sulfoxide at 10 mM and diluted ten-fold in assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl). Ten microliters of solution of each compound to be tested for inhibition were introduced into each cell of the plate. Zero inhibition of enzyme activity was taken to be the result obtained in cells in which 10 mL of assay buffer was placed.
  • compounds of formula (1) can be converted to compounds of formula (2) by treatment with a reducing agent.
  • reducing agents include sodium borohydride, calcium borohydride, lithium borohydride, zinc borohydride, lithium aluminum hydride, borane, sodium cyanoborohydride, diisobutylaluminum hydride, and sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al®).
  • solvents used in these reactions include toluene, dichloromethane, ethanol, THF, dioxane, diethyl ether, or mixtures thereof.
  • the reaction temperature is about ⁇ 78° C. to 60° C. and depends on the method chosen. Reaction times are typically about 0.5 to 24 hours.
  • Compounds of formula (2) can be converted to compounds of formula (3) by treatment with an oxidizing reagent.
  • Representative oxidizing agents include Dess-Martin periodinane, PDC, MnO 2 , DMSO/oxalyl chloride, and DMSO/SO 3 -pyridine/triethylamine.
  • solvents used in these reactions include DMSO, dichloromethane, chloroform, and THF.
  • the reaction temperature is about ⁇ 78° C. to 60° C. and depends on the method chosen. Reaction times are typically about 0.5 to 24 hours.
  • Conversion of compounds of formula (3) to compounds of formula (4) can be accomplished by the addition of sodium bisulfite, followed by the addition of sodium cyanide or potassium cyanide.
  • solvents used in these reactions include water, ethyl acetate, and acetonitrile.
  • the reaction temperature is about ⁇ 10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-36 hours.
  • Compounds of formula (4) can be converted to compounds of formula (5) by hydrolysis with aqueous acid or by hydrolysis with aqueous base followed by acidification.
  • Representative aqueous acids include HBr, HCl, HOAc, and H 2 SO 4
  • representative aqueous bases include NaOH, KOH, and Ba(OH) 2 .
  • solvents used in these reactions include dioxane, water, ethylene glycol, and DME.
  • the reaction temperature is about 25° C. to 150° C. and depends on the method chosen. Reaction times are typically about 2-36 hours.
  • Conversion of compounds of formula (5) to compounds of formula (6) can be accomplished by coupling with substituted hydrazines (HNR 3 NR 6 R 7 ) in the presence of a carbonyl activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and base.
  • a carbonyl activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP
  • Representative bases include NMM, diisopropylethylamine, and DBU.
  • solvents used in these reactions include dichloromethane, chloroform, DMA, THF, and NMP.
  • the reaction temperature is about ⁇ 10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-72 hours.
  • a method for the preparation of compounds of formula (11) is shown in Scheme 2.
  • Aldehydes of formula (7) can be reacted with compounds of formula (8) (R d is alkyl or arylalkyl) in the presence of a base and lithium bromide to provide compounds of formula (9).
  • bases include triethyl amine and diisopropylethylamine.
  • Representative solvents include THF, diethyl ether, and methyl tert-butyl ether. The reaction is conducted at about 25 to about 30° C. for about 12 to about 24 hours.
  • Compounds of formula (9) can be treated with an appropriately substituted amine or amide in the presence of tert-butylhypochlorite and base, then treated with potassium osmate dihydrate and hydroquini dine 1 ,4-phathalazinediyl diether to provide compounds of formula (10) (R 2 is a nitrogen protecting group).
  • bases include sodium hydroxide, potassium hydroxide, and lithium hydroxide.
  • Representative solvents include water, 1-propanol, isopropanol, acetonitrile, and mixtures thereof. The reaction is typically conducted at about 0 to about 30° C. for about 30 minutes to about 4 hours.
  • Conversion of compounds of formula (10) to compounds of formula (5) can be accomplished by treatment with hydrogen peroxide in the presence of hydroxide such as lithium hydroxide.
  • hydroxide such as lithium hydroxide.
  • solvents include THF, water, and mixtures thereof. The reaction is conducted at about 0 to about 25° C. for about 1 to about 6 hours.
  • Compounds of formula (5) can be converted to compounds of formula (12) (Re is aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycle, or (heterocycle)alkyl) either by the methods desribed in Schemes 1 and 3, or by sequentially coupling the carboxylic acid with hydrazine and then coupling with an appropriately substituted carboxylic acid. Conditions for these couplings are similar to those described in Scheme 1 and are known to those of ordinary skill in the art.
  • compounds of formula (5) can be converted to compounds of formula (12) by coupling with substituted hydroxylamines (HNR 3 OR 4 ) in the presence of a carbonyl activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and base.
  • Representative bases include NMM, diisopropylethylamine, and DBU.
  • solvents used in these reactions include dichloromethane, chloroform, DMA, THF, and DMF.
  • the reaction temperature is about ⁇ 10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-72 hours.
  • compounds of formula (5) are treated with HOBT, NMM, EDCI, and a substituted hydroxylamine in dichloromethane/DMF at room temperature for 16 hours to provide compounds of formula (12).
  • Example 1A A solution of Example 1A (25.8 g,100 mmol), sulfur trioxide pyridine complex (79.6 g, 500 mmol), and triethylamine (69.7 mL, 500 mmol) in DMSO (70 mL) at room temperature was stirred for 30 minutes, cooled to 0° C., treated with water and saturated aqueous KHSO 4 , and extracted with ethyl acetate. The extract was washed with saturated aqueous KHSO 4 and brine, dried (MgSO 4 ), filtered, and concentrated to provide the desired product.
  • Example 1B A solution of Example 1B (19.7 g, 77.1 mmol) and sodium bisulfite (8.0 g, 77.1 mmol) in water (500 mL) at 5° C. was stirred for 24 hours, warmed to room temperature, treated with a solution of potassium cyanide (5.1 g, 78.8 mmol) in ethyl acetate (350 mL), and stirred for 5 hours. The aqueous phase was separated and extracted with ethyl acetate.
  • the concentrate was dissolved in dioxane (150 mL), treated with 12N HCl (150 mL), heated to reflux, stirred for 21 hours, and cooled to room temperature.
  • the mixture was concentrated, dissolved in a mixture of water (30 mL) and acetone (200 mL), adjusted to pH 5.5 with 1N NaOH, treated with acetone (3.5 L), and cooled to 0° C. for 4 hours.
  • the resulting precipitate was collected by filtration and dried to provide (3R)-3-amino-4-cyclohexyl-2-hydroxybutanoic acid.
  • Example 1C A solution of Example 1C (50 mg, 0.17 mmol), 1-hydroxybenzotriazole hydrate (30 mg, 0.22mmol), and N-methylmorpholine (0.07 mL, 0.63 mmol) in 5:1/dichloromethane:N,N-dimethylacetamide (2 mL) at 0° C. was treated with 1,3-diisopropylcarbodiimide (0.03 mL, 0.21 mmol), and stirred for 5 minutes. The solution was treated with 1-benzylhydrazine dihydrochloride (0.05 g, 0.25 mmol), stirred for 2 hours, and warmed to room temperature over 44 hours.
  • 1-benzylhydrazine dihydrochloride 0.05 g, 0.25 mmol
  • the reaction was washed with 2N HCl and saturated NaHCO 3 , and concentrated.
  • the concentrate was purified by silica gel chromatography with 3:1/hexanes:ethyl acetate then 1:1/hexanes:ethyl acetate, then dissolved in 4N HCl in dioxane (1 mL), stirred for 1 hour, and concentrated, then purified by HPLC to provide the desired product.
  • the desired product was prepared by substituting diphenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-phenethyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-methyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2,4,6-trimethylbenzenesulfonohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting ethyl hydrazinoacetate for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(1-naphthyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • Example 1 C (1.10 g, 3.65 mmol) in dichloromethane at 0° C. was treated with dicyclohexylcarbodiimide (0.83 g, 4.02 mmol), stirred for 30 minutes, treated with benzyl carbazate (0.69 g, 4.02 mmol), warmed to room temperature, and stirred for 32 hours. The mixture was filtered, and concentrated, and the concentrate was purified by flash column chromatography on silica gel with ethyl acetate in hexanes to provide the desired product.
  • Example 13A (0.09 g, 0.2 mmol) was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, and precipitated from diethyl ether to provide the desired product.
  • Example 13A A solution of Example 13A (0.37 g, 0.82 mmol) in methanol (15mL) was treated with Pd-carbon (0.05 g), stirred under a hydrogen atmosphere for 16 hours, filtered, and concentrated to provide the desired product.
  • Example 14A A solution of Example 14A (0.064 g, 0.20 mmol) in ethanol (3 mL) was treated with pyridine (2 mL) and 4-chlorobenzaldehyde (0.033 mL, 0.23 mmol), heated to 85° C., stirred for 16 hours, and concentrated.
  • the concentrate was purified by flash column chormatography on silica gel with ethyl acetate in hexanes, and the purified concntrate was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, precipitated from diethyl ether, and collected by filtration to provide the desired product.
  • Example 14A A solution of Example 14A (0.096 g, 0.30 mmol) in dichloromethane (8 mL) at 0° C. was treated with N-methylmorpholine (0.094 mL, 0.67 mmol) and ethyl-3-chloro-3-oxo propionate (0.049 mL, 0.38 mmol), stirred for 30 minutes, warmed to room temperature and stirred for 16 hours. The mixture was treated with dichloromethane, washed sequentially with 0.5M HCl, water, and brine, dried (MgSO 4 ), filtered, and concentrated.
  • the concentrate was purified by flash column chromatography on silica gel with ethyl acetate in hexanes, and the purified concentrate was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, precipitated from diethyl ether, and collected by filtration to provide the desired product.
  • the concentrate was dissolved in water (150 mL), cooled to 0° C., adjusted to pH ⁇ 7 with 3N HCl, and extracted with diethyl ether. The combined extracts were washed with brine, dried (MgSO 4 ), filtered, and concentrated to provide the desired product.
  • the desired product was prepared by substituting 1-bromopropane for (bromomethyl)cyclohexane in Example 16.
  • the desired product was prepared by substituting 1-(2,2,2-trifluoroethyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting (2S)-2-(methoxymethyl)-1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2,4-difluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 4-hydrazinobenzenesulfonamide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 3-amino-2-thioxo-1,3-thiazolidin-4-one for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 4-chloro-2-methyl-5-(1-methylhydrazino)-3(2H)-pyridazinone for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-bromophenyl)hydrazine for 1-benzylhydrazine in Example 1.
  • the desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid and 1-(4-methylphenyl)hydrazine for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid and 1-benzylhydrazine dihydrochloride, respectively, in Example 1.
  • the desired product was prepared by substituting 1-(4-methoxyphenyl)hydrazine for 1-(4-methylphenyl)hydrazine in Example 36.
  • the desired product was prepared by substituting 1-(1-naphthyl)hydrazine for 1-(4-methylphenyl)hydrazine in Example 36.
  • the desired product was prepared by substituting methyl 2-hydrazino-4-(trifluoromethyl)-5-pyrimidinecarboxylate for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-(trifluoromethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(1-methylhydrazino)-3-(3-(trifluoromethyl)phenoxy)-2-propanol for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2-pyridinecarbohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2,5-dichlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2,4-dihydroxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting ethyl 3-hydrazino-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-iodophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-isopropylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-(trifluoromethoxy)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-mesitylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 2-((1E)-3-(4-hydrazinophenyl)-1-propenyl)pyridine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(4-(trfluoromethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2,5-difluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting N-((1R)-1-(hydrazinocarbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzarnide for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 3-chloro-6-hydrazinopyridazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C.
  • Example 98A (0.39 g, 1.3 mmol), O-phenyl hydroxylamine hydrochloride (0.27 g, 1.9 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.29 g, 1.5 mmol), 1-hydroxybenzotriazole hydrate (0.20 g, 1.5 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 3:1 dichloromethane/DMF (8 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO 3 , brine, 10% KHSO4, and brine, dried (MgSO 4 ), filtered, and concentrated.
  • the concentrate was purified by flash column chromatography on silica gel with 95:5/dichloromethane:methanol, and the purified concentrate was dissolved in saturated HCl/dioxane (2 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • Example IC for Example 98A in Example 98B.
  • Example 1C A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl hydroxylamine hydrochloride (0.22 g, 1.4 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17 g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF (6 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO 3 , brine, 10% KHSO4, and brine, dried (MgSO 4 ), filtered, and concentrated.
  • the concentrate was purified by flash column chromatography on silica gel with 98:2/dichloromethane:methanol, and the purified concentrate was dissolved in saturated HCl/dioxane (8 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • the desired product was prepared by substituting 0-methyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • the desired product was prepared by substituting 0-tert-butyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • the desired product was prepared by substituting O-ethyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • the desired product was prepared by substituting O-allyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • the desired product was prepared by substituting O-isobutyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • Example 1C A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl hydroxylamine hydrochloride (0.22 g, 1.4 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17 g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF (6 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO 3 , brine, 10% KHSO4, and brine, dried (MgSO 4 ), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 98:2/dichloromethane:methanol to provide the desired product.
  • Example 106A (0.33 g, 0.82 mmol), and 10% palladium on charcoal (0.13 g) in THF (8 mL) at room temperature was stirred for 16 hours under an atmosphere of hydrogen gas, filtered, and concentrated. The concentrate was dissolved in saturated HCl/dioxane (5 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 122A for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 195B for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 125A for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 199A for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 238A for Example 97A in Example 193.
  • the desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 200B for Example 97A in Example 193.
  • the desired product was prepared by substituting O-(carboethoxy)methyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100.
  • the desired product was prepared by substituting O-(carbobenzyloxy)methyl hydroxylamine for O-(carboethoxy)methyl hydroxylamine hydrochloride in Example 106A.
  • Example 117A was dissolved in saturated HCl/dioxane (3 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • Example 117A (0.99 g, 2.1 mmol), and 10% Palladium on charcoal (0.21 g) in THF (10 mIL) at room temperature was stirred for 4 hours under an atmosphere of hydrogen gas, filtered, and concentrated to provide the desired product.
  • Example 118A (0.17 g, 0.45 mmol) was dissolved in saturated HCl/dioxane (4 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • Example 118A A solution of Example 118A (0.17 g, 0.45 mmol), L-alanine ethyl ester hydrochloride (0.098 g, 0.64 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.098 g, 0.51 mmol), 1-hydroxybenzotriazole (0.091 g, 0.67 mmol), and N-methylmorpholine (0.11 mL, 1.0 mmol) in dichloromethane (5 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with 1 M HCl, aqueous NaHCO 3 , dried (MgSO 4 ), filtered, and concentrated. The concentrate was dissolved in saturated HCl/dioxane (4 mL), stirred for 1 hour, concentrated, then purified by HPLC to provide the desired product.
  • the desired product was prepared by substituting 2-phenylethylamine for L-alanine ethyl ester hydrochloride in Example 119.
  • the desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride in Example 98B.
  • the desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-2-(cyclohexyl)ethanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C.
  • the desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 122A for Example 98A in Example 98B.
  • a solution of D-homocystine (20 g, 75 mmol) in liquid ammonia (600 mL) was treated sequentially with sodium (8.9 g, 390 mmol) and 2-bromopropane (20 mL, 210 mmol).
  • the ammonia was allowed to evaporate under a stream of nitrogen, and the residues take up in 1:1 2-propanol/water (500 mL), then treated with di-tert-butyl dicarbonate (50 g, 230 mmol) at room temperature for 6 hours, then concentrated.
  • the residues were taken up in water and the pH adjusted to 10 with NaOH.
  • the desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B.
  • the desired product was prepared by substituting D-cystine for D-homocystine and 1-bromo-2-methylpropane for 2-bromopropane in Example 123A.
  • the desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 124B for Example 98A in Example 98B.
  • the desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C.
  • the desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 125A for Example 98A in Example 98B.
  • Example 124B A solution of Example 124B (0.921 g, 3.0 mmol), pentafluorophenol (0.61 g, 3.3 mmol), 1-hydroxybenzotriazole (0.61 g, 4.5 mmol) and 1,3-dicyclohexyl-carbodiimide (0.62 g, 3.0 mmol in dichloromethane (10 mL) was stirred at 0° C. for 1 h and room temperature for 18 h. Dicyclohexyl urea was removed by filtration, and the filtrate was diluted with ether, washed with NaHCO 3 and then brine, dried (MgSO 4 ), filtered, and concentrated. The crude material was purified by silica gel chromatography (10:90/ethylacetate:hexanes) to give the title compound.
  • Example 126B (0.24 g, 0.5 mmol) and Example 126A (0.065 g, 0.5 mmol) in DMF (5 mL) was stirred at room temperature for 18h, diluted with ether, washed with brine, dried (Na 2 SO 4 ) and concentrated, purified by silica gel chromatography (10:90/ethylacetate:hexanes),then treated with 4M HCl in dioxane to give the title compound.
  • Example 127A for Example 126B in Example 126C.
  • N-hydroxyphthalamide (2.31g, 14.2 mmol), Example 128A (2.62g, 14.2 mmol) and potassium carbonate (4.91g, 35.5 mmol) in N,N-dimethylformamide (35 mL) were stirred at room temperature for 1 day, and stirred in 50° C. oil bath for 5 hours. The mixture was poured into ice-water, the precipitate was collected by filtration, washed with water and dried to yield 2.69g of the title compound.
  • Example 128B (2.18g, 8.2 mmol) and hydrazine hydrate (0.306 ml, 9.84mmol) in ethanol (35 mL) was stirred at room temperature for 1.5 hours. The solvent was removed, the residue triturated with 30 ml of ether, filtered, and the filtrate was concentrated in vacuo to yield the title compound (1.09g) as an oil.
  • Example 128C O-phenyl hydroxylamine hydrochloride
  • reaction was quenched with 1N HCl, diluted with ether, washed with brine, dried (Na 2 SO 4 ), concentrated, purified by silica gel chromatography (20:80/ethyl acetate:hexanes) and treated with 4M HCl in dioxane to give the title compound.
  • Example 129A for Example 126A in Example 126C.
  • Example 129A for O-phenyl hydroxylamine hydrochloride
  • Example 123B for Example 98A in Example 98B.
  • Example 128C for O-phenyl hydroxylamine hydrochloride
  • Example 123B for Example 98A in Example 98B.
  • the desired product was prepared by substituting 1-(3-(methylsulfanyl)butyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(3-phenylpropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-methylpropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-pentyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-methylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-hexyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-methylpentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2-ethylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-dodecyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(3,5,5-trimethylhexyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-(2,2,5-trichloropentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-propyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.
  • the desired product was prepared by substituting 1-heptyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds having the formula
Figure US20020002152A1-20020103-C00001
are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. provisional patent application 60/197,262, filed April 14, 2000, which is hereby incorporated by reference.[0001]
    • TECHNICAL FIELD
  • The present invention relates to substituted hydrazides and N-alkoxyamides which are useful for preventing angiogenesis, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds. [0002]
    • BACKGROUND OF THE INVENTION
  • Angiogenesis, the fundamental process by which new blood vessels are formed, is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state (i.e., one of no capillary growth) for prolonged periods which may last for as long as weeks or in some cases, decades. When necessary, however, (such as during wound repair), these same cells undergo rapid proliferation and turnover within a 5 day period. ([0003] The Journal of Biological Chemistry, 267:10931-10934 (1987), Science, 235:442-447 (1987)).
  • Although angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as “angiogenic diseases”) are driven by persistent unregulated angiogenesis. For example, ocular angiogenesis has been implicated as the most common cause of blindness and dominates approximately 20 eye diseases. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Cancer Research, 46:467-473 (1986), [0004] Journal of the National Cancer Institute, 82:4-6 (1989). Because the pivotal role played by angiogenesis in tumor formation, metastasis, other disease conditions such as arthritis, inflammation, macular degeneration of age, and diabetic retinopathy, agents which inhibit angiogenesis have been the subject of active current research for their clinical potential.
  • In [0005] Proc. Natl. Acad. Sci. USA, 94:6099-6103 (1997) and Chemistry and Biology, 4(6): 461-471 (1997) it is reported that both AGM-1470 and ovalicin, a sequiterpene isolated from the fungus Pseudorotium ocalis have been found to covalently inactivate a common bifunctional protein, type 2-methionine aminopeptidase (MetAP2) and is concluded that MetAP2 plays a critical role in the proliferation of endothelial cells and may serve as a promising target for the development of new anti-angiogenic drugs. The literature has thus established a casual link between inhibition of MetAP2 and the resultant inhibition of endothelial cell proliferation and angiogenesis. There is a need for discovery of new agents which inhibit MetAP2 for their potential as new drugs in combating angiogenesis and disease conditions which depend upon angiogenesis for their development.
    • SUMMARY OF THE INVENTION
  • In its principle embodiment, the present invention provides a compound of formula (I), [0006]
    Figure US20020002152A1-20020103-C00002
  • or a therapeutically acceptable salt or prodrug thereof, wherein [0007]
  • R[0008] 1 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, and R5S-(alkylene)-;
  • wherein each group is drawn with its right-hand end being the end that is attached to the parent molecular moiety; [0009]
  • R[0010] 3 is selected from the group consisting of hydrogen, alkyl, and arylalkyl;
  • R[0011] 4 is selected from the group consisting of -NR6R7, and —OR8;
  • wherein each group is drawn with its left-hand end being the end that is attached to the parent molecular moiety; [0012]
  • R[0013] 5 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;
  • R[0014] 6 and R7 are independently selected from the group consisting of hydrogen, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl, aryl, arylalkanoyl, arylalkoxyalkyl, arylalkoxycarbonyl, arylalkyl, aryloxyalkyl, (aryl)oyl, arylsulfonyl, carboxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (cycloalkyl)alkanoyl, (cycloalkyl)oyl, haloalkanoyl, haloalkyl, heterocycle, (heterocycle)alkanoyl, (heterocycle)oyl, hydroxyalkyl, a nitrogen protecting group, and —C(O)NR 9R10 ; or R6 and R7 together are arylalkylidene; or
  • R[0015] 6 and R7, together with the nitrogen atom to which they are attached, form a heterocycle;
  • R[0016] 8 is selected from the group consisting of hydrogen, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, arylalkoxycarbonylalkyl, (aryl)oylalkyl, carboxyalkyl, and (cycloalkyl)alkyl; and
  • R[0017] 9 and R10 are independently selected from the group consisting of hydrogen, alkyl and aryl.
  • In another embodiment, the present invention provides a compound of formula (II) [0018]
    Figure US20020002152A1-20020103-C00003
  • or a therapeutically acceptable salt or prodrug thereof, wherein R[0019] 1, R3, R6, and R7 are as previously defined.
  • In a preferred embodiment, the present invention provides a compound of formula (II) wherein R[0020] 1 is R5S-(alkylene)-, R3 is hydrogen, one of R6 and R7 is hydrogen, and the other is (aryl)oyl.
  • In another embodiment, the present invention provides a compound of formula (III) [0021]
    Figure US20020002152A1-20020103-C00004
  • or a therapeutically acceptable salt or prodrug thereof, wherein R[0022] 1 and R3 are as previously defined and RA is selected from the group consisting of aryl, alkyl, and arylalkyl.
  • In another embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a therapeutically acceptable salt or prodrug thereof, in combination with a therapeutically acceptable carrier. [0023]
  • In another embodiment, the present invention provides a method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising adminstering to the mammal a therapeutically acceptable amount of a compound of formula (I). [0024]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Compounds of the present invention comprise hydrazines and hydroxylamines substituted with substituted 2-hydroxy-3-amino alkanoic acids. [0025]
  • Compounds of the present invention exist as stereoisomers, wherein asymmetric or chiral centers are present. These compounds are designated by the symbols “R” or “S” depending on the configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers are designated (RS). Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. [0026]
  • Because carbon-carbon double bonds may exist in the present compounds, the invention contemplates various geometric isomers and mixtures thereof resulting from the arrangement of substituents around these carbon-carbon double bonds. These substituents are designated as being in the E or Z configuration wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon double bond, and the term “Z” represents higher order substituents on the same side of the carbon-carbon double bond. [0027]
  • When used throughout this specification and the appended claims, the following terms have the meanings indicated: [0028]
  • The term “alkanoyl” refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. The alkanoyl groups of this invention can be unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of alkoxycarbonyl, alkylsulfanyl, amino, and hydroxy. [0029]
  • The term “alkanoylalkyl” refers to an alkanoyl group attached to the parent molecular moiety through an alkyl group. [0030]
  • The term “alkenyl” refers to a monovalent straight or branched chain groups having from two to fourteen carbon atoms containing at least one carbon-carbon double bond. [0031]
  • The term “alkenyloxy” refers to an alkenyl group attached to the parent molecular moiety through an oxygen atom. [0032]
  • The term “alkenyloxyalkyl” refers to an alkenyloxy group attached to the parent molecular moiety through an alkyl group. [0033]
  • The term “alkoxy” refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. [0034]
  • The term “alkoxyalkyl” refers to an alkoxy group attached to the parent molecular moiety through an alkyl group. [0035]
  • The term “alkoxycarbonyl” refers to an alkoxy group attached to the parent molecular moiety through a carbonyl group. [0036]
  • The term “alkoxycarbonylalkyl” refers to an alkoxycarbonyl group attached to the parent molecular moiety through an alkyl group. [0037]
  • The term “alkyl” refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon having from one to fourteen carbons by the removal of a single hydrogen atom. [0038]
  • The term “alkylene” refers to a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon having from one to fourteen carbons by the removal of two hydrogen atoms. [0039]
  • The term “alkylsulfanyl” refers to an alkyl group attached to the parent molecular moiety through a sulfur atom. [0040]
  • The term “alkylsulfanylalkyl” refers to an alkylsulfanyl group attached to the parent molecular moiety through an alkyl group. [0041]
  • The term “alkylsulfonyl” refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group. [0042]
  • The term “amido” refers to an amino group attached to the parent molecular moiety through a carbonyl group. [0043]
  • The term “amidoalkyl” refers to an amido group attached to the parent molecular moiety through an alkyl group. [0044]
  • The term “amino” refers to —NR[0045] aRb, wherein Ra and Rb are independently selected from the group consisting of hydrogen, unsubstituted alkanoyl, alkoxycarbonylalkyl, alkyl, aryl, arylalkyl, (aryl)oyl, cycloalkyl, and (cycloalkyl)alkyl. The aryl and the aryl part of the arylalkyl and the (aryl)oyl can be unsubstituted or substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxycarbonyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.
  • The term “aminoalkoxy” refers to an amino group attached to the parent molecular moiety through an alkoxy group. [0046]
  • The term “aminoalkyl” refers to an amino group attached to the parent molecular moiety through an alkyl group. [0047]
  • The term “aminosulfonyl” refers to an amino group attached to the parent molecular moiety through a sulfonyl group. [0048]
  • The term “aryl” refers to phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, and indenyl. Aryl groups having an unsaturated or partially saturated ring fused to an aromatic ring can be attached through either the saturated or unsaturated part of the group. The aryl groups of this invention can be unsubstituted or substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylsulfanyl, alkylsulfanylalkyl, amino, aminoalkoxy, aminoalkyl, aminosulfonyl, carboxy, cyano, (cycloalkyl)alkylsulfanyl, cycloalkylsulfanyl, halo, haloalkoxy, haloalkyl, haloalkylsulfanyl, (heterocycle)alkenyl, hydroxy, hydroxyalkoxy, nitro, oxo, and thioxo. The aryl groups of this invention can be further substituted with an additional aryl group or an arylalkyl, arylalkylsulfanyl, aryloxy, aryloxyalkyl, heterocycle, or (heterocycle)alkenyl group, wherein the aryl, the aryl part of the arylalkyl, the arylalkylsulfanyl, the aryloxy, and the aryloxyalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkenyl can be further substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, haloalkoxy, haloalkyl, and nitro. [0049]
  • The term “arylalkanoyl” refers to an aryl group attached to the parent molecular moiety through an alkanoyl group. [0050]
  • The term “arylalkoxy” refers to an aryl group attached to the parent molecular moiety through an alkoxy group. [0051]
  • The term “arylalkoxyalkyl” refers to an arylalkoxy group attached to the parent molecular moiety through an alkyl group. [0052]
  • The term “arylalkoxycarbonyl” refers to an arylalkoxy group attached to the parent molecular moiety through a carbonyl group. [0053]
  • The term “arylalkoxycarbonylalkyl” refers to an arylalkoxycarbonyl group attached to the parent molecular moiety through an alkyl group. [0054]
  • The term “arylalkyl” refers to an aryl group attached to the parent group through an alkyl group. The alkyl part of the arylalkyl can be unsubstituted or substituted with a cyano group. [0055]
  • The term “arylalkylidene” refers to =CHRC, wherein Rc is aryl. [0056]
  • The term “arylalkylsulfanyl” refers to an arylalkyl group attached to the parent molecular moiety through a sulfur atom. [0057]
  • The term “aryloxy” refers to an aryl group attached to the parent molecular moiety through an oxygen atom. [0058]
  • The term “aryloxyalkyl” refers to an aryloxy group attached to the parent molecular moiety through an alkyl group. The alkyl part of the aryloxyalkyl can be unsubstituted or substituted with a hydroxy group. [0059]
  • The term “(aryl)oyl” refers to an aryl group attached to the parent molecular moiety through a carbonyl group. [0060]
  • The term “(aryl)oylalkyl” represnts an (aryl)oyl group attached to the parent molecular moiety through an alkyl group. [0061]
  • The term “arylsulfonyl” refers to an aryl group attached to the parent molecular moiety through a sulfonyl group. [0062]
  • The term “carbonyl” refers to —C(O)—. [0063]
  • The term “carboxy” refers to —CO[0064] 2H.
  • The term “carboxyalkyl” refers to a carboxy group attached to the parent molecular moiety through an alkyl group. [0065]
  • The term “cyano” refers to —CN. [0066]
  • The term “cycloalkyl” refers to a monovalent saturated cyclic hydrocarbon having from three to ten carbon atoms. [0067]
  • The term “cycloalkylalkanoyl” refers to a cycloalkyl group attached to the parent molecular moiety through an alkanoyl group. [0068]
  • The term “(cycloalkyl)alkyl” refers to a cycloalkyl group attached to the parent molecular moiety through an alkyl group. [0069]
  • The term “(cycloalkyl)alkylsulfanyl” refers to a (cycloalkyl)alkyl group attached to the parent molecular moiety through a sulfur atom. [0070]
  • The term “(cycloalkyl)oyl” refers to a cycloalkyl group attached to the parent molecular moiety through a carbonyl group. [0071]
  • The term “cycloalkylsulfanyl” refers to a cycloalkyl group attached to the parent molecular moiety through a sulfur atom. [0072]
  • The term “halo” or “halogen” refers to F, Cl, Br, or I. [0073]
  • The term “haloalkanoyl” refers to a haloalkyl group attached to the parent molecular moiety through a carbonyl group. [0074]
  • The term “haloalkoxy” refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. [0075]
  • The term “haloalkyl” refers to an alkyl group substituted by one, two, three, or four halogen atoms. [0076]
  • The term “haloalkylsulfanyl” refers to a haloalkyl group attached to the parent molecular moiety through a sulfur atom. [0077]
  • The term “heterocycle” refers to a five-, six- or seven-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The five-membered ring has zero to two double bonds and the six- and seven-membered rings have zero to three double bonds. The term “heterocycle” also includes bicyclic groups in which the heterocycle ring is fused to a phenyl group or a cycloalkyl group. The heterocycle groups of the present invention can be attached through a carbon atom or a nitrogen atom in the group. Examples of heterocycles include, but are not limited to, benzodioxolyl, benzothiazolyl, benzothienyl, chromenyl, dihydropyridazinyl, furyl, isoxazolyl, morpholinyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinolinyl, quinoxolinyl, tetrahydrobenzothienyl, tetrahydrofuryl, thiazolidinyl, thiazolyl, thienyl, and the like. The heterocycle groups of this invention can be unsubstituted or substituted with one, two, three, or four, substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfanylalkyl, amino, aminosulfonyl, carboxy, halo, haloalkoxy, haloalkyl, hydroxy, nitro, oxo, and thioxo. The heterocycle groups of this invention can be further substituted with an aryl, arylalkyl, aryloxy, aryloxycarbonyl, or (heterocycle)alkenyl group, wherein the aryl, the aryl portion of the aryloxy, the arylalkyl, and the aryloxycarbonyl, and the heterocycle portion of the (heterocycle)alkenyl can be further substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkanoyl, alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, haloalkoxy, haloalkyl, and nitro. [0078]
  • The term “(heterocycle)alkanoyl” refers to a heterocycle group attached to the parent molecular moiety through an alkanoyl group. [0079]
  • The term “(heterocycle)alkenyl” refers to a heterocycle group attached to the parent molecular moiety through an alkenyl group. [0080]
  • The term “(heterocycle)alkyl” refers to a heterocycle group attached to the parent molecular moiety through an alkyl group. [0081]
  • The term “(heterocycle)oyl” refers to a heterocycle group attached to the parent molecular moiety through a carbonyl group. [0082]
  • The term “hydroxy” refers to —OH. [0083]
  • The term “hydroxyalkoxy” refers to a hydroxyalkyl group attached to the parent molecular moiety through an oxygen atom. [0084]
  • The term “hydroxyalkyl” refers to an alkyl group substituted with one, two, or three hydroxy groups. [0085]
  • The term “nitro” refers to —NO[0086] 2.
  • The term “nitrogen protecting group” refers to groups intended to protect an amino group against undersirable reactions during synthetic procedures. Common N-protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, ortho-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, and 4-nitrobenzoyl; sulfonyl groups such as benzenesulfonyl, and para-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, para-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and the like. [0087]
  • The term “oxo” refers to (═O). [0088]
  • The term “sulfonyl” refers to —SO[0089] 2—.
  • The term “thioxo” refers to (═S). [0090]
  • The compounds of the present invention can exist as therapeutically acceptable salts. The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the instant invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino groups in the compounds of the present invention can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. [0091]
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine. [0092]
  • The present compounds can also exist as therapeutically acceptable prodrugs. The term “therapeutically acceptable prodrug,” refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The term “prodrug,” refers to compounds which are rapidly transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood. [0093]
  • In accordance with methods of treatment and pharmaceutical compositions of the invention, the compounds can be administered alone or in combination with other anti-angiogenesis agents. When using the compounds, the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used. The compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof. The term “parenteral” includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection. [0094]
  • Parenterally adminstered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents. The injectable preparation can also be an injectable solution or suspension in a diluent or solvent. Among the acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides. [0095]
  • The anti-angiogenesis effect of parenterally administered compounds can be prolonged by slowing their absorption. One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound. The rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state. Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension. Yet another way to slow absorption of a particular compound is administering injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides. Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release can be controlled. [0096]
  • Transdermal patches can also provide controlled delivery of the compounds. The rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to increase absorption. [0097]
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose. Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings. Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefor. [0098]
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents. [0099]
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches. The compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers. These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina. Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention. [0100]
  • The total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight. Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose. [0101]
    • DETERMINATION OF BIOLOGICAL ACTIVITY
  • Assays for the inhibition of catalytic activities of MetAP2 were performed in 96-well microtiter plates. Compounds to be tested were dissolved in dimethyl-sulfoxide at 10 mM and diluted ten-fold in assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl). Ten microliters of solution of each compound to be tested for inhibition were introduced into each cell of the plate. Zero inhibition of enzyme activity was taken to be the result obtained in cells in which 10 mL of assay buffer was placed. A mixture totaling 90 mL per well and made up of of 84 mL of assay buffer containing 100 mM MnCl[0102] 2, 1 mL of L-amino acid oxidase (Sigma Catalog No. A-9378, ˜11 mg/mL), 1 mL of horseradish peroxidase (Sigma Catalog No. P-8451, dissolved in assay buffer at a concentration of 10 mg/mL), 1 mL of the tripeptide Met-Ala-Ser (Bachem) dissolved in assay buffer at concentration of 50 mM, 1 mL of ortho-dianisidine (Sigma Catalog No. D-1954, freshly made solution in water at a concentration of 10 mg/mL), and MetAP1 at final concentration of 6 mg/ml or MetAP2 at a final concentration of 1.5 mg/mL was rapidly mixed and added to each cell containing test or control compound. The absorbence at 450 nanometers was measured every 20 seconds over a period of twenty minutes using an automaic plate reader (Molecular Devices, CA, USA). The Vmax in mOD/min, calculated for each well, was used to represent MetAP1 or MetAP2 activity. The IC50 for each inhibitor was obtained by plotting the remaining activity versus inhibitor concentrations. All of the compounds of the invention displayed IC50's below 15 μM. Preferred compounds of the invention displayed IC50's below 1 μM, and most preferred compounds displayed IC50's below 0.1 μM. Thus, the compounds are useful for treating diseases caused or exacerbated by angiogenesis.
    • SYNTHETIC METHODS
  • Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: THF for tetrahydrofuran, PDC for pyridinium dichromate, DMSO for dimethylsulfoxide, DME for 1,2-dimethoxyethane, DCC for 1,3-diicyclohexylcarbodiimide, DIC for 1,3-diisopropylcarbodiimide, HOBT for 1-hydroxybenzotriazole, HOAT for 1-hydroxy-7-azabenzotriazole, EDCI for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, PyBOP for benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, DBU for 1,8-diazabicyclo(5.4.0)undec-7-ene, NMM for N-methylmorpholine, DMA for N,N-dimethylacetamide, NMP for N-methylpyrrolidinone, BOC-ON for (2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile, and DMF for N,N dimethylformaide. [0103]
  • The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention may be prepared. Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those of ordinary skill in the art. The groups R[0104] 1, R3, R4, R5, and R6 are defined above. It will be readily apparent to one of ordinary skill in the art that the compounds defined above can be synthesized by substitution of the appropriate reactants and agents in the syntheses shown below.
    Figure US20020002152A1-20020103-C00005
  • As shown in Scheme 1, compounds of formula (1) (R[0105] 2 is a nitrogen protecting group) can be converted to compounds of formula (2) by treatment with a reducing agent. Representative reducing agents include sodium borohydride, calcium borohydride, lithium borohydride, zinc borohydride, lithium aluminum hydride, borane, sodium cyanoborohydride, diisobutylaluminum hydride, and sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al®). Examples of solvents used in these reactions include toluene, dichloromethane, ethanol, THF, dioxane, diethyl ether, or mixtures thereof. The reaction temperature is about −78° C. to 60° C. and depends on the method chosen. Reaction times are typically about 0.5 to 24 hours.
  • Compounds of formula (2) can be converted to compounds of formula (3) by treatment with an oxidizing reagent. Representative oxidizing agents include Dess-Martin periodinane, PDC, MnO[0106] 2, DMSO/oxalyl chloride, and DMSO/SO3-pyridine/triethylamine. Examples of solvents used in these reactions include DMSO, dichloromethane, chloroform, and THF. The reaction temperature is about −78° C. to 60° C. and depends on the method chosen. Reaction times are typically about 0.5 to 24 hours.
  • Conversion of compounds of formula (3) to compounds of formula (4) can be accomplished by the addition of sodium bisulfite, followed by the addition of sodium cyanide or potassium cyanide. Examples of solvents used in these reactions include water, ethyl acetate, and acetonitrile. The reaction temperature is about −10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-36 hours. [0107]
  • Compounds of formula (4) can be converted to compounds of formula (5) by hydrolysis with aqueous acid or by hydrolysis with aqueous base followed by acidification. Representative aqueous acids include HBr, HCl, HOAc, and H[0108] 2SO4, and representative aqueous bases include NaOH, KOH, and Ba(OH)2. Examples of solvents used in these reactions include dioxane, water, ethylene glycol, and DME. The reaction temperature is about 25° C. to 150° C. and depends on the method chosen. Reaction times are typically about 2-36 hours.
  • Conversion of compounds of formula (5) to compounds of formula (6) can be accomplished by coupling with substituted hydrazines (HNR[0109] 3NR6R7) in the presence of a carbonyl activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and base. Representative bases include NMM, diisopropylethylamine, and DBU. Examples of solvents used in these reactions include dichloromethane, chloroform, DMA, THF, and NMP. The reaction temperature is about −10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-72 hours.
    Figure US20020002152A1-20020103-C00006
  • A method for the preparation of compounds of formula (11) is shown in Scheme 2. Aldehydes of formula (7) can be reacted with compounds of formula (8) (R[0110] d is alkyl or arylalkyl) in the presence of a base and lithium bromide to provide compounds of formula (9). Examples of bases include triethyl amine and diisopropylethylamine. Representative solvents include THF, diethyl ether, and methyl tert-butyl ether. The reaction is conducted at about 25 to about 30° C. for about 12 to about 24 hours.
  • Compounds of formula (9) can be treated with an appropriately substituted amine or amide in the presence of tert-butylhypochlorite and base, then treated with potassium osmate dihydrate and hydroquini dine 1 ,4-phathalazinediyl diether to provide compounds of formula (10) (R [0111] 2is a nitrogen protecting group). Examples of bases include sodium hydroxide, potassium hydroxide, and lithium hydroxide. Representative solvents include water, 1-propanol, isopropanol, acetonitrile, and mixtures thereof. The reaction is typically conducted at about 0 to about 30° C. for about 30 minutes to about 4 hours.
  • Conversion of compounds of formula (10) to compounds of formula (5) can be accomplished by treatment with hydrogen peroxide in the presence of hydroxide such as lithium hydroxide. Examples of solvents include THF, water, and mixtures thereof. The reaction is conducted at about 0 to about 25° C. for about 1 to about 6 hours. [0112]
  • Compounds of formula (5) can be converted to compounds of formula (12) (Re is aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycle, or (heterocycle)alkyl) either by the methods desribed in Schemes 1 and 3, or by sequentially coupling the carboxylic acid with hydrazine and then coupling with an appropriately substituted carboxylic acid. Conditions for these couplings are similar to those described in Scheme 1 and are known to those of ordinary skill in the art. [0113]
    Figure US20020002152A1-20020103-C00007
  • As shown in Scheme 3, compounds of formula (5) (made as described in Scheme 1) can be converted to compounds of formula (12) by coupling with substituted hydroxylamines (HNR[0114] 3OR4) in the presence of a carbonyl activating group such as DCC, DIC, HOBT, HOAT, EDCI, and PyBOP, and base. Representative bases include NMM, diisopropylethylamine, and DBU. Examples of solvents used in these reactions include dichloromethane, chloroform, DMA, THF, and DMF. The reaction temperature is about −10° C. to 60° C. and depends on the method chosen. Reaction times are typically about 2-72 hours. In a preferred embodiment, compounds of formula (5) are treated with HOBT, NMM, EDCI, and a substituted hydroxylamine in dichloromethane/DMF at room temperature for 16 hours to provide compounds of formula (12).
  • The present invention will now be described in connection with certain preferred embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include preferred embodiments, will illustrate the preferred practice of the present invention, it being understood that the examples are for the purposes of illustration of certain preferred embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects. [0115]
  • Compounds of the invention were named by ACD/ChemSketch version 4.01 (developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada) or were given names which appeared to be consistent with ACD nomenclature. [0116]
    • EXAMPLE 1 (2RS,3R)-3-amino-N′-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide EXAMPLE 1A tert-butyl (1R)-2-cyclohexyl-1-(hydroxymethyl)ethylcarbamate
  • A solution of (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid (30.4 g,112 mmol) in toluene (300 mL) at 0° C. was treated with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al®) (115 mmol) over 45 minutes. The mixture was stirred for 30 minutes, warmed to room temperature, stirred for 1 hour, treated with aqueous Rochelle salt, and extracted with diethyl ether. The extract was washed with brine and aqueous NaHCO[0117] 3, dried (MgSO4), filtered, and concentrated to provide the desired product.
    • EXAMPLE 1B tert-butyl (1R)-2-cyclohexyl-1-formylethylcarbamate
  • A solution of Example 1A (25.8 g,100 mmol), sulfur trioxide pyridine complex (79.6 g, 500 mmol), and triethylamine (69.7 mL, 500 mmol) in DMSO (70 mL) at room temperature was stirred for 30 minutes, cooled to 0° C., treated with water and saturated aqueous KHSO[0118] 4, and extracted with ethyl acetate. The extract was washed with saturated aqueous KHSO4 and brine, dried (MgSO4), filtered, and concentrated to provide the desired product.
    • EXAMPLE 1C (2RS,3R)-3-((tert-butoxycarbonyl)amino)-4-cyclohexyl-2-hydroxybutanoic acid
  • A solution of Example 1B (19.7 g, 77.1 mmol) and sodium bisulfite (8.0 g, 77.1 mmol) in water (500 mL) at 5° C. was stirred for 24 hours, warmed to room temperature, treated with a solution of potassium cyanide (5.1 g, 78.8 mmol) in ethyl acetate (350 mL), and stirred for 5 hours. The aqueous phase was separated and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried (MgSO[0119] 4), filtered, and concentrated to provide tert-butyl (1R)-2-cyano-1-(cyclohexylmethyl)-2-hydroxyethylcarbamate.
  • The concentrate was dissolved in dioxane (150 mL), treated with 12N HCl (150 mL), heated to reflux, stirred for 21 hours, and cooled to room temperature. The mixture was concentrated, dissolved in a mixture of water (30 mL) and acetone (200 mL), adjusted to pH 5.5 with 1N NaOH, treated with acetone (3.5 L), and cooled to 0° C. for 4 hours. The resulting precipitate was collected by filtration and dried to provide (3R)-3-amino-4-cyclohexyl-2-hydroxybutanoic acid. A solution of the acid, BOC-ON (1.2 eq.), and triethylamine (2 eq.) in 1:1 water/dioxane at 45° C. was stirred for 15 hours, treated with 10% aqueous KHS0[0120] 4, and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO4), filtered, and concentrated to provide the desired product.
    • EXAMPLE 1D (2RS,3R)-3-amino-N′-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide
  • A solution of Example 1C (50 mg, 0.17 mmol), 1-hydroxybenzotriazole hydrate (30 mg, 0.22mmol), and N-methylmorpholine (0.07 mL, 0.63 mmol) in 5:1/dichloromethane:N,N-dimethylacetamide (2 mL) at 0° C. was treated with 1,3-diisopropylcarbodiimide (0.03 mL, 0.21 mmol), and stirred for 5 minutes. The solution was treated with 1-benzylhydrazine dihydrochloride (0.05 g, 0.25 mmol), stirred for 2 hours, and warmed to room temperature over 44 hours. The reaction was washed with 2N HCl and saturated NaHCO[0121] 3, and concentrated. The concentrate was purified by silica gel chromatography with 3:1/hexanes:ethyl acetate then 1:1/hexanes:ethyl acetate, then dissolved in 4N HCl in dioxane (1 mL), stirred for 1 hour, and concentrated, then purified by HPLC to provide the desired product.
  • MS(APCI) m/e 306 (M+H)[0122] +;
  • [0123] 1H NMR (300 MHz, CD3OD) δ 7.43-7.26 (m, 5H), 4.13 (d, 1H), 4.01 (s, 2H), 3.53 (m, 1H), 3.39 (s, 1H), 1.80-1.67 (m, 5H), 1.57-1.51 (m, 1H), 1.46-1.17 (m, 5H), 1.00-0.90 (m, 2H).
    • EXAMPLE 2 (2RS,3R)-3-amino-N′-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting diphenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0124]
  • MS(APCI) m/e 368 (M+H)[0125] +;
  • [0126] 1H NMR (300 MHz, CD3OD) δ 7.32-7.26 (m, 4H), 7.16-7.13 (m, 4H), 7.06-7.01 (m, 211), 4.26 (d, 1H), 3.52 (m, 1H), 1.72-1.12 (m, 13H).
    • EXAMPLE 3 (2RS,3R)-3-amino-N′-(7-chloro-4-quinolinyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 7-chloro-4-hydrazinoquinoline for 1-benzylhydrazine dihydrochloride in Example 1. [0127]
  • MS(APCI) m/e 377 (M+H)[0128] +;
  • [0129] 1H NMR (300 MHz, CD3OD) δ 8.51 (d, 1H), 8.35 (d, 1H), 7.96 (d, 1H), 7.76 (dd, 1H), 6.96 (d, 1H), 4.47 (d, 1H), 3.70 (m, 1H), 1.86-0.98 (m, 13H).
    • EXAMPLE 4 (2RS 3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-phenylethyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2-phenethyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0130]
  • MS(APCI) m/e 320 (M+H)[0131] +;
  • [0132] 1H NMR (300 MHz, CD3OD) δ 7.30-7.21 (m, 5H), 4.16 (d, 1H), 3.59 (m, 1H), 3.09 (t, 2H), 2.82 (t, 2H), 1.81-0.91 (m, 13H).
    • EXAMPLE 5 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-methyl-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-methyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0133]
  • MS(APCI) m/e 306 (M+H)[0134] +;
  • [0135] 1H NMR (300 MHz, CD3OD) δ 7.21-7.26 (m, 2H), 6.82-6.91 (m, 3H), 4.28 (d, 1H), 3.63 (m, 1H), 3.16 (s, 3H), 1.68-1.88 (m, 6H), 1.48-1.58 (m, 2H), 1.19-1.38 (m, 3H), 0.92-1.08 (m, 2H).
    • EXAMPLE 6 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide
  • The desired product was prepared by substituting 1-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0136]
  • MS(APCI) m/e 370 (M+H)[0137] +;
  • [0138] 1H NMR (300 MHz, CD3OD) δ 8.37 (m, 1H), 8.05 (d, 1H), 7.95 (m, 1H), 7.77 (dd, 1H), 7.57 (m, 3H), 4.42 (d, 1H), 3.77 (m, 1H), 1.90-0.97 (m, 13H).
    • EXAMPLE 7 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0139]
  • MS(APCI) m/e 306 (M+H)[0140] +;
  • [0141] 1H NMR (300 MHz, CD3OD) δ 7.01 (d, 2H), 6.76 (d, 2H), 4.27 (d, 1H), 3.61 (m, 1H), 2.23 (s, 3H), 1.85-1.64 (m, 6H), 1.54-1.42 (m, 2H), 1.36-1.15 (m, 3H), 1.06-0.89 (m, 2H).
    • EXAMPLE 8 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-iodophenyl)hydrazinecarboxamide
  • The desired product was prepared by substituting N-(4-iodophenyl)hydrazinecarboxamide for 1-benzylhydrazine dihydrochloride in Example 1. [0142]
  • MS(APCI) m/e 461 (M+H)[0143] +;
  • [0144] 1H NMR (300 MHz, CD3OD) δ 7.59 (d, 2H), 7.23 (d, 2H), 4.33 (d, 1H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.59-1.19 (m, 5H), 1.09-0.93 (m, 2H).
    • EXAMPLE 9 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4,6-trimethylbenzenesulfonohydrazide
  • The desired product was prepared by substituting 2,4,6-trimethylbenzenesulfonohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0145]
  • MS(APCI) m/e 398 (M+H)[0146] +;
  • [0147] 1H NMR (300 MHz, CD3OD) δ 7.01 (s, 2H), 4.01 (d, 1H), 3.36 (m, 1H), 2.67 (s, 6H), 2.29 (s, 3H), 1.78-1.65 (m, 4H), 1.47-1.20 (m, 7H), 1.00-0.78 (m, 2H).
    • EXAMPLE 10 ethyl (2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)acetate
  • The desired product was prepared by substituting ethyl hydrazinoacetate for 1-benzylhydrazine dihydrochloride in Example 1. [0148]
  • MS(APCI) m/e 302 (M+H)[0149] +;
  • [0150] 1H NMR (300 MHz, CD3OD) δ 4.20 (q, 2H), 4.18 (d, 1H), 3.62 (d, 2H), 3.60 (m, 1H), 1.82-1.57 (m, 7H), 1.56-1.20 (m, 4H), 1.28 (t, 3H), 1.05-0.90 (m, 2H).
    • EXAMPLE 11 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-methoxyphenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0151]
  • MS(APCI) m/e 322 (M+H)[0152] +;
  • [0153] 1H NMR (300 MHz, CD3OD) δ 6.82 (m, 4H), 4.27 (d, 1H), 3.72 (s, 3H), 3.61 (m, 1H), 1.85-1.62 (m, 6H), 1.55-1.18 (m, 5H), 1.08-0.90 (m, 2H).
    • EXAMPLE 12
  • (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(1-naphthyl)butanohydrazide [0154]
  • The desired product was prepared by substituting 1-(1-naphthyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0155]
  • MS(APCI) m/e 342 (M+H)[0156] +;
  • [0157] 1H NMR (300 MHz, CD3OD) δ 8.06 (m, 1H), 7.82 (m, 1H), 7.48 (m, 2H), 7.41-7.29 (m, 2H), 6.91 (dd, 1H), 4.38 (d, 1H), 3.68 (m, 1H), 1.89-1.66 (m, 6H), 1.60-1.47 (m, 2H), 1.19-1.31 (m, 3H), 1.09-0.92 (m, 2H).
    • EXAMPLE 13 benzyl 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazinecarboxylate EXAMPLE 13A benzyl 2-((2RS,3R)-3-((tert-butoxvcarbonyl)amino)-4-cyclohexyl-2-hydroxybutanoyl)hydrazinecarboxylate
  • A solution of Example 1 C (1.10 g, 3.65 mmol) in dichloromethane at 0° C. was treated with dicyclohexylcarbodiimide (0.83 g, 4.02 mmol), stirred for 30 minutes, treated with benzyl carbazate (0.69 g, 4.02 mmol), warmed to room temperature, and stirred for 32 hours. The mixture was filtered, and concentrated, and the concentrate was purified by flash column chromatography on silica gel with ethyl acetate in hexanes to provide the desired product. [0158]
    • EXAMPLE 13B benzyl 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)h drazinecarboxylate Example 13A (0.09 g, 0.2 mmol) was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, and precipitated from diethyl ether to provide the desired product.
  • MS(APCI) m/e 350 (M+H)[0159] +;
  • [0160] 1H NMR (300 MHz, DMSO-d6) δ 10.23 (m, 1H), 10.08 (m, 1H), 9.32 (m, 1H), 7.85 (m, 2H), 7.38 (m, 5H), 6.51 (m, 1H), 5.18 (s, 1H), 5.10 (s, 1H), 4.07 (m, 1H), 3.69 (m, 1H), 3.49 (m 1H), 3.23 (m, 1H), 1.63 (m, 5H), 1.47 (m, 3H), 1.19 (m, 2H).
    • EXAMPLE 14 (2RS,3R)-3-amino-N′-((E)-(4-chlorophenyl)methylidene)-4-cyclohexyl-2-hydroxybutanohydrazide EXAMPLE 14A tert-butyl (1R,2RS)-1-(cyclohexylmethyl)-3-hydrazino-2-hydroxy-3-oxopropylcarbamate
  • A solution of Example 13A (0.37 g, 0.82 mmol) in methanol (15mL) was treated with Pd-carbon (0.05 g), stirred under a hydrogen atmosphere for 16 hours, filtered, and concentrated to provide the desired product. [0161]
    • EXAMPLE 14B (2RS,3R)-3-amino-N′-((E)-(4-chlorophenvl)methylidene)-4-cyclohexyl-2-hydroxybutanohydrazide
  • A solution of Example 14A (0.064 g, 0.20 mmol) in ethanol (3 mL) was treated with pyridine (2 mL) and 4-chlorobenzaldehyde (0.033 mL, 0.23 mmol), heated to 85° C., stirred for 16 hours, and concentrated. The concentrate was purified by flash column chormatography on silica gel with ethyl acetate in hexanes, and the purified concntrate was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, precipitated from diethyl ether, and collected by filtration to provide the desired product. [0162]
  • MS(APCI) m/e 336 (M−H)[0163] −;
  • [0164] 1H NMR (300 MHz, DMSO-d6) δ11.60 (m, 1H), 8.42 (m, 1H), 7.83 (m, 2H), 7.71 (m, 2H), 7.53 (m, 2H), 6.61 (m, 1H), 4.18 (m, 1H), 4.12 (m, 1H), 3.70 (m, 1H), 1.66 (m, 5H), 1.43 (m, 3H), 1.19 (m, 2H).
    • EXAMPLE 15 ethyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-3-oxopropanoate
  • A solution of Example 14A (0.096 g, 0.30 mmol) in dichloromethane (8 mL) at 0° C. was treated with N-methylmorpholine (0.094 mL, 0.67 mmol) and ethyl-3-chloro-3-oxo propionate (0.049 mL, 0.38 mmol), stirred for 30 minutes, warmed to room temperature and stirred for 16 hours. The mixture was treated with dichloromethane, washed sequentially with 0.5M HCl, water, and brine, dried (MgSO[0165] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with ethyl acetate in hexanes, and the purified concentrate was treated with 4N HCl in dioxane, stirred for 4 hours, concentrated, precipitated from diethyl ether, and collected by filtration to provide the desired product.
  • MS(APCI) m/e 330 (M+H)[0166] +;
  • [0167] 1H NMR (300 MHz, DMSO-d6) δ10.24 (m, 1H), 7.71 (m, 2H), 6.53 (m, 1H), 4.10 (m, 5H), 3.70 (m, 1H), 3.49 (m, 2H), 3.37 (m, 1H), 1.65 (m, 5H), 1.43 (m, 3H), 1.20 (m, 5H).
    • EXAMPLE 16 benzyl 2-((2RS, 3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)hydrazinecarboxylate EXAMPLE 16A (2S)-2-((tert-butoxycarbonyl)amino)-3-((cyclohexylmethyl)sulfanyl)propanoic acid
  • A solution of D-cysteine hydrochloride (4.78 g, 39.4 mmol) in liquid ammonia (250 mL) at −70° C. was slowly treated with sodium (3.78 g, 161 mmol), stirred for 30 minutes, treated with (bromomethyl)cyclohexane (6.33 mL, 45.4 mmol), warmed to room temperature, and stirred until the ammonia evaporated. The residue was treated with water(75 mL), isopropanol (50 mL) and di-tert-butyl dicarbonate (9.97 mL, 43.3 mmol), stirred for 24 hours, and concentrated. The concentrate was dissolved in water (150 mL), cooled to 0° C., adjusted to pH<7 with 3N HCl, and extracted with diethyl ether. The combined extracts were washed with brine, dried (MgSO[0168] 4), filtered, and concentrated to provide the desired product.
  • MS(APCI) m/e 318 (M+H)[0169] +.
    • EXAMPLE 16B (2RS,3R) 3-(tert-butoxycarbonylamino)-2-hydroxy-4-(cyclohexylmethylthio)butanoic acid
  • The desired product was prepared by substituting Example 16A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-1C. [0170]
  • MS(APCI) m/e 346 (M+H)[0171] +.
    • EXAMPLE 16C benzyl 2-((2RS, 3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)hydrazinecarboxylate
  • The desired product was prepared by substituting Example 16B for Example 1C in Example 13. [0172]
  • MS(APCI) m/e 396 (M+H)[0173] +;
  • [0174] 1H NMR (300 MHz, DMSO-d6) δ9.32 (m, 1H), 7.97 (m, 2H), 7.38 (m, 5H), 6.63 (m, 1H), 5.10 (m, 2H), 4.23 (m, 1H), 3.69 (m, 3H), 2.43 (m, 2H), 1.83-1.58 (m, 6H), 1.18 (m, 5H).
    • EXAMPLE 17 benzyl 2-((2RS, 3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)hydrazinecarboxylate EXAMPLE 17A N-(tert-butoxycarbonyl)-S -propyl-D-cysteine
  • The desired product was prepared by substituting 1-bromopropane for (bromomethyl)cyclohexane in Example 16. [0175]
  • MS(APCI) m/e 264 (M+H)[0176] +.
    • EXAMPLE 17B (2RS,3R) 3-(tert-butoxycarbonylamino)-2-hydroxy-4-(propylthio)butanoic acid
  • The desired product was prepared by substituting Example 17A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-1C. [0177]
  • MS(APCI) m/e 294 (M+H)[0178] +.
    • EXAMPLE 17C benzyl 2-((2RS, 3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)hydrazinecarboxylate
  • The desired product was prepared by substituting Example 17B for Example 1C in Example 13. [0179]
  • MS(APCI) m/e 342 (M+H)[0180] +;
  • [0181] 1H NMR (300 MHz, DMSO-d6) δ 9.30 (m, 1H), 8.12 (m, 2H), 7.38 (m, 1H), 6.63 (m, 1H), 5.10 (m, 2H), 4.28 (m, 1H), 3.70 (m, 2H), 3.49(m, 1H), 2.84 (m, 1H), 2.48 (m, 1H), 1.52 (m, 2H), 0.95 (m, 3H).
    • EXAMPLE 18 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2,2,2-trifluoroethyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2,2,2-trifluoroethyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0182]
  • MS(APCI) m/e 298 (M+H)[0183] +;
  • [0184] 1H NMR (300 MHz, CD3OD) δ 4.17 (d, 1H), 3.48 (t, 2H), 3.68 (m, 1H), 1.84-0.90 (m, 13H).
    • EXAMPLE 19 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting tert-butyl hydrazinecarboxylate for 1-benzylhydrazine dihydrochloride in Example 1. [0185]
  • MS(APCI) m/e 216 (M+H)[0186] +;
  • [0187] 1H NMR (300 MHz, CD3OD) δ 4.39 (d, 1H), 3.68 (m, 1H), 1.84-0.92 (m, 13H).
    • EXAMPLE 20 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-methyl-N′-(3-nitro-2-pyridinyl)butanohydrazide
  • The desired product was prepared by substituting 2-(1-methylhydrazino)-3-nitropyridine for 1-benzylhydrazine dihydrochloride in Example 1. [0188]
  • MS(APCI) m/e 352 (M+H)[0189] +;
  • [0190] 1H NMR (300 MHz, CD3OD) δ 8.39 (dd, 1H), 8.01 (d, 1H), 6.99 (dd, 1H), 4.14 (d, 1H), 3.66 (s, 3H), 3.53 (m, 1H), 1.84-0.92 (m, 13H).
    • EXAMPLE 21 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2S)-2-(methoxymethyl)pyrrolidinyl)butanamide
  • The desired product was prepared by substituting (2S)-2-(methoxymethyl)-1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example 1. [0191]
  • MS(APCI) m/e 314 (M+H)[0192] +;
  • [0193] 1H NMR (300 MHz, CD3OD) δ 4.33 (d, 1H), 4.21 (m, 1H), 3.68 (m, 2H), 3.60-3.42 (m, 2H), 3.34 (m, 5H), 1.98 (m, 2H), 1.88-1.65 (m, 7H), 1.52 (t, 2H), 1.37-1.20 (m, 4H), 1.60-0.89 (m, 2H).
    • EXAMPLE 22 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-pyrrolidinyl)butanamide
  • The desired product was prepared by substituting 1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example 1. [0194]
  • MS(APCI) m/e 270 (M+H)[0195] +;
  • [0196] 1H NMR (300 MHz, CD3OD) δ 4.43 (d, 1H), 3.78-3.63 (m, 5H), 2.19 (m, 4H), 1.84-0.92 (m, 13H).
    • EXAMPLE 23 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2,4-difluorophenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2,4-difluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0197]
  • MS(APCI) m/e 328 (M+H)[0198] +;
  • [0199] 1H NMR (300 MHz, CD3OD) δ 6.98-6.88 (m, 2H), 6.81 (m, 1H), 4.30 (d, 1H), 3.60 (m, 1H), 1.83-1.65 (m, 6H), 1.55-1.41 (m, 2H), 1.38-1.20 (m, 3H), 1.08-0.92 (m, 2H).
    • EXAMPLE 24 (2RS,3R)-3-amino-N′,4-dicyclohexvl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-cyclohexylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0200]
  • MS(APCI) m/e 298 (M+H)[0201] +;
  • [0202] 1H NMR (300 MHz, CD3OD) δ 4.42 (d, 1H), 3.79 (m, 1H), 3.67 (m, 1H), 2.14-2.05 (m, 2H), 1.95-1.86 (m, 2H), 1.81-1.68 (m, 6H), 1.55-1.25 (m, 11H), 1.08-0.92 (m, 2H).
    • EXAMPLE 25 4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)benzenesulfonamide
  • The desired product was prepared by substituting 4-hydrazinobenzenesulfonamide for 1-benzylhydrazine dihydrochloride in Example 1. [0203]
  • MS(APCI) m/e 371 (M+H)[0204] +;
  • [0205] 1H NMR (300 MHz, CD3OD) δ 7.72 (d, 2H), 6.90 (d, 2H), 4.34 (d, 1H), 3.67 (m, 1H), 1.88-1.65 (m, 6H), 1.60-1.47 (m, 2H), 1.37-1.21 (m, 3H), 1.02-0.92 (m, 2H).
    • EXAMPLE 26 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0206]
  • MS(APCI) m/e 292 (M+H)[0207] +;
  • [0208] 1H NMR (300 MHz, CD3OD) δ 7.19 (m, 2H), 6.83 (m, 3H), 4.29 (d, 1H), 3.61 (m, 1H), 1.84-1.64 (m, 6H), 1.56-1.42 (m, 2H), 1.38-1.17 (m, 3H), 1.18-0.90 (m, 2H).
    • EXAMPLE 27 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-pyridinyl)butanohydrazide
  • The desired product was prepared by substituting 2-hydrazinopyridine for 1-benzylhydrazine dihydrochloride in Example 1. [0209]
  • MS(APCI) m/e 293 (M+H)[0210] +;
  • [0211] 1H NMR (300 MHz, CD3OD) δ 8.01 (m, 1H), 7.78 (m, 1H), 6.93 (m, 2H), 4.39 (d, 1H), 3.68 (m, 1H), 1.85-0.98 (m, 13H).
    • EXAMPLE 28 N′((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-ethoxybenzohydrazide
  • The desired product was prepared by substituting 4-ethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0212]
  • MS(APCI) m/e 364 (M+H)[0213] +;
  • [0214] 1H NMR (300 MHz, CD3OD) δ 7.86 (d, 2H), 7.00 (d, 2H), 4.35 (d, 1H), 4.11 (q, 2H), 3.69 (m, 1H), 1.88-1.70 (m, 6H), 1.66-1.52 (m, 2H), 1.41 (t, 3H), 1.37-1.20 (m, 3H), 1.10-0.96 (m, 2H).
    • EXAMPLE 29 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)butanamide
  • The desired product was prepared by substituting 3-amino-2-thioxo-1,3-thiazolidin-4-one for 1-benzylhydrazine dihydrochloride in Example 1. [0215]
  • MS(APCI) m/e 332 (M+H)[0216] +;
  • [0217] 1H NMR (300 MHz, CD3OD) δ 4.38 (d, 1H), 4.25 (br s, 1H), 3.74 (m, 1H), 1.86-0.96 (m, 13H).
    • EXAMPLE 30 (2RS 3R)-3-amino-N′-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxy-N′-methylbutanohydrazide
  • The desired product was prepared by substituting 3-chloro-6-(1-methylhydrazino)pyridazine for 1-benzylhydrazine dihydrochloride in Example 1. [0218]
  • MS(APCI) m/e 342 (M+H)[0219] +;
  • [0220] 1H NMR (300 MHz, CD3OD) δ 7.57 (d, 1H), 7.33 (d, 1H), 4.40 (d, 1H), 3.64 (m, 1H), 3.40 (s, 3H), 1.86-1.67 (m, 6H), 1.64-1.16 (m, 5H), 1.08-0.92 (m, 2H).
    • EXAMPLE 31 (2RS,3R)-3-amino-N′-(5-chloro-1-methyl-6-oxo-1,6-dihydro-4-pyridazinyl)-4-cyclohexyl-2-hydroxy-N′-methylbutanohydrazide
  • The desired product was prepared by substituting 4-chloro-2-methyl-5-(1-methylhydrazino)-3(2H)-pyridazinone for 1-benzylhydrazine dihydrochloride in Example 1. [0221]
  • MS(APCI) m/e 372 (M+H)[0222] +.
    • EXAMPLE 32 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-piperidinyl)butanamide
  • The desired product was prepared by substituting 1-aminopiperidine for 1-benzylhydrazine dihydrochloride in Example 1. [0223]
  • MS(APCI) m/e 284 (M+H)[0224] +;
  • [0225] 1H NMR (300 MHz, CD3OD) δ 4.47 (d, 1H), 3.75-3.58 (m, 2H), 3.54-3.40 (m, 3H), 1.86-1.50 (m, 13H), 1.47-1.37 (m, 1H), 1.37-1.16 (m, 3H), 1.06-0.89 (m, 2H).
    • EXAMPLE 33 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 3,5-dimethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0226]
  • MS(APCI) m/e 380 (M+H)[0227] +;
  • [0228] 1H NMR (300 MHz, CD3OD) δ 7.03 (m, 2H), 6.70 (m, 1H), 4.36 (d, 1H), 3.81 (m, 611), 3.68 (m, 1H), 1.87-1.68 (m, 6H), 1.63-1.41 (m, 2H), 1.38-1.19 (m, 3H), 1.10-0.93 (m, 2H).
    • EXAMPLE 34 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1,3-benzodioxole-5-carbohydrazide
  • The desired product was prepared by substituting 1,3-benzodioxole-5-carbohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0229]
  • MS(APCI) m/e 364 (M+H)[0230] +;
  • [0231] 1H NMR (300 MHz, CD3OD) δ 7.50 (dd, 1H), 7.35 (d, 1H), 6.92 (d, 1H), 4.35 (d, 1H), 4.27 (d, 1H), 3.80 (s, 2H), 3.61 (m, 1H), 1.86-1.18 (m, 11H), 1.10-0.92 (m, 2H).
    • EXAMPLE 35 (2RS,3R)-3-amino-N′-(4-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(4-bromophenyl)hydrazine for 1-benzylhydrazine in Example 1. [0232]
  • MS(APCI) m/e 371(M+H)[0233] +;
  • [0234] 1H NMR (300 MHz, CD3OD) δ 7.30 (d. 2H), 6.77 (d, 2H), 4.29 (d, 1H), 3.62 (m, 1H), 1.86-1.64 (m, 6H), 1.56-1.16 (m, 5H), 1.07-0.98 (m, 2H).
    • EXAMPLE 36 (2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N′-(4-methylphenyl)pentanohydrazide
  • The desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid and 1-(4-methylphenyl)hydrazine for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid and 1-benzylhydrazine dihydrochloride, respectively, in Example 1. [0235]
  • MS(ESI) m/e 298 (M+H)[0236] +;
  • [0237] 1H NMR (300 MHz, DMSO-d6) δ 10.04 (bs, 1H), 7.87 (bs, 1H), 6.95 (d, 2H), 6.68 (d, 2H), 4.13 (t, 1H), 3.43 (m, 1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 2.18 (s, 3H), 1.98-1.78 (m, 2H), 1.21 (t, 3H).
    • EXAMPLE 37 (2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N′-(4-methoxyphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(4-methoxyphenyl)hydrazine for 1-(4-methylphenyl)hydrazine in Example 36. [0238]
  • MS(ESI) m/e 314 (M+H)[0239] +;
  • [0240] 1H NMR (300 MHz, DMSO-d6) δ 10.03 (bs, 1H), 7.86 (bs, 1H), 6.74 (m, 4H), 4.13 (m, 1H), 3.37 (s, 3H), 3.40 (m, 1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t, 3H).
    • EXAMPLE 38 (2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N′-(1-naphthyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(1-naphthyl)hydrazine for 1-(4-methylphenyl)hydrazine in Example 36. [0241]
  • MS(ESI) m/e 334 (M+H)[0242] +;
  • [0243] 1H NMR (300 MHz, DMSO-d6) δ 10.27 (bs, 1H), 8.21 (m, 1H), 7.92 (bs, 1H), 7.83 (m, 1H), 7.48 (m, 2H), 7.32 (m, 1H), 6.80-6.72 (m, 2H), 4.25 (t, 1H), 3.48 (m, 1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t, 3H).
    • EXAMPLE 39 methyl 2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate
  • The desired product was prepared by substituting methyl 2-hydrazino-4-(trifluoromethyl)-5-pyrimidinecarboxylate for 1-benzylhydrazine dihydrochloride in Example 1. [0244]
  • MS(APCI) m/e 420 (M+H)[0245] +.
    • EXAMPLE 40 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-methylphenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0246]
  • MS(APCI) m/e 306 (M+H)[0247] +;
  • [0248] 1H NMR (300 MHz, CD3OD) δ 7.10-7.02 (m, 2H), 6.85-6.73 (m, 2H), 4.32 (d, 1H), 3.75 (m, 1H), 2.25 (s, 3H), 1.88-1.65 (m, 6H), 1.58-1.46 (m, 2H), 1.38-1.18 (m, 3H), 1.09-0.92 (m, 2H).
    • EXAMPLE 41 (2RS,3R)-3-amino-N′-(2-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0249]
  • MS(APCI) m/e 326 (M+H)[0250] +;
  • [0251] 1H NMR (300 MHz, CD3OD) δ 7.28 (dd, 1H), 7.18 (m, 1H), 7.93 (dd, 1H), 6.82 (m, 1H), 4.34 (d, 1H), 3.66 (m, 1H), 1.86-1.66 (m, 6H), 1.58-1.18 (m, 5H), 1.06-0.89 (m, 2H).
    • EXAMPLE 42 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-(trifluoromethyl)phenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2-(trifluoromethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0252]
  • MS(APCI) m/e 360 (M+H)[0253] +;
  • [0254] 1H NMR (300 MHz, CD3OD) δ 7.36 (m, 1H), 7.08 (m, 3H), 4.32 (d, 1H), 3.62 (m, 1H), 1.88-1.62 (m, 6H), 1.58-1.16 (m, 5H), 1.08-0.87 (m, 2H).
    • EXAMPLE 43 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-hydroxy-3-(3-(trifluoromethyl)phenoxy)propyl)-N′-methylbutanohydrazide
  • The desired product was prepared by substituting 1-(1-methylhydrazino)-3-(3-(trifluoromethyl)phenoxy)-2-propanol for 1-benzylhydrazine dihydrochloride in Example 1. [0255]
  • MS(APCI) m/e 448 (M+H)[0256] +;
  • [0257] 1H NMR (300 MHz, CD3OD) δ 7.49 (m, 1H), 7.28-7.18 (m, 3H), 4.40 (dd, 1H), 4.33 (m, 1H), 4.10 (m, 2H), 3.58 (m, 1H), 3.34 (d, 3H), 3.12 (d, 2H), 1.84-1.62 (m, 6H), 1.58-1.20 (m, 5H), 1.06-0.87 (m, 2H).
    • EXAMPLE 44 methyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-2-thiophenecarboxylate
  • The desired product was prepared by substituting methyl 3-hydrazino-2-thiophenecarboxylate for 1-benzylhydrazine dihydrochloride in Example 1. [0258]
  • MS(APCI)m/e 356 (M+H)[0259] +;
  • [0260] 1H NMR (300 MHz, CD3OD) δ 7.52 (d, 1H), 6.78 (d, 1H), 4.32 (d, 1H), 3.83 (s, 3H), 3.68 (m, 1H), 1.86-1.62 (m, 6H), 1.55-1.12 (m, 5H), 1.05-0.91 (m, 2H).
    • EXAMPLE 45 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-pyrndinylcarbonyl)butanohydrazide
  • The desired product was prepared by substituting 2-pyridinecarbohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0261]
  • MS(APCI) m/e 321 (M+H)[0262] +;
  • [0263] 1H NMR (300 MHz, CD3OD) δ 8.81 (m, 1H), 8.33 (m, 2H), 7.88 (m, 1H), 4.40 (d, 111), 3.71 (m, 1H), 1.88-1.64 (m, 6H), 1.64-1.42 (m, 2H), 1.42-1.22 (m, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 46 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-chlorobenzohydrazide
  • The desired product was prepared by substituting 2-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0264]
  • MS(APCI) m/e 354 (M+H)[0265] +;
  • [0266] 1H NMR (300 MHz, CD3OD) δ7.62 (m, 1H), 7.50 (m, 2H), 7.42 (m, 1H), 4.37 (d, 1H), 3.72 (m, 1H), 1.86-1.63 (m, 6H), 1.63-1.40 (m, 2H), 1.40-1.16 (m, 3H), 1.10-0.92 (m, 2H).
    • EXAMPLE 47 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-bromobenzohydrazide
  • The desired product was prepared by substituting 3-bromobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0267]
  • MS(APCI) m/e 399 (M+H)[0268] +;
  • [0269] 1H NMR (300 MHz, CD3OD) δ 8.06 (t, 1H), 7.87 (m, 1H), 7.78 (m, 1H), 7.45 (t, 1H), 4.38 (d, 1H), 3.69 (m, 1H), 1.88-1.66 (m, 6H), 1.62-1.42 (m, 2H), 1.38-1.18 (m, 3H), 1.10-0.95 (m, 2H).
    • EXAMPLE 48 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methoxybenzohydrazide
  • The desired product was prepared by substituting 3-methoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0270]
  • MS(APCI) m/e 350 (M+H)[0271] +;
  • [0272] 1H NMR (300 MHz, CD3OD) δ 7.48 (d, 1H), 7.42 (q, 2H), 7.17 (d, 1H), 4.37 (d, 1H), 3.86 (s, 3H), 3.70 (m, 1H), 1.88-1.67 (m, 6H), 1.63-1.40 (m, 2H), 1.40-1.18 (m, 3H), 1.10-0.95 (m, 2H).
    • EXAMPLE 49 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dichlorobenzohydrazide
  • The desired product was prepared by substituting 2,5-dichlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0273]
  • MS(APCI) m/e 389 (M+H)[0274] +;
  • [0275] 1H NMR (300 MHz, CD3OD) δ 7.67 (m, 1H), 7.52 (d, 2H), 4.36 (d, 1H), 3.68 (m, 1H), 1.87-1.67 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.40-1.20 (m, 3H), 1.10-0.95 (m, 2H).
    • EXAMPLE 50 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methoxybenzohydrazide
  • The desired product was prepared by substituting 2-methoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0276]
  • MS(APCI) m/e 350 (M+H)[0277] +;
  • [0278] 1H NMR (300 MHz, CD3OD) δ 7.99 (dd, 1H), 7.57 (dt, 1H), 7.20 (d, 1H), 7.10 (t, 1H), 4.38 (d, 1H), 4.01 (s, 3H), 3.71 (m, 1H), 1.88-1.68 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, iH), 1.38-1.17 (m, 3H), 1.10-0.96 (m, 2H).
    • EXAMPLE 51 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0279]
  • MS(APCI) m/e 354 (M+H)[0280] +;
  • [0281] 1H NMR (300 MHz, CD3OD) δ 7.91 (m, 1H), 7.82 (m, 1H), 7.62 (m, 1H), 7.51 (t, 1H), 4.38 (d, 1H), 3.69 (m, 1H), 1.88-1.68 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.40 (m, 1H), 1.38-1.20 (m, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 52 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methylbenzohydrazide
  • The desired product was prepared by substituting 3-methylbenzohydrazide for 1-benzylhydrazide dihydrochloride in Example 1. [0282]
  • MS(APCI) m/e 334 (M+H)[0283] +;
  • [0284] 1H NMR (300 MHz, CD3OD) δ 7.75-7.66 (m, 2H), 7.48-7.34 (m, 2H), 4.37 (d, 1H), 3.69 (m, 1H), 2.41 (s, 3H), 1.88-1.67 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.40-1.18 (m, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 53 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dihydroxybenzohydrazide
  • The desired product was prepared by substituting 2,4-dihydroxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0285]
  • MS(APCI) m/e 352 (M+H)[0286] +;
  • [0287] 1H NMR (300 MHz, CD3OD) δ 7.72 (d, 1H), 6.38 (dt, 2H), 4.37 (d, 1H), 3.67 (m, 1H), 1.87-1.65 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.49 (m, 1H), 1.39-1.18 (m, 3H), 1.10-0.97 (m, 2H).
    • EXAMPLE 54 ethyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate
  • The desired product was prepared by substituting ethyl 3-hydrazino-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate for 1-benzylhydrazine dihydrochloride in Example 1. [0288]
  • MS(APCI) m/e 466 (M+H)[0289] +;
  • [0290] 1H NMR (300 MHz, CD3OD) δ 4.38 (d, 1H), 4.28 (q, 2H), 3.67 (m, 1H), 2.54 (d, 2H), 2.39 (s, 2H), 1.90-1.71 (m, 6H), 1.71-1.43 (m, 2H), 1.40-1.16 (m, 6H), 1.08 (s, 3H), 1.06 (s, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 55 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-iodophenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-iodophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0291]
  • MS(APCI) m/e 418 (M+H)[0292] +;
  • [0293] 1H NMR (300 MHz, CD3OD) δ 7.47 (d, 2H), 6.66 (d, 2H), 4.28 (d, 1H), 3.62 (m, 1H), 1.85-1.62 (m, 6H), 1.55-1.42 (m, 2H), 1.37-1.17 (m, 3H), 1.08-0.88 (m, 2H).
    • EXAMPLE 56 (2RS,3R)-3-amino-N′-(1,3-benzothiazol-2-yl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 2-hydrazino-1,3-benzothiazole for 1-benzylhydrazine dihydrochloride in Example 1. [0294]
  • MS(APCI) m/e 349 (M+H)[0295] +;
  • [0296] 1H NMR (300 MHz, CD3OD) δ 7.76 (dd, 1H), 7.51 (m, 2H), 7.33 (m, 1H), 3.87 (d, 1H), 3.78 (m, 1H), 1.82-1.60 (m, 6H), 1.48-1.16 (m, 5H), 1.16-0.91 (m, 2H).
    • EXAMPLE 57 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 2,5-dimethoxybenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0297]
  • MS(APCI) m/e 380 (M+H)[0298] +;
  • [0299] 1H NMR (300 MHz, CD3OD) δ 7.54 (m, 1H), 7.14 (m, 2H), 4.38 (d, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 3.71 (m, 1H), 1.88-1.67 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.40 (m, 1H), 1.38-1.18 (m, 3H), 1.10-0.93 (m, 2H).
    • EXAMPLE 58 (2RS,3R)-3-amnino-N′-(3-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(3-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0300]
  • MS(APCI) m/e 326 (M+H)[0301] +;
  • [0302] 1H NMR (300 MHz, CD3OD) δ 7.15 (t, 1H), 6.84-6.73 (m, 2H), 4.30 (d, 1H), 3.62 (m, 1H), 1.88-1.64 (m, 6H), 1.58-1.42 (m, 2H), 1.37-1.17 (m, 3H), 1.08-0.87 (m, 2H).
    • EXAMPLE 59 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-methoxyphenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(3-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0303]
  • MS(APCI) m/e 322 (M+H)[0304] +;
  • [0305] 1H NMR (300 MHz, CD3OD) δ 7.12-7.05 (m, 1H), 6.46-6.39 (m, 2H), 4.27 (d, 1H), 3.73 (s, 3H), 3.61 (m, 1H), 1.84-1.63 (m, 6H), 1.56-1.40 (m, 2H), 1.40-1.25 (m, 3H), 1.08-0.96 (m, 2H).
    • EXAMPLE 60 (2RS,3R)-3-amino-4-cyclohexyl-N′-(3,5-dichlorophenyl)-2-hydrox butanohvdrazide
  • The desired product was prepared by substituting 1-(3,5-dichlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0306]
  • MS(APCI) m/e 361 (M+H)[0307] +;
  • [0308] 1H NMR (300 MHz, CD3OD) δ 6.82 (m, 1H), 6.77 (m, 2H), 4.30 (d, 1H), 3.61 (m, =1H), 1.88-1.63 (m, 6H), 1.57-1.43 (m, 2H), 1.28-1.17 (m, 3H), 1.09-0.98 (m, 2H).
    • EXAMPLE 61 (2RS,3R)-3-amino-N′-(3-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(3-bromophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0309]
  • MS(APCI) m/e 371 (M+H)[0310] +;
  • [0311] 1H NMR (300 MHz, CD3OD) δ 7.09 (t, 1H), 7.00-6.91 (m, 2H), 6.81 (m, 1H), 4.29 (d, 1H), 3.62 (m, 1H), 1.87-1.63 (m, 6H), 1.56-1.43 (m, 2H), 1.37-1.18 (m, 3H), 1.09-0.90 (m, 2H).
    • EXAMPLE 62 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(trifluoroacetyl)butanohvdrazide
  • The desired product was prepared by substituting 2,2,2-trifluoroacetohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0312]
  • MS(APCI) m/e 312 (M+H)[0313] +;
  • [0314] 1H NMR (300 MHz, CD3OD) δ 4.36 (d, 1H), 3.68 (m, 1H), 1.85-1.67 (m, 6H), 1.59-1.18 (m, 5H), 1.08-0.93 (m, 2H).
    • EXAMPLE 63 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-isopropylphenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-isopropylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0315]
  • MS(APCI) m/e 334 (M+H)[0316] +;
  • [0317] 1H NMR (300 MHz, CD3OD) δ 7.12 (d, 2H), 6.78 (d, 2H), 4.29 (d, 1H), 3.61 (m, 1H), 2.83 (m, 1H), 1.82-0.95 (m, 19H).
    • EXAMPLE 64 (2RS,3R)-3-amino-N′-(3-chloro-4-methylphenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(3-chloro-4-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0318]
  • MS(APCI) m/e 340 (M+H)[0319] +;
  • [0320] 1H NMR (300 MHz, CD3OD) δ 7.91 (d, 1H), 7.85 (s, 1H), 6.73 (d, 1H), 4.28 (d, 1H), 3.62 (m, 1H), 2.25 (s, 3H), 1.83-1.00 (m, 13H).
    • EXAMPLE 65 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-(trifluoromethoxy)phenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-(trifluoromethoxy)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0321]
  • MS(APCI) m/e 376 (M+H)[0322] +;
  • [0323] 1H NMR (300 MHz, CD3OD) δ 7.11 (d, 2H), 6.93 (m, 2H), 4.28 (d, 1H), 3.62 (m, 1H), 1.80-1.02 (m,13H).
    • EXAMPLE 66 (2RS,3R)-3-amino-4-cyclohexyl-N′-(4-fluorophenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(4-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0324]
  • MS(APCI) m/e 310 (M+H)[0325] +;
  • [0326] 1H NMR (300 MHz, CD3OD) δ 6.94 (m, 4H), 4.31 (d, 1H), 3.58 (m, 1H), 1.83-0.97 (m,13H).
    • EXAMPLE 67 (2RS,3R)-3-amino-N′-(4-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(4-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0327]
  • MS(APCI) m/e 326 (M+H)[0328] +;
  • [0329] 1H NMR (300 MHz, CD3OD) δ 7.20 (d, 2H), 6.83 (d, 2H), 4.29 (d, 1H), 3.61 (m, 1H), 1.80-1.00 (m,13H).
    • EXAMPLE 68 (2RS,3R)-3-amino-4-cvclohexyl-N′-(2-ethylphenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2-ethylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0330]
  • MS(APCI) m/e 320 (M+H)[0331] +;
  • [0332] 1H NMR (300 MHz, CD3OD) δ 7.10 (m, 2H), 6.82 (m, 2H), 4.31 (d, 1H), 3.58 (m, 1H), 2.61 (q, 2H), 1.80-1.00 (m, 16H).
    • EXAMPLE 69 (2RS,3R)-3-amino-4-cyclohexyl-N′-(3-fluorophenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(3-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0333]
  • MS(APCI) m/e 310 (M+H)[0334] +;
  • [0335] 1H NMR (300 MHz, CD3OD) δ 7.17 (m, 1H), 6.62 (m, 3H), 4.30 (d, 1H), 3.61 (m, 1H), 2.63 (q, 2H), 1.80-1.00 (m, 13H).
    • EXAMPLE 70 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chloro-1-benzothiophene-2-carbohydrazide
  • The desired product was prepared by substituting 3-chloro-1-benzothiophene-2-carbohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0336]
  • MS(APCI) m/e 410 (M+H)[0337] +;
  • [0338] 1H NMR (300 MHz, CD3OD) δ 8.01 (d, 2H), 7.60 (d, 2H), 4.38 (d, 1H), 3.71 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 71 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methylbenzohydrazide
  • The desired product was prepared by substituting 4-methylbenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0339]
  • MS(APCI) m/e 334 (M+H)[0340] +;
  • [0341] 1H NMR (300 MHz, CD3OD) δ 7.80 (d, 2H), 7.32 (d, 2H), 4.39 (d, 1H), 3.70 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 72 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-nitrobenzohydrazide
  • The desired product was prepared by substituting 4-nitrobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0342]
  • MS(APCI) m/e 365 (M+H)[0343] +;
  • [0344] 1H NMR (300 MHz, CD3OD) δ 8.42 (d, 2H), 8.08 (d, 2H), 4.42 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 73 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-naphthohydrazide
  • The desired product was prepared by substituting 2-naphthohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0345]
  • MS(APCI) mle 370 (M+H)[0346] +;
  • [0347] 1H NMR (300 MHz, CD3OD) δ 8.53 (s, 1H), 8.01 (m, 5H), 7.59 (m, 2H), 4.38 (d, 1H), 3.72 (m, 1H),1.80-1.00 (m, 13H).
    • EXAMPLE 74 (2RS,3R)-3-amino-N′-(4-chloro-2-methylphenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(4-chloro-2-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0348]
  • MS(APCI) m/e 340 (M+H)[0349] +;
  • [0350] 1H NMR (300 MHz, CD3OD) δ 7.08-7.01 (m, 2H), 6.77 (d, 1H), 4.33 (d, 1H), 3.66 (m, 1H), 2.23 (s, 3H), 1.86-1.64 (m, 6H), 1.57-1.44 (m, 2H), 1.37-1.22 (m, 3H), 1.05-0.92 (m, 2H).
    • EXAMPLE 75 (2RS,3R)-3-amino-4-cvclohexvl-2-hydroxy-N′-mesitylbutanohydrazide
  • The desired product was prepared by substituting 1-mesitylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0351]
  • MS(APCI) m/e 334 (M+H)[0352] +;
  • [0353] 1H NMR (300 MHz, CD3OD) δ 6.77 (bs, 1H), 6.74 (bs, 1H), 4.14 (d, 1H), 3.52 (m, 1H), 2.32 (d, 6H), 2.18 (d, 3H), 1.78-1.61 (m, 6H), 1.48-1.14 (m, 5H), 1.02-0.75 (m, 2H).
    • EXAMPLE 76 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-((E)-2-(2-pyridinyl)ethenyl)phenyl)butanohydrazide
  • The desired product was prepared by substituting 2-((1E)-3-(4-hydrazinophenyl)-1-propenyl)pyridine for 1-benzylhydrazine dihydrochloride in Example 1. [0354]
  • MS(APCI) m/e 395 (M+H)[0355] +.
    • EXAMPLE 77 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2-fluorophenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0356]
  • MS(APCI) m/e 310 (M+H)[0357] +;
  • [0358] 1H NMR (300 MHz, CD3OD) δ 7.04 (dt, 1H), 7.00 (dd, 1H), 6.94 (dt, 1H), 6.82 (m, 1H), 4.31 (d, 1H), 3.64 (m, 1H), 1.86-1.64 (m, 6H), 1.57-1.42 (m, 2H), 1.42-1.17 (m, 3H), 1.08-0.92 (m, 2H).
    • EXAMPLE 78 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-quinoxalinyl)butanohydrazide
  • The desired product was prepared by substituting 2-hydrazinoquinoxaline for 1-benzylhydrazine dihydrochloride in Example 1. [0359]
  • MS(APCI) m/e 344 (M+H)[0360] +;
  • [0361] 1H NMR (300 MHz, CD3OD) δ 8.71 (s, 1H), 8.03 (d, 1H), 7.93 (d, 1H), 7.78 (t, 1H), 7.66 (t, 1H), 4.55 (d, 1H), 3.77 (m, 1H), 1.87-1.65 (m, 6H), 1.65-1.44 (m, 2H), 1.44-1.16 (m, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 79 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-(trifluoromethyl)phenyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4-(trfluoromethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0362]
  • MS(APCI) m/e 360 (M+H)[0363] +;
  • [0364] 1H NMR (300 MHz, CD3OD) δ 8.07 (d, 2H), 7.84 (d, 2H), 4.39 (d, 1H), 3.70 (m, 1H), 1.87-1.67 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.42 (m, 1H), 1.42-1.16 (m, 3H), 1.10-0.94 (m, 2H).
    • EXAMPLE 80 (2RS,3R)-3-amino-N′-(2-chloro-6-fluorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2-chloro-6-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0365]
  • MS(APCI) m/e 344 (M+H)[0366] +;
  • [0367] 1H NMR (300 MHz, CD3OD) δ 7.16 (dt, 1H), 7.07-6.99 (m, 1H), 6.92 (dt, 1H), 4.20 (d, 1H), 3.55 (m, 1H), 1.80-1.66 (m, 6H), 1.50-1.35 (m, 2H), 1.35-1.18 (m, 3H), 1.03-0.87 (m, 2H).
    • EXAMPLE 81 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-methyl-N′-(5-(trifluoromethyl)-2-pyridinyl)butanohydrazide
  • The desired product was prepared by substituting 2-(1-methylhydrazino)-5-(trifluoromethyl)pyridine for 1-benzylhydrazine dihydrochloride in Example 1. [0368]
  • MS(APCI) m/e 375 (M+H)[0369] +;
  • [0370] 1H NMR (300 MHz, CD3OD) δ 8.42 (bs, 1H), 8.11 (dd, 1H), 7.25 (d, 1H), 4.50 (d, 1H), 3.72 (m, 1H), 3.48 (s, 3H), 1.87-1.66 (m, 6H), 1.62-1.52 (m, 1H), 1.52-1.45 (m, 1H), 1.38-1.21 (m, 3H), 1.08-0.93 (m, 2H).
    • EXAMPLE 82 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2,5-difluorophenyl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2,5-difluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0371]
  • MS(APCI) m/e 328 (M+H)[0372] +;
  • [0373] 1H NMR (300 MHz, CD3OD) δ 7.01 (m, 1H), 6.67 (m, 1H), 6.50 (m, 1H), 4.33 (d, 1H), 3.65 (m, 1H), 1.86-1.65 (m, 6H), 1.58-1.44 (m, 2H), 1.38-1.18 (m, 3H), 1.06-0.92 (m, 2H).
    • EXAMPLE 83 (2RS,3R)-3-amino-4-cyclohexyl-N′-(1,3-dimethyl-4-nitro-1 H-pyrazol-5-yl)-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 5-hydrazino-1,3-dimethyl-4-nitro-1H-pyrazole for 1-benzylhydrazine dihydrochloride in Example 1. [0374]
  • MS(APCI) m/e 355 (M+H)[0375] +;
  • [0376] 1H NMR (300 MHz, CD3OD) δ 4.39 (d, 1H), 3.74 (s, 3H), 3.67 (m, 1H), 2.40 (s, 3H), 1.83-1.64 (m, 611), 1.55-1.17 (m, 5H), 1.08-0.90 (m, 2H).
    • EXAMPLE 84 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-phenylhydrazinecarboxamide
  • The desired product was prepared by substituting N-phenylhydrazinecarboxamide for 1-benzylhydrazine dihydrochloride in Example 1. [0377]
  • MS(APCI) m/e 335 (M+H)[0378] +;
  • [0379] 1H NMR (300 MHz, CD3OD) δ 7.41 (d, 2H), 7.28 (t, 2H), 7.03 (t, 1H), 4.33 (d, 1H), 3.68 (m, 1H), 1.87-1.67 (m, 6H), 1.60-1.50 (m, 1H), 1.50-1.38 (m, 1H), 1.37-1.18 (m, 3H), 1.08-0.97 (m, 2H).
    • EXAMPLE 85 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-chloro-2-methoxyphenyl)hydrazinecarboxamide
  • The desired product was prepared by substituting N-(4-chloro-2-methoxyphenyl)hydrazinecarboxamide for 1-benzylhydrazine dihydrochloride in Example 1. [0380]
  • MS(APCI) m/e 399 (M+H)[0381] +;
  • [0382] 1H NMR (300 MHz, CD3OD) δ 8.10 (d, 1H), 6.96 (d, 2H), 4.34 (d, 1H), 3.90 (s, 3H), 3.68 (m, 1H), 1.86-1.66 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.38 (m, 1H), 1.38-1.17 (m, 3H), 1.11-0.93 (m, 2H).
    • EXAMPLE 86 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(3-fluorophenyl)hydrazinecarboxamide
  • The desired product was prepared by substituting N-(3-fluorophenyl)hydrazinecarboxamide for 1-benzylhydrazine dihydrochloride in Example 1. [0383]
  • MS(APCI) m/e 353 (M+H)[0384] +;
  • [0385] 1H NMR (300 MHz, CD3OD) δ 7.41 (d, 1H), 7.26 (q, 1H), 7.09 (d, 1H), 6.75 (t, 1H), 4.34 (d, 1H), 3.68 (m, 1H), 1.87-1.66 (m, 6H), 1.62-1.50 (m, 1H), 1.50-1.48 (m, 1H), 1.48-1.18 (m, 3H), 1.00-0.93 (m, 2H).
    • EXAMPLE 87 N-((1R)-1-((2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)carbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzamide
  • The desired product was prepared by substituting N-((1R)-1-(hydrazinocarbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzarnide for 1-benzylhydrazine dihydrochloride in Example 1. [0386]
  • MS(APCI) m/e 519 (M+H)[0387] +;
  • [0388] 1H NMR (300 MHz, CD3OD) δ 8.05 (d, 2H), 7.79 (d, 2H), 4.31 (d, 1H), 3.81 (q, 1H), 3.65 (m, 1H), 2.68 (m, 2H), 2.30-2.15 (m, 2H), 2.12 (s, 3H), 1.84-1.63 (m, 6H), 1.58-1.48 (m, 1H), 1.48-1.36 (m, 1H), 1.36-1.20 (m, 3H), 1.06-0.95 (m, 2H).
    • EXAMPLE 88 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-thienylcarbonyl)butanohydrazide
  • The desired product was prepared by substituting 2-thiophenecarbohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0389]
  • MS(APCI) m/e 326 (M+H)[0390] +;
  • [0391] 1H NMR (300 MHz, CD3OD) δ 7.81 (dd, 2H), 7.18 (d, 1H), 4.42 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 89 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-chlorobenzohydrazide
  • The desired product was prepared by substituting 4-chlorobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0392]
  • MS(APCI) m/e 354 (M+H)[0393] +;
  • [0394] 1H NMR (300 MHz, CD3OD) δ 7.91 (d, 2H), 7.55 (d, 2H), 4.43 (d, 1H), 3.68 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 90 (2RS,3R)-3-amino-N′-benzovl-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting benzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0395]
  • MS(APCI) m/e 320 (M+H)[0396] +;
  • [0397] 1H NMR (300 MHz, CD3OD) δ 7.91 (d, 2H), 7.58 (m, 3H), 4.42 (d, 1H), 3.68 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 91 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-bromobenzohydrazide
  • The desired product was prepared by substituting 3-bromobenzohydrazide for 1-benzylhydrazine dihydrochloride in Example 1. [0398]
  • MS(APCI) m/e 400 (M+H)[0399] +;
  • [0400] 1H NMR (300 MHz, CD3OD) δ 7.81 (d, 2H), 7.72 (d, 2H), 4.37 (d, iH), 3.69 (m, 1H), 1.80-1.00 (m, 13H).
    • EXAMPLE 92 N ′-((2RS,3R)-3-amino-4-cyclohexvl-2-hydroxybutanoyl)-4-tert-butylbenzohydrazide
  • The desired product was prepared by substituting for 1-benzylhydrazine dihydrochloride in Example 1. [0401]
  • MS(APCI) m/e 376 (M+H)[0402] +;
  • [0403] 1H NMR (300 MHz, CD3OD) δ 7.83 (d, 2H), 7.55 (d, 2H), 4.41 (d, 1H), 3.73 (m, 1H), 1.80-1.00 (m, 22H).
    • EXAMPLE 93 4-chlorobenzyl 2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate
  • The desired product was prepared by substituting 4-chlorobenzyl 2-hydrazino-4-(trifluoromethyl)-5-pyrimidinecarboxylate for 1-benzylhydrazine dihydrochloride in Example 1. [0404]
  • MS(APCI) m/e 530 (M+H)[0405] +;
  • [0406] 1H NMR (300 MHz, CD3OD) δ 8.96 (bs, 1H), 7.41 (m, 4H), 4.34 (d, 1H), 3.62 (m, 1H), 1.85-1.67 (m, 6H), 1.62-1.40 (m, 2H), 1.40-1.17 (m, 3H), 1.08-0.93 (m, 2H).
    • EXAMPLE 94 (2RS,3R)-3-amino-N′-(3-chloro-4-fluorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 3-chloro-4-fluorophenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0407]
  • MS(APCI) m/e 344 (M+H)[0408] +;
  • [0409] 1H NMR (300 MHz, CD3OD) δ 7.06 (t, 1H), 6.91 (q, 1H), 6.78 (m, 1H), 4.31 (d, 1H), 3.62 (m, 1H), 1.88-1.63 (m, 6H), 1.57-1.41 (m, 2H), 1.41-1.12 (m, 2H), 1.12-0.90 (m, 2H).
    • EXAMPLE 95 (2RS,3R)-3-amino-N′-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 3-chloro-6-hydrazinopyridazine for 1-benzylhydrazine dihydrochloride in Example 1. [0410]
  • MS(APCI) m/e 328 (M+H)[0411] +;
  • [0412] 1H NMR (300 MHz, CD3OD) δ 7.55 (d, 1H), 7.17 (d, 1H), 4.38 (d, 1H), 3.64 (m, 1H), 1.87-1.68 (m, 6H), 1.56-1.49 (m, 1H), 1.49-1.37 (m, 1H), 1.37-1.17 (m, 3H), 1.07-0.95 (m, 2H).
    • EXAMPLE 96 (2RS,3R)-3-amino-N′-(2-chlorobenzvl)-4-cyclohexyl-2-hydroxybutanohydrazide
  • The desired product was prepared by substituting 1-(2-chlorobenzyl)hydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0413]
  • MS(APCI) m/e 340 (M+H)[0414] +;
  • [0415] 1H NMR (300 MHz, CD3OD) δ 7.54 (m, 1H), 7.49 (m, 1H), 7.28 (m, 2H), 4.13 (q, 2H), 4.11 (d, 1H), 3.52 (m, 1H), 1.80-1.66 (m, 6H), 1.60-1.50 (m, 1H), 1.45-1.16 (m, 4H), 1.00-0.96 (m, 2H).
    • EXAMPLE 97 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2R)-2-(methoxymethyl)pyrrolidinyl)butanarmide
  • The desired product was prepared by substituting (2R)-2-(methoxymethyl)-1-pyrrolidinamine for 1-benzylhydrazine dihydrochloride in Example 1. [0416]
  • MS(APCI) mle 314 (M+H)[0417] +;
  • [0418] 1H NMR (300 MHz, CD3OD) δ 4.11 (d, 1H), 3.58 (m, 1H), 3.45 (q, 1H), 3.35 (t, 1H), 3.32 (s, 3H), 3.21 (m, 1H), 3.07 (m, 1H), 2.80 (q, 2H), 2.08-1.93 (m, 1H), 1.88-1.68 (m, 6H), 1.67-1.53 (ml 1H), 1.53-1.48 (m, 2H), 1.48-1.18 (m, 3H), 1.04-0.98 (m, 2H).
    • EXAMPLE 98 (2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N-phenoxypentamide EXAMPLE 98A 3-amino-3,4-dideoxy-5-S-ethyl-5-thio-D-glycero-pentonic acid
  • The desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-(ethylsulfanyl)butanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0419]
    • EXAMPLE 98B (2RS,3R)-3-amino-5-ethylsulfanyl-2-hydroxy-N-phenoxypentamide
  • A solution of Example 98A (0.39 g, 1.3 mmol), O-phenyl hydroxylamine hydrochloride (0.27 g, 1.9 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.29 g, 1.5 mmol), 1-hydroxybenzotriazole hydrate (0.20 g, 1.5 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 3:1 dichloromethane/DMF (8 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO[0420] 3, brine, 10% KHSO4, and brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 95:5/dichloromethane:methanol, and the purified concentrate was dissolved in saturated HCl/dioxane (2 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • MS(ESI) m/e 285 (M+H)[0421] +;
  • [0422] 1H NMR (300 MHz, DMSO-d6) δ 12.31 (bs, 1H), 8.08 (bs, 0.4H), 7.94 (bs, 0.6H), 7.34 (m, 2H), 7.03 (m, 3H), 6.73 (d, 0.6H), 6.62 (d, 0.4H), 4.41 (m, 0.4H), 4.28 (t, 0.6H), 3.48 (m, 1H), 2.73-2.60 (m, 2H), 2.56 (q, 2H), 1.98-1.78 (m, 2H), 1.21 (t, 3H).
    • EXAMPLE 99 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-phenoxybutanamide
  • The desired product was prepared by substituting Example IC for Example 98A in Example 98B. [0423]
  • MS(ESI) m/e 293 (M+H)[0424] +;
  • [0425] 1H NMR (300 MHz, DMSO-d6) δ 7.92 (bs, 1H), 7.34 (m, 2H), 7.06 (m, 3H), 6.73 (d, 0.4H), 6.70 (d, 0.6H), 4.21 (m, 1H), 3.36 (m, 1H), ), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 100 (2RS,3R)-3-amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxybutanamide
  • A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl hydroxylamine hydrochloride (0.22 g, 1.4 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17 g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF (6 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO[0426] 3, brine, 10% KHSO4, and brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 98:2/dichloromethane:methanol, and the purified concentrate was dissolved in saturated HCl/dioxane (8 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product.
  • MS(ESI) m/e 307 (M+H)[0427] +;
  • [0428] 1H NMR (300 MHz, DMSO-d6) δ 7.78 (br s, 1H), 7.40 (m, 5H), 6.42 (d, 1H), 4.84 (s, 2H), 3.95 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 101 (2RS 3R)-3-amino-N-(methoxy)-4-cyclohexyl-2-hvdroxybutanamide
  • The desired product was prepared by substituting 0-methyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0429]
  • MS(APCI) m/e 231 (M+H)[0430] +;
  • [0431] 1H NMR (300 MHz, DMSO-d6) δ 7.74 (br s, 1H), 6.42 (d, 1H) 3.95 (m, 1H), 3.63 (s, 3H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (mn, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 102 (2RS,3R)-3-amino-N-(tert-butoxy)-4-cyclohexyl-2-hydroxvbutanamide
  • The desired product was prepared by substituting 0-tert-butyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0432]
  • MS(APCI) m/e 273 (M+H)[0433] +;
  • [0434] 1H NMR (300 MHz, DMSO-d6) δ 7.74 (br s, 1H), 6.44 (d, 1H) 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 1.19 (s, 9H), 0.96-0.80 (m, 2H).
    • EXAMPLE 103 (2RS,3R)-3-amino-4-cyclohexyl-N-ethoxy-2-hydroxybutanamide
  • The desired product was prepared by substituting O-ethyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0435]
  • MS(APCI) m/e 245 (M+H)[0436] +;
  • [0437] 1H NMR (300 MHz, DMSO-d6) δ 7.73 (br s, 1H), 6.41 (d, 1H), 3.92 (m, 1H), 3.84 (q, 2H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 1.14 (t, 3H), 0.96-0.80 (m, 2H).
    • EXAMPLE 104 (2RS,3R)-N-(allyloxy)-3-amino-4-cvclohexyl-2-hydroxybutanamide
  • The desired product was prepared by substituting O-allyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0438]
  • MS(APCI) m/e 257 (M+H)[0439] +;
  • [0440] 1H NMR (300 MHz, DMSO-d6) δ 7.74 (br s, 1H), 6.43 (d, 1H), 5.95 (m, 1H), 5.32 (dd, 1H), 5.27 (m, 1H), 4.32 (d, 2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 105 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-isobutoxybutanamide
  • The desired product was prepared by substituting O-isobutyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0441]
  • MS(APCI) m/e 273 (M+H)[0442] +;
  • [0443] 1H NMR (300 MHz, DMSO-d6) δ 7.73 (br s, 1H), 6.39 (d, 1H), 3.92 (m, 1H), 3.58 (d, 2H), 1.88 (sept, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.91 (d, 6H), 0.90-0.75 (m, 2H).
    • EXAMPLE 106 (2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide EXAMPLE 106A (2RS,3R)-3-(tert-butoxycarbonyl)amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxybutanamide
  • A solution of Example 1C (0.20 g, 0.66 mmol), O-benzyl hydroxylamine hydrochloride (0.22 g, 1.4 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17 g, 0.89 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 mmol), and N-methylmorpholine (0.40 mL, 3.6 mmol) in 5:1 dichloromethane/DMF (6 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO[0444] 3, brine, 10% KHSO4, and brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 98:2/dichloromethane:methanol to provide the desired product.
  • MS(APCI) m/e 407 (M+H)[0445] +.
    • EXAMPLE 106B (2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide
  • A solution of Example 106A (0.33 g, 0.82 mmol), and 10% palladium on charcoal (0.13 g) in THF (8 mL) at room temperature was stirred for 16 hours under an atmosphere of hydrogen gas, filtered, and concentrated. The concentrate was dissolved in saturated HCl/dioxane (5 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product. [0446]
  • MS(APCI) m/e 217 (M+H)[0447] +;
  • H [0448] 1NMR (300 MHz, DMSO-d6) δ 10.89 (br s, 1H), 8.89 (br s, 1H), 7.80 (br s, 2H), 6.31 (d, 1H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.90-0.75 (m, 2H).
    • EXAMPLE 107 (2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N-phenoxybutanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine in Example 193. [0449]
  • MS(ESI) m/e 271 (M+H)[0450] +;
  • [0451] 1H NMR (500 MHz, CD3OD) δ 7.32 (t, 2H), 7.10 (d, 2H), 7.06 (m, 1H), 4.56 (d, 0.65H), 4.54 (d, 0.35H), 3.66 (m, 1H), 2.95 (dd, 1H), 2.78 (dd, 1H), 2.64 (dd, 1.3H), 2.59 (dd, 0.7H), 1.29 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 108 (2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N-phenoxypropanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 122A for Example 97A in Example 193. [0452]
  • MS(ESI) m/e 279 (M+H)[0453] +;
  • [0454] 1H NMR (500 MHz, CD3OD) δ 7.33 (t, 2H), 7.08 (m, 3H), 4.51 (d, 0.65H), 4.48 (d, 0.35H), 3.37 (dd, 1H), 1.87-1.72 (m, 6H), 1.35-1.11 (m, 5H).
    • EXAMPLE 109 (2RS,3S)-3-amino-2-hydroxy-N-phenoxy-4-(propylsulfanyl)butanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 195B for Example 97A in Example 193. [0455]
  • MS(ESI) m/e 285 (M+H)[0456] +;
  • [0457] 1H NMR (500 MHz, CD3OD) δ 7.33 (t, 2H), 7.08 (m, 3H), 4.58 (d, 0.65H), 4.56 (d, 0.35H), 3.68 (m, 1H), 2.94 (dd, 0.65H), 2.87 (dd, 0.35H), 2.78 (m, 1H), 2.60 (dd, 1H), 2.54 (m, 1H), 1.65 (dd, 1H), 1.60 (dd, 1H), 1.02 (t, 1.95 H), 0.99 (t, 1.05H).
    • EXAMPLE 110 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-phenoxypentanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193. [0458]
  • MS(ESI) m/e 299 (M+H)[0459] +;
  • [0460] 1H NMR (500 MHz, CD3OD) δ 7.33 (dd, 2H), 7.08 (m, 3H), 4.48 (d, 0.35H), 4.31 (d, 0.65H), 3.75 (m, 1H), 2.97 (dd, 0.65H), 2.93 (dd, 0.35H), 2.71 (m, 1.65H), 2.67 (m, 0.35H), 2.10 (dd, 0.65H), 1.99 (dd, 0.35H), 1.92 (dd, 1H), 1.28 (d, 3 H), 1.27 (d, 3H).
    • EXAMPLE 111 (2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-phenoxybutanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193. [0461]
  • MS(ESI) m/e 299 (M+H)[0462] +;
  • [0463] 1H NMR (500 MHz, CD3OD) δ 7.33 (t, 2H), 7.08 (m, 3H), 4.60 (d, 1H), 3.69 (ddd, 1H), 2.93 (dd, 1H), 2.78 (dd, 1H), 2.50 (m, 2H), 1.83 (ddd, 1H), 1.03 (d, 6H).
    • EXAMPLE 112 (2RS,3R)-3-amino-5-phenyl-2-hydroxy-N-phenoxypentanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 125A for Example 97A in Example 193. [0464]
  • MS(ESI) m/e 301 (M+H)[0465] +;
  • [0466] 1H NMR (500 MHz, CD3OD) δ 7.30 (m, 3H), 7.26-7.20 (m, 4H), 7.06 (m, 3H), 4.48 (d, 0.5H), 4.45 (d, 0.5H), 3.59 (m, 1H), 2.79 (m, 1.5H), 2.71 (m, 0.5H), 2.15 (m, 0.5H), 2.02 (m, 1H), 1.94 (m, 0.5H).
    • EXAMPLE 113 (2RS,3R)-3-amino-3-cyclooctyl-2-hydroxy-N-phenoxypropanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 199A for Example 97A in Example 193. [0467]
  • MS(ESI) mle 307 (M+H)[0468] +;
  • [0469] 1H NMR (500 MHz, CD30D) δ7.33 (m, 2H), 7.10 (m, 3H), 3.86 (m, 1H), 3.79 (m, 1H), 1.80-1.52 (m, 15H).
    • EXAMPLE 114 (2RS .3R)-3-amino-5-cyclohexyl-2-hvdroxy-N-phenoxypentanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 238A for Example 97A in Example 193. [0470]
  • MS(ESI) m/e 307 (M+H)[0471] +;
  • [0472] 1H NMR (500 MHz, CD3OD) δ 7.33 (m, 2H), 7.10 (m, 311), 3.89 (m, 1H), 3.71 (d, 1H), 1.74 (m, 3H), 1.65 (m, 2H), 1.53 (m, 2H), 1.29 (m, 4H), 1.20 (m, 2H), 0.95 (m, 2H).
    • EXAMPLE 115 (2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-phenoxybutanamide
  • The desired product was prepared by substituting O-phenylhydroxylamine for 4-methylphenylhydrazine and Example 200B for Example 97A in Example 193. [0473]
  • MS(ESI) m/e 339 (M+H)[0474] +;
  • [0475] 1H NMR (500 MHz, CD3OD) δ 7.32 (dd, 2H), 7.08 (dd, 3H), 4.60 (d, 0.65H), 4.56 (d, 0.35H), 3.70 (m, 1H), 2.91 (dd, 1H), 2.82 (dd, 0.35H), 2.77 (dd, 0.65H), 2.51 (m, 1.5H), 2.43 (m, 0.5H), 1.88 (m, 2H), 1.75-1.66 (m, 3H), 1.32-1.16 (m, 4H), 0.98 (m, 2H).
    • EXAMPLE 116 ethyl ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate
  • The desired product was prepared by substituting O-(carboethoxy)methyl hydroxylamine hydrochloride for O-benzyl hydroxylamine hydrochloride in Example 100. [0476]
  • MS(APCI) m/e 303 (M+H)[0477] +;
  • [0478] 1H NMR (300 MHz, DMSO-d6) δ7.95 (br s, 1H), 6.39 (d, 1H), 4.50 (d, 2H), 4.18 (m, 2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 1.23 (t, 3H), 0.90-0.75 (m, 2H).
    • EXAMPLE 117 benzyl ((((2RS,3R)-3-amino-4-cyclohexYl-2-hydroxybutanoyl)amino)oxy)acetate EXAMPLE 117A benzyl ((((2RS,3R)-3-(tert-butoxycarbonyl)amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate
  • The desired product was prepared by substituting O-(carbobenzyloxy)methyl hydroxylamine for O-(carboethoxy)methyl hydroxylamine hydrochloride in Example 106A. [0479]
  • MS(APCI) m/e 465 (M+H)[0480] +.
    • EXAMPLE 117B benzyl ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate
  • Example 117A was dissolved in saturated HCl/dioxane (3 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product. [0481]
  • MS(APCI) m/e 365 (M+H)[0482] +;
  • [0483] 1H NMR (300 MHz, DMSO-d6) δ7.96 (br s, 1H), 7.39 (m, 5H), 6.39 (d, IH), 5.20 (s, 2H), 4.49 (s, 2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.90-0.75 (m, 2H).
    • EXAMPLE 118 ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic acid EXAMPLE 118A ((((2RS,3R)-3-(tert-butoxycarbonvl)amino-4-cyclohexyl-2-hydroxvbutanoyl)amino)oxy)acetic acid
  • A solution of Example 117A (0.99 g, 2.1 mmol), and 10% Palladium on charcoal (0.21 g) in THF (10 mIL) at room temperature was stirred for 4 hours under an atmosphere of hydrogen gas, filtered, and concentrated to provide the desired product. [0484]
  • MS(APCI) m/e 375 (M+H)[0485] +;
    • EXAMPLE 118B ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic acid
  • Example 118A (0.17 g, 0.45 mmol) was dissolved in saturated HCl/dioxane (4 mL), stirred for 1 hour, concentrated, treated with diethyl ether, then concentrated to provide the desired product. [0486]
  • MS(APCI) m/e 275 (M+H)[0487] +;
  • [0488] 1H NMR (300 MHz, DMSO-d6) δ 7.96 (br s, 1H), 6.39 (d, 1H), 5.20 (s, 2H), 3.92 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.90-0.75 (m, 2H).
    • EXAMPLE 119 ethyl (2S)-2-((((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetyl)amino)propanoate
  • A solution of Example 118A (0.17 g, 0.45 mmol), L-alanine ethyl ester hydrochloride (0.098 g, 0.64 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.098 g, 0.51 mmol), 1-hydroxybenzotriazole (0.091 g, 0.67 mmol), and N-methylmorpholine (0.11 mL, 1.0 mmol) in dichloromethane (5 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with 1 M HCl, aqueous NaHCO[0489] 3, dried (MgSO4), filtered, and concentrated. The concentrate was dissolved in saturated HCl/dioxane (4 mL), stirred for 1 hour, concentrated, then purified by HPLC to provide the desired product.
  • MS(ESI) m/e 374 (M+H)[0490] +;
  • [0491] 1H NMR (300 MHz, DMSO-d6) δ 11.71 (br s, 1H), 8.56 (br s, 1), 7.74 (br s, 2H), 6.55 (d, 1H), 4.35 (d, 2H), 4.29 (m, 1H), 4.09 (m, 2H), 4.03 (m, 1H), 1.74-1.60 (m, 6H), 1.40-1.35 (m, 1H), 1.31 (d, 3H), 1.33-1.15 (m, 4H), 1.19 (t, 3H), 0.96-0.80 (m, 2H).
    • EXAMPLE 120 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(2-oxo-2-((2-phenylethyl)amino)ethoxy)butanamide
  • The desired product was prepared by substituting 2-phenylethylamine for L-alanine ethyl ester hydrochloride in Example 119. [0492]
  • MS (APCI) m/e 378 (M+H)[0493] +;
  • [0494] 1H NMR (300 MHz, DMSO-d6) δ 11.69 (br s, 1H), 8.29 (br s, 1H), 7.75 (br s, 2H), 7.30 (m, 3H), 7.22 (m, 2H), 6.56 (d, 1H), 4.28 (d, 2H), 4.01 (m, 1H), 2.75 (m, 2H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.36 (m, 2H), 1.33-1.15 (m, 4H), 0.90-0.75 (m, 2H).
    • EXAMPLE 121 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-benzyloxypentanamide
  • The desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride in Example 98B. [0495]
  • MS(ESI) m/e 299 (M+H)[0496] +;
  • [0497] 1H NMR (300 MHz, DMSO-d6) δ 11.51 (br s, 1H), 7.92 (br s, 0.3H), 7.84 (br s, 0.7H), 7.39 (m, 5H), 6.49 (d, 0.7H), 6.40 (d, 0.3H), 4.84 (s, 1.4H), 4.82 (s, 0.6H), 4.17 (m, 0.3H), 4.03 (m, 0.7H), 3.48 (m, 1H), 2.60 (m, 2H), 2.48 (q, 2H), 1.73 (m, 2H), 1.18 (t, 3H).
    • EXAMPLE 122 (2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hydroxypropanamide EXAMPLE 122A (2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoic acid
  • The desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-2-(cyclohexyl)ethanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0498]
  • MS(ESI) m/e 288 (M+H)[0499] +.
    • EXAMPLE 122B (2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hvdroxypropanamide
  • The desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 122A for Example 98A in Example 98B. [0500]
  • MS(ESI) m/e 293 (M+H)[0501] +;
  • [0502] 1H NMR (300 MHz, DMSO-d6) δ 11.52 (s, 1H), 7.73 (br s, 2H), 7.41 (m, 5H), 6.40 (m, 1H), 4.85 (s, 2H), 4.08 (m, 1H), 1.77-1.44 (m, 6H), 1.20-0.94 (m, 5H).
    • EXAMPLE 123 (2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide EXAMPLE 123A (2R)-2-((tert-butoxvcarbonyl)amino)-4-((isopropyl)sulfanvl)butanoic acid
  • A solution of D-homocystine (20 g, 75 mmol) in liquid ammonia (600 mL) was treated sequentially with sodium (8.9 g, 390 mmol) and 2-bromopropane (20 mL, 210 mmol). The ammonia was allowed to evaporate under a stream of nitrogen, and the residues take up in 1:1 2-propanol/water (500 mL), then treated with di-tert-butyl dicarbonate (50 g, 230 mmol) at room temperature for 6 hours, then concentrated. The residues were taken up in water and the pH adjusted to 10 with NaOH. The solution was washed twice with ether, then adjusted to pH 2 with HCl, then extracted twice with ethyl acetate. The ethyl acetate extracts were dried (MgSO[0503] 4), filtered, then concentrated to provide the desired product.
  • MS(ESI) m/e 279 (M+H)[0504] +.
    • EXAMPLE 123B (2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoic acid
  • The desired product was prepared by substituting Example 123A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0505]
  • MS(ESI) m/c 308 (M+H)[0506] +.
    • EXAMPLE 123C (2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide
  • The desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [0507]
  • MS(ESI) m/e 313 (M+H)[0508] +;
  • [0509] 1H NMR (300 MHz, DMSO-d6) δ 11.50 (br s, 1H), 7.92 (br s, 0.6H), 7.84 (br s, 1.4H), 7.40 (m, 5H), 6.48 (d, 0.7H), 6.38 (d, 0.3H), 4.84 (s, 1.4H), 4.82 (s, 0.6H), 4.17 (m, 0.3H), 4.03 (m, 0.7H), 3.48 (m, 1H), 2.91 (m, 1H), 2.73 (m, 2H), 1.74 (m, 2H), 1.20 (d, 6H).
    • EXAMPLE 124 (2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide EXAMPLE 124A (2S)-2-((tert-butoxycarbonyl)amino)-3-(isobutylsulfanyl)propanoic acid
  • The desired product was prepared by substituting D-cystine for D-homocystine and 1-bromo-2-methylpropane for 2-bromopropane in Example 123A. [0510]
  • MS(ESI) m/e 279 (M+H)[0511] +.
    • EXAMPLE 124B (2RS,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-(isobutylsulfanyl)butanoic acid
  • The desired product was prepared by substituting Example 124A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0512]
  • MS(ESI) m/e 308 (M+H)[0513] +.
    • EXAMPLE 124C (2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide
  • The desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 124B for Example 98A in Example 98B. [0514]
  • MS(ESI) m/e 360 (M+H)[0515] +;
  • [0516] 1H NMR (300 MHz, DMSO-d6) δ 11.55 (br s, 1H), 7.93 (br s, 2H), 7.40 (m, 5H), 6.56 (m, 1H), 4.86 (s, 2H), 4.21 (m, 1H), 2.63 (m, 2H), 2.42 (d, 2H), 1.75 (m, 1H), 0.95 (d, 6H).
    • EXAMPLE 125 (2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenylpentanamide EXAMPLE 125A (2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoic acid
  • The desired product was prepared by substituting (2R)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoic acid for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0517]
  • MS(ESI) m/e 309 (M+H)[0518] +.
    • EXAMPLE 125B (2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenvlpentanamide
  • The desired product was prepared by substituting O-benzyl hydroxylamine hydrochloride for O-phenyl hydroxylamine hydrochloride and Example 125A for Example 98A in Example 98B. [0519]
  • MS(ESI) m/e 315 (M+H)[0520] +;
  • [0521] 1H NMR (300 MHz, DMSO-d6) δ7.86 (br s, 2H), 7.35 (m, 5H), 7.20 (m, 5H), 6.48 (m, 1H), 4.82 (s, 211), 4.05 (m, 1H), 2.65 (m, 2H), 1.78 (m, 2H).
    • EXAMPLE 126 (2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hydroxy-4-(isobutysulfanyl)butanamide EXAMPLE 126A O-Cyclohexylmethylhydroxylamine
  • The title compound was prepared by substituting cyclohexylmethyl bromide for Example 128A in Example 128B-128C. [0522]
  • [0523] 1H NMR (300 MHz, DMSO-d6) δ 5.85 (s, 2H), 1.70-1.60 (m, 5H), 1.26-1.08 (m, 4H), 0.94-0.80 (m, 2H).
    • EXAMPLE 126B (2S,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-(isobutylsulfanyl)butanoic acid pentafluorophenyl ester
  • A solution of Example 124B (0.921 g, 3.0 mmol), pentafluorophenol (0.61 g, 3.3 mmol), 1-hydroxybenzotriazole (0.61 g, 4.5 mmol) and 1,3-dicyclohexyl-carbodiimide (0.62 g, 3.0 mmol in dichloromethane (10 mL) was stirred at 0° C. for 1 h and room temperature for 18 h. Dicyclohexyl urea was removed by filtration, and the filtrate was diluted with ether, washed with NaHCO[0524] 3 and then brine, dried (MgSO4), filtered, and concentrated. The crude material was purified by silica gel chromatography (10:90/ethylacetate:hexanes) to give the title compound.
  • MS(ESI) m/e 472 (M−H)[0525] +.
  • [0526] 1H NMR (300 MHz, DMSO-d6) δ 6.64 (d, 1H), 6.10 (d, 1H), 4.85 (dd, 1H), 4.14 (m, 1H), 2.74 (m, 1H), 2.56 (m, 1H), 2.47 (d, 2H), 1.77 (m, 1H), 1.37 (s, 9H), 0.95 (d, 6H).
    • EXAMPLE 126C (2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hdroxy-4-(isobutylsulfanyl)butanamide
  • A solution of Example 126B (0.24 g, 0.5 mmol) and Example 126A (0.065 g, 0.5 mmol) in DMF (5 mL) was stirred at room temperature for 18h, diluted with ether, washed with brine, dried (Na[0527] 2SO4) and concentrated, purified by silica gel chromatography (10:90/ethylacetate:hexanes),then treated with 4M HCl in dioxane to give the title compound.
  • MS(ESI) m/e 317 (M−H)[0528] +.
  • [0529] 1H NMR (300 MHz, DMSO-d6) δ 11.38 (br s, 1H), 7.9 (br s, 2H), 6.5 (d, 1H), 4.18 (dd, 111), 3.63 (d, 2H), 3.4 (m, 1H), 2.75-2.59 (m, 2H), 2.53 (d, 2H), 1.8-1.6 (m, 7H), 1.24-1.10 (m, 4H), 1.0-0.9 (m, 1H), 0.95 (d, 6H).
    • EXAMPLE 127 (2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)butanamide Example 127A O-2,4,6-trimethylbenzylhydroxylamine
  • The title compound was prepared by substituting 2,4,6-trimethylbenzyl bromide for Example 128A in Example 128B-128C. [0530]
  • [0531] 1H NMR (300 MHz, DMSO-d6) δ 6.80 (s, 2H), 5.96 (s, 2H), 4.57 (s, 2H), 2.30 (s, 6H), 2.20 (s, 3H).
    • EXAMPLE 127B (2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)butanamide
  • The title compound was prepared by substituting Example 127A for Example 126B in Example 126C. [0532]
  • MS(ESI) m/e 353 (M-H)+. [0533]
  • [0534] 1H NMR (300 MHz, DMSO-d6) δ 11.55 (br s, 1H), 7.78 (br s, 2H), 6.85 (s, 2H), 6.57 (d, 1H), 4.87 (s, 2H), 4.24 (dd, 1H), 3.44(m, 1H), 2.75-2.59 (m, 2H), 2.44 (d, 2H), 2.38 (s, 6H), 2.21 (s, 3H), 1.8-1.7 (m,1H), 0.95 (d, 6H).
    • EXAMPLE 128 (2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((IRS)-1-phenylethoxy)pentanamide EXAMPLE 128A 1-bromoethylbenzene
  • To a solution of DL-sec-phenethyl alcohol (1.81 ml, 15 mmol) in chloroform (20 ml) was added phosphorus tribromide (15.75 ml, 15.75 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 18 hours, poured into wet ice, washed with brine (4X), dried (MgSO[0535] 4), then evaporated to dryness to yield 2.62 g of the title compound.
    • EXAMPLE 128B N-(1-phenylethoxy)phthalimide
  • N-hydroxyphthalamide (2.31g, 14.2 mmol), Example 128A (2.62g, 14.2 mmol) and potassium carbonate (4.91g, 35.5 mmol) in N,N-dimethylformamide (35 mL) were stirred at room temperature for 1 day, and stirred in 50° C. oil bath for 5 hours. The mixture was poured into ice-water, the precipitate was collected by filtration, washed with water and dried to yield 2.69g of the title compound. [0536]
    • EXAMPLE 128C O-(1-(phenyl)ethyl)hydroxylamine
  • Example 128B (2.18g, 8.2 mmol) and hydrazine hydrate (0.306 ml, 9.84mmol) in ethanol (35 mL) was stirred at room temperature for 1.5 hours. The solvent was removed, the residue triturated with 30 ml of ether, filtered, and the filtrate was concentrated in vacuo to yield the title compound (1.09g) as an oil. [0537]
    • EXAMPLE 128D (2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((lRS)-1-phenylethoxy)pentanamide
  • The desired product was prepared by substituting Example 128C for O-phenyl hydroxylamine hydrochloride in Example 98B. [0538]
  • MS(ESI) m/e 313(M+H)[0539] +;
  • [0540] 1H NMR (300 MHz, DMSO-d6) δ 11.28 (d, 0.5H), 11.25 (d, 0.5H), 7.89-8.08 (br. 3H), 7.28-7.43 (m, 5H), 6.43 (d, 0.6H), 6.33 (d, 0.4H), 4.92-5.03 (m, 1H), 4.17 (br., 0.4H), 3.98 (br., 0.6H), 2.42-2.67 (m, 4H), 1.60-1.73 (m, 2H), 1.42-1.46 (m, 3H), 1.13-1.21 (m, 3H).
    • EXAMPLE 129 (2S,3S)-3-amino-N-(benzloxy)-2-hydroxy-4-(isobutylsulfanyl)-N-methylbutanamide EXAMPLE 129A N-methyl-O-benzylhydroxylamine hydrochloride
  • O-Benzylhydroxylamine hydrochloride (1.59 g, 0.01 mol), di-tert-butyl dicarbonate (2.18 g, 0.01 mol) and N-methyl morpholine (1.1 mL, 0.01 mol) in dichloromethane (40 mL) were stirred at room temperature for 16 hours. The reaction mixture was diluted with ether, washed with 10% NaHSO[0541] 4, then brine, dried over (Na2SO4), and concentrated. The residue was treated with methyl iodide (1.6 mL, 0.025 mmol) in the presence of NaH (0.4 g, 0.01 mol) in THF at 0° C., then stirred at room temperature for 16 hours. The reaction was quenched with 1N HCl, diluted with ether, washed with brine, dried (Na2SO4), concentrated, purified by silica gel chromatography (20:80/ethyl acetate:hexanes) and treated with 4M HCl in dioxane to give the title compound.
    • EXAMPLE 129B (2S,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)-N-methylbutanamide
  • The title compound was prepared by substituting Example 129A for Example 126A in Example 126C. [0542]
  • MS(ESI) m/e 327 (M+H)[0543] +.
  • [0544] 1H NMR (300 MHz, DMSO-d6) δ7.9 (br s, 2H), 7.49 (m, 2H), 7.4 (m, 3H), 6.22 (br s, 1H), 4.98 (m, 2H), 4.79 (br s, 1H), 3.24(s, 3H), 2.55 (m, 2H), 2.3 (m, 2H),), 1.68 (m,1H), 0.9 (d, 6H).
    • EXAMPLE 130 (2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)-N-methylpentanamide
  • The desired product was prepared by substituting Example 129A for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [0545]
  • MS(ESI) m/e 327 (M+H)+. [0546]
  • [0547] 1H NMR (300 MHz, DMSO-d6) δ 8.08 & 7.88 (br s, 2H), 7.55-7.38 (m, 5H), 6.25 & 5.97 (br s, 1H), 4.98 (br s, 2H), 4.77 & 4.55 (br s, 1H), 3.7 & 3.48 (m, 1H), 3.2 (br s, 3H), 2.85 (m, 1H), 1.8-1.6 (m, 2H), 1.15 (m,6H).
    • EXAMPLE 131 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-((IRS)-1-phenylethoxy)pentanamide
  • The desired product was prepared by substituting Example 128C for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [0548]
  • MS(ESI) m/e 327(M+H)[0549] +;
  • [0550] 1H NMR (300 MHz, DMSO-d6) δ11.26 (d, 0.6H), 11.24 (d, 0.4H), 7.88-8.10 (br., 3H), 7.30-7.44 (m, 5H), 6.45 (d, 0.6H), 6.36 (d, 0.4H), 4.90-5.02 (m, 1H), 3.97 (br.m, 1H) 3.64-3.73 (m, 1H), 2.82-2.94 (m, 2H), 2.53-2.73 (m, 2H), 1.58-1.72 (m, 2H), 1.42-1.47 (m, 3H), 1.16-1.23 (m, 6H).
    • EXAMPLE 132 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-3-(methylsulfanyl)butyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3-(methylsulfanyl)butyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0551]
  • MS(ESI) m/e 394 (M+H)[0552] +;
  • [0553] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.88 (m, 2H), 6.80 (m, 1H), 4.27 (dd, 1H), 3.57 (m, 3H), 2.17 (m, 1H), 2.07 (s, 3H), 1.42-1.91 (m, 6H), 1.11-1.42 (m, 4H), 0.76-1.11 (m, 8H).
    • EXAMPLE 133 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(3 phenylpropyl)butanohydrazide
  • The desired product was prepared by substituting 1-(3-phenylpropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0554]
  • MS(ESI) m/e 410 (M+H)[0555] +;
  • [0556] 1H NMR (300 MHz, CD3OD) δ 7.05-7.41 (m, 8H), 6.83 (m, 2H), 4.26 (d, 1H), 3.57 (m, 1H), 3.48 (m, 2H), 2.74 (t, 2H), 1.86-2.07 (m, 2H), 1.55-1.86 (m, 7H), 1.47 (m, 2H), 1.07-1.39 (m, 2H), 0.75-1.07 (m, 2H).
    • EXAMPLE 134 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-isobutyl-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-methylpropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0557]
  • MS(ESI) m/e 348 (M+H)[0558] +;
  • [0559] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 5H), 6.87 (m, 2H), 6.80 (m, 1H), 4.24 (d, 1H), 3.54 (m, 1H), 3.28 (d, 2H), 1.99 (m, 1H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.91 (m, 2H).
    • EXAMPLE 135 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-pentyl-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-pentyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0560]
  • MS(ESI) m/e 362 (M+H)[0561] +;
  • [0562] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.59 (m, 1H), 3.46 (dd, 2H), 1.58-1.92 (m, 6H), 1.11-1.58 (m, 12H), 0.83-1.11 (m, 4H).
    • EXAMPLE 136 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-methylbutyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-methylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0563]
  • MS(ESI) m/e 362 (M+H)[0564] +;
  • [0565] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.88 (m, 2H), 6.80 (m, 1H), 4.24 (dd, 1H), 3.53 (m, 1H), 3.40 (m, 1H), 3.24 (m, 1H), 1.42-1.91 (m, 9H), 1.11-1.42 (m, 4H), 0.76-1.11 (m, 8H).
    • EXAMPLE 137 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-isopentyl-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3-methylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0566]
  • MS(ESI) m/e 362 (M+H)[0567] +;
  • [0568] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 2H), 6.83 (m, 1H), 4.28 (d, 1H), 3.58 (m, 1H), 3.49 (m, 2H), 1.61-1.92 (m, 7H), 1.52 (m, 4H), 1.11-1.42 (m, 3H), 0.83-1.11 (m, 8H).
    • EXAMPLE 138 (2RS,3R)-3-amino-4-cyclohexyl-N′-hexyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-hexyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0569]
  • MS(ESI) m/e 376 (M+H)[0570] +;
  • [0571] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.90 (m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.57 (m, 1H), 3.45 (m, 2H), 1.59-1.91 (m, 7H), 1.11-1.59 (m, 12H), 0.84-1.11 (m, 5H).
    • EXAMPLE 139 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-methylpentyl)-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-methylpentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0572]
  • MS(ESI) m/e 376 (M+H)[0573] +;
  • [0574] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.87 (m, 2H), 6.80 (m, 1H), 4.19-4.28 (m, 1H), 3.53 (dt, 1H), 3.39 (m, 1H), 3.24 (m, 1H), 1.59-1.99 (m, 7H), 1.50 (m, 4H), 1.04-1.42 (m, 6H), 1.00 (d, 3H), 0.93 (t, 3H), 0.83-1.05 (m, 2H).
    • EXAMPLE 140 (2RS 3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-methylpentyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3-methylpentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0575]
  • MS(ESI) m/e 376 (M+H)[0576] +;
  • [0577] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.39-3.65 (m, 3H), 1.59-1.93 (m, 7H), 1.37-1.59 (m, 5H), 1.10-1.37 (m, 4H), 0.83-1.10 (m, 8H).
    • EXAMPLE 141 (2RS,3R)-3-amino-4-cyclohexyl-N-(3,3-dimethylbutyl)-2-hydroxy-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3,3-dimethylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0578]
  • MS(ESI) m/e 376 (M+H)[0579] +;
  • [0580] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.83 (m, 1H), 4.29 (d, 1H), 3.52 (m, 4H), 1.42-1.91 (m, 10H), 1.11-1.42 (m, 3H), 0.76-1.11 (m, 11H).
    • EXAMPLE 142 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2-ethylbutyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-ethylbutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0581]
  • MS(ESI) m/e 376 (M+H)[0582] +;
  • [0583] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.88 (m, 2H), 6.81 (m, 1H), 4.23 (d, 1H), 3.52 (dt, 1H), 3.37 (d, 2H), 1.58-1.92 (m, 7H), 1.38-1.58 (m, 6H), 1.10-1.38 (m, 3H), 0.82-1.10 (m, 8H).
    • EXAMPLE 143 (2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclopropylmethyl)-2-hydroxy-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(cyclopropylmethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1 [0584]
  • MS(ESI) m/e 346 (M+H)[0585] +;
  • [0586] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.93 (m, 2H), 6.85 (m, 1H), 4.30 (d, 1H), 3.60 (ddd, 1H), 3.43 (m, 1H), 3.28 (m, 1 H), 1.64-1.94 (m, 6H), 1.42-1.64 (m, 2H), 1.16-1.42 (m, 3H), 0.69-1.16 (m, 3H), 0.41-0.69 (m, 2H), 0.15-0.41 (m, 2H).
    • EXAMPLE 144 (2RS,3R)-3-amino-4-cyclohexyl-N′-dodecyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-dodecyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0587]
  • MS(ESI) m/e 460 (M+H)[0588] +;
  • [0589] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.83 (m, 1H), 4.26 (d, 1H), 3.56 (dt, 1H), 3.46 (m, 2H), 1.57-1.93 (m, 8H), 1.51 (m, 2H), 1.10-1.45 (m, 21H), 0.82-1.10 (m, 5H).
    • EXAMPLE 145 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(3,5,5-trimethylhexyl)butanohydrazide
  • The desired product was prepared by substituting 1-(3,5,5-trimethylhexyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0590]
  • MS(ESI) r/e 418 (M+H)[0591] +;
  • [0592] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 2H), 6.83 (m, 1H), 4.27 (d, 11H), 3.40-3.63 (m, 3H), 1.59-1.98 (m, 8H), 1.51 (m, 3H), 1.18-1.42 (m, 4H), 1.14 (m, 1H), 1.03 (m, 4H), 0.70-0.97 (m, 10H).
    • EXAMPLE 146 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-octyl-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-octyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0593]
  • MS(ESI) m/e 404 (M+H)[0594] +;
  • [0595] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.56 (dt, 1H), 3.46 (m, 2H), 1.59-1.97 (m, 8H), 1.52 (m, 2H), 1.09-1.45 (m, 13H), 0.76-1.09 (m, 5H).
    • EXAMPLE 147 (2RS,3R)-3-amino-N′-(2-(benzyloxy)ethyl)-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-benzyloxymethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0596]
  • MS(ESI) m/e 426 (M+H)[0597] +;
  • [0598] 1H NMR (300 MHz, CD3OD) δ 7.35 (m, 10H), 6.92 (m, 2H), 6.83 (m, 1H), 4.53 (m, 4H), 4.32 (d, 1H), 3.60 (m, 3H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
    • EXAMPLE 148 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(2,2,5-trichloropentyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2,2,5-trichloropentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0599]
  • MS(ESI) m/e 464 (M+H)[0600] +;
  • [0601] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.85 (m, 3H), 4.38 (d, 1H), 3.79 (m, 11H), 3.68 (m, 2H), 2.46 (m, 2H), 2.17 (m, 2H), 1.58-1.91 (m, 8H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
    • EXAMPLE 149 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-propylbutanohydrazide
  • The desired product was prepared by substituting 1-propyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0602]
  • MS(ESI) m/e 334 (M+H)[0603] +;
  • [0604] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.90 (m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.59 (m, 1H), 3.45 (m, 2H), 1.59-1.99 (m, 8H), 1.51 (m, 2H), 1.12-1.43 (m, 3H), 0.78-1.12 (m, 5H).
    • EXAMPLE 150 (2RS,3R)-3-amino-4-cyclohexyl-N′-heptyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-heptyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0605]
  • MS(ESI) m/e 390 (M+H)[0606] +;
  • [0607] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.82 (m, 1H), 4.27 (d, 1H), 3.56 (dt, 1H), 3.45 (m, 2H), 1.59-1.96 (m, 8H), 1.52 (m, 2H), 1.12-1.45 (m, 11H), 0.83-1.12 (m, 5H).
    • EXAMPLE 151 (2RS,3R)-3-amino-4-cyclohexyl-N′-ethyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-ethyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0608]
  • MS(ESI) m/e 320 (M+H)[0609] +;
  • [0610] 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 2H), 6.91 (m, 2H), 6.83 (m, 1H), 4.30 (d, 1H), 3.61 (m, 1H), 3.54 (dd, 2H), 1.59-1.92 (m, 6H), 1.50 (m, 2H), 1.4-1.12 (m, 3H), 1.22 (t, 3H), 0.85-1.18 (m, 2H).
    • EXAMPLE 152 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-(methylsulfanyl)propyl)-N′-phenylbutanohydrazide
  • [0611]
  • The desired product was prepared by substituting 1-(3-(methylsulfanyl)propyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0612]
  • MS(ESI) m/e 380 (M+H)[0613] +;
  • [0614] 1H NMR (300 MLz, CD3OD) δ 7.22 (m, 2H), 6.92 (m, 2H), 6.83 (m, 1H), 4.28 (d, 1H), 3.47-3.72 (m, 3H), 2.50-2.75 (m, 2H), 2.10 (s, 3H), 1.93 (m, 2H), 1.58-1.87 (m, 6H), 1.51 (m, 2H), 1.13-1.42 (m, 3H), 0.82-1.12 (m, 2H).
    • EXAMPLE 153 (2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclopentylmethyl)-2-hydroxy-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(cyclopentylmethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0615]
  • MS(ESI) m/e 374 (M+H)[0616] +;
  • [0617] 1H NMR (300 MHz, CD3OD) δ 7.21 (m, 2H), 6.89 (m, 2H), 6.82 (m, 1H), 4.25 (d, 1H), 3.54 (dt, 1H), 3.41 (d, 2H), 2.26 (m, 1H), 1.42-2.00 (m, 15H), 1.10-1.43 (m, 5H), 0.80-1.10 (m, 2H).
    • EXAMPLE 154 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(5-hydroxypentyl)-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(5-hydroxypentyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0618]
  • MS(ESI) m/e 378 (M+H)[0619] +;
  • [0620] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.90 (m, 2H), 6.82 (m, 1H), 4.28 (d, 1H), 3.68 (m, 1H), 3.57 (t, 2H), 3.48 (m, 2H), 1.41-2.11 (m, 14H), 1.12-1.41 (m, 4H), 0.80-1.12 (m, 2H).
    • EXAMPLE 155 (2RS,3R)-3-amino-4-cyclohexyl-N′-((2R)-2,3-dihydroxypropyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-((2R)-2,3-dihydroxypropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0621]
  • MS(ESI) m/e 366 (M+H)[0622] +;
  • [0623] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.86 (m, 3H), 4.27 (d, 1H), 3.62 (m, 3H), 3.28 (d, 4H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
    • EXAMPLE 156 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2,2-dichlorohexyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2,2-dichlorohexyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0624]
  • MS(ESI) m/e 444 (M+H)[0625] +;
  • [0626] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.87 (m, 3H), 4.29 (d, 1H), 3.57 (m, 3H), 2.27 (m, 2H), 1.58-1.91 (m, 6H), 1.50 (m, 4H), 1.17-1.42 (m, 5H), 1.05 (m, 2H), 0.92 (t, 3H).
    • EXAMPLE 157 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-7-methoxy-3,7-dimethyloctyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(7-methoxy-3,7-dimethyloctyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0627]
  • MS(ESI) m/e 462 (M+H)[0628] +;
  • [0629] 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 2H), 6.89 (m, 2H), 6.83 (m, 1H), 4.27 (s, 1H), 3.38-3.65 (m, 3H), 3.17 (s, 3H), 1.14 (s, 6H), 0.97 (d, 3H), 0.85-1.12 (m, 2H), 0.85-1.12 (m, 20H).
    • EXAMPLE 158 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-(4-methylphenyl)ethyl)-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-(4-methylphenyl)ethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0630]
  • MS(ESI) m/e 410 (M+H)[0631] +;
  • [0632] 1H NMR (300 MHz, CD3OD) δ 7.24 (m, 2H), 7.13 (m, 4H), 6.91 (m, 2H), 6.83 (m, 1H), 4.29 (d, 1H), 3.69 (m, 2H), 3.57 (m, 1H), 2.90 (t, 2H), 2.30 (s, 3H), 1.59-1.95 (m, 5H), 1.50 (m, 2H), 1.12-1.40 (m, 4H), 0.75-1.12 (m, 2H).
    • EXAMPLE 159 (2RS,3R)-3-amino-4-cyclohexyl-N′-((2RS)-2-ethylhexyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-ethylhexyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0633]
  • MS(ESI) m/e 404 (M+H)[0634] +;
  • [0635] 1H NMR (300 MHz, CD3OD) δ 7.21 (m, 2H), 6.88 (m, 2H), 6.81 (m, 1H), 4.23 (m, 1H), 3.52 (dt, 1H), 3.37 (m, 2H), 1.61-1.92 (m, 6H), 1.10-1.61 (m, 14H), 0.75-1.10 (m, 8H).
    • EXAMPLE 160 (2RS,3R)-3-amino-N′-((2RS)-2-(4-chlorophenyl)-2-cyanoethyl)-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-(4-chlorophenyl)-2-cyanoethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0636]
  • MS(ESI) m/e 456 (M+H)[0637] +;
  • [0638] 1H NMR (300 MHz, CD3OD) δ 7.50-7.10 (m, 9H), 6.84 (m, 1H), 4.57 (d, 1H), 3.82 (m, 1H), 3.41 (m, 2H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.91 (m, 2H).
    • EXAMPLE 161 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-((2RS)-2-phenylpropyl)butanohydrazide
  • The desired product was prepared by substituting 1-(2-phenylpropyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0639]
  • MS(ESI) m/e 410 (M+H)[0640] +;
  • [0641] 1H NMR (300 MHz, CD3OD) δ 7.32 (m, 5H), 7.18 (m, 2H), 6.87 (m, 2H), 6.80 (m, 1H), 4.18 (d, 1H), 3.65 (m, 2H), 3.52 (m, 1H), 3.13 (m, 1H), 1.58-1.91 (m, 6H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 1.37 (d, 3H), 0.91 (m, 2H).
    • EXAMPLE 162 (2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclooctylmethyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(cyclooctylmethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0642]
  • MS(ESI) m/e 416 (M+H)[0643] +;
  • [0644] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.88 (m, 2H), 6.80 (m, 1H), 4.24 (d, 1H), 3.53 (dt, 1H), 3.27 (m, 2H), 1.11-2.08 (m, 26H), 0.82-1.11 (m, 2H).
    • EXAMPLE 163 (2RS,3R)-3-amino-4-cyclohexyl-N′-((11Z)-11-hexadecenyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-((11Z)-11-hexadecenyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0645]
  • MS(ESI) m/e 514 (M+H)[0646] +;
  • [0647] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.88 (m, 2H), 6.82 (m, 1H), 5.34 (m, 2H), 4.27 (d, 1H), 3.56 (dt, 1H), 3.46 (m, 2H), 1.92-2.14 (m, 4H), 1.58-1.92 (m, 7H), 1.51 (m, 2H), 1.12-1.44 (m, 22H), 0.94-1.12 (m, 2H), 0.89 (m, 3H).
    • EXAMPLE 164 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-tridecylbutanohydrazide
  • The desired product was prepared by substituting 1-tridecyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0648]
  • MS(ESI) m/e 474 (M+H)[0649] +;
  • [0650] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.90 (m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.56 (m, 1H), 3.46 (m, 2H), 1.57-1.91 (m, 7H), 1.51 (m, 2H), 1.12-1.44 (m, 21H), 1.01 (m, 2H), 0.90 (t, 3H).
    • EXAMPLE 165 4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-phenylhydrazino)butanoic acid
  • The desired product was prepared by substituting 4-(1-phenylhydrazino)butanoic acid for 1-benzylhydrazine dihydrochloride in Example 1. [0651]
  • MS(ESI) m/e 378 (M+H)[0652] +;
  • [0653] 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 2H), 6.88 (m, 3H), 4.29 (m, 1H), 3.64 (m, 1H), 3.53 (m, 1H), 3.31 (m, 1H), 2.46 (t, 1H), 1.94 (m, 1H), 1.59-1.88 (m, 7H), 1.50 (m, 3H), 1.12-1.41 (m, 4H), 0.86-1.12 (m, 2H).
    • EXAMPLE 166 (2RS.3R)-3-amino-4-cvclohexyl-2-hydroxy-N′-((6Z)-6-nonenyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-((6Z)-6-nonenyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0654]
  • MS(ESI) m/e 416 (M+H)[0655] +;
  • [0656] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 2H), 6.83 (m, 1H), 5.35 (m, 2H), 4.27 (d, 1H), 3.57 (dt, 1H), 3.46 (m, 2H), 2.06 (m, 4H), 1.58-1.90 (m, 7H), 1.52 (m, 2H), 1.42 (m, 4H), 1.12-1.38 (m, 4H), 0.95 (t, 3H), 0.86-1.09 (m, 2H).
    • EXAMPLE 167 (2RS,3R)-3-amino-4-cyclohexyl-N′-((4Z)-4-decenvl)-2-hydroxy-N ′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-((4Z)-4-decenyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0657]
  • MS(ESI) m/e 430 (M+H)[0658] +;
  • [0659] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 211), 6.83 (m, 1H), 5.41 (m, 2H), 4.26 (d, 1H), 3.57 (m, 1H), 3.47 (m, 2H), 2.05 (m, 4H), 1.59-1.90 (m, 7H), 1.51 (m, 2H), 1.12-1.42 (m, 10H), 0.82-1.08 (m, 5H).
    • EXAMPLE 168 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-pentenyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(4-pentenyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0660]
  • MS(ESI) m/e 360 (M+H)[0661] +;
  • [0662] 1H NMR (300 MHz, CD3OD) δ 7.20 (m, 2H), 6.87 (m, 2H), 6.78 (m, 1H), 5.87 (m, 1H), 5.05 (m, 2H), 4.27 (d, 1H), 3.58 (m, 1H), 3.48 (m, 2H), 2.20 (m, 2H), 1.58-1.91 (m, 8H), 1.50 (m, 2H), 1.17-1.42 (m, 3H), 0.97 (m, 2H).
    • EXAMPLE 169 (2RS,3R)-3-amino-4-cyclohexyl-N′-((3RS)-3,7-dimethyl-6-octenyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3,7-dimethyl-6-octenyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0663]
  • MS(ESI) m/e 430 (M+H)[0664] +;
  • [0665] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.87 (m, 2H), 6.80 (m, 1H), 5.12 (m, 1H), 4.28 (d, 1H), 3.55 (m, 3H), 2.04 (m, 2H), 1.58-1.91 (m, 6H), 1.50 (m, 5H), 1.17-1.42 (m, 5H), 1.12 (s, 6H), 0.97 (d, 31H), 0.91 (m, 2H).
    • EXAMPLE 170 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(4,4,4-trifluorobutyl)butanohydrazide
  • The desired product was prepared by substituting 1-(4,4,4-trifluorobutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0666]
  • MS(ESI) m/e 402 (M+H)[0667] +;
  • [0668] 1H NMR (300 MHz, CD3OD) δ 7.25 (m, 2H), 6.93 (m, 2H), 6.86 (m, 1H), 3.57 (m, 3H), 2.25-2.46 (m, 2H), 1.91 (m, 3H), 1.62-1.84 (m, 6H), 1.42-1.62 (m, 2H), 1.12-1.42 (m, 3H), 0.84-1.12 (m, 2H).
    • EXAMPLE 171 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((3RS)-3-hydroxybutyl)-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(3-hydroxybutyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0669]
  • MS(ESI) m/e 364 (M+H)[0670] +;
  • [0671] 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 2H), 6.92 (m, 2H), 6.84 (m, 1H), 4.30 (d, 1H), 3.44-3.71 (m, 4H), 1.63-1.91 (m, 7H), 1.54 (m, 3H), 1.35 (m, 3H), 1.19 (m, 4H), 0.84-1.12 (m, 2H).
    • EXAMPLE 172 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2-(((3RS)-3,7-dimethyl-6-octenyl)oxy)ethyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-((3,7-dimethyl-6-octenyl)oxy)ethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0672]
  • MS(ESI) m/e 474 (M+H)[0673] +;
  • [0674] 1H NMR (300 MHz, CD3OD) δ 7.24 (m, 2H), 6.93 (m, 2H), 6.85 (m, 1H), 5.09 (m, 1H), 4.33 (d, 1H), 3.72 (m, 2H), 3.67 (m, 2H), 3.50 (m, 3H), 2.04 (m, 2H), 1.58-1.91 (m, 6H), 1.50-1.20 (m, 10H), 1.17 (s, 3H), 1.12 (s, 3H), 0.91 (m, 2H), 0.87 (d, 3H).
    • EXAMPLE 173 (2RS,3R)-3-amino-4-cyclohexyl-N′-(2-((lRS)-3,3-dimethylcyclohexyl)ethyl)-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-(2-(3,3-dimethylcyclohexyl)ethyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0675]
  • MS(ESI) m/e 430 (M+H)[0676] +;
  • [0677] 1H NMR (300 MHz, CD3OD) δ 7.22 (m, 2H), 6.89 (m, 2H), 6.82 (m, 1H), 4.26 (d, 1H), 3.53 (m, 3H), 1.65-1.94 (m, 7H), 1.18-1.65 (m, 11H), 0.94-1.18 (m, 4H), 0.92 (s, 3H), 0.91 (s, 3H), 0.65-0.87 (m, 2H).
    • EXAMPLE 174 (2RS 3R)-3-amino-N′-((4S)-6-bromo-4-methylhexyl)-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide
  • The desired product was prepared by substituting 1-((4S)-6-bromo-4-methylhexyl)-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0678]
  • MS(ESI) m/e 468, 470 (M+H)[0679] +;
  • [0680] 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 2H), 6.89 (m, 2H), 6.83 (m, 1H), 4.27 (d, 1H), 3.55 (m, 3H), 1.65-1.89 (m, 6H), 1.45-1.65 (m, 9H), 1.17-1.42 (m, 5H), 0.97 (d, 3H), 0.95 (m, 2H).
    • EXAMPLE 175 (2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclohexylmethyl)-2-hydroxy-N′ phenylbutanohydrazide
  • The desired product was prepared by substituting 1-cyclohexylmethyl-1-phenylhydrazine for 1-benzylhydrazine dihydrochloride in Example 1. [0681]
  • MS(ESI) m/e 388 (M+H)[0682] +;
  • [0683] 1H NMR (300 MHz, CD3OD) δ 7.21 (m, 2H), 6.86 (m, 2H), 6.80 (m, 1H), 4.25 (d, 1H), 3.54 (dt, 1H), 3.31 (d, 2H), 1.92 (m, 2H), 1.59-1.84 (m, 10H), 1.51 (m, 2H), 1.13-1.42 (m, 6H), 0.81-1.13 (m, 4H).
    • EXAMPLE 176 ((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-naphthohydrazide
  • The desired product was prepared by substituting 2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0684]
  • MS(ESI) m/e 362 (M+H)[0685] +;
  • [0686] 1H NMR (300 MHz, CD3OD) δ 8.48 (m, 1H), 7.89-8.09 (m, 4H), 7.47-7.75 (m, 2H), 4.54 (d, 0.34H), 4.48 (d, 0.66H), 3.56-3.87 (m, 1H), 2.76 (m, 2H), 2.62 (q, 1.32H), 2.60 (q, 0.68H), 2.10-2.31 (m, 0.68H), 1.84-2.08 (m, 1.32H), 1.28 (t, 1.98H), 1.27 (t, 1.02H).
    • EXAMPLE 177 (2RS 3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-(1-piperidinyl)pentanamide
  • The desired product was prepared by substituting 1-aminopiperidine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0687]
  • MS(ESI) m/e 276 (M+H)[0688] +;
  • [0689] 1H NMR (300 MHz, CD3OD) δ 4.67 (m, 0.28H), 4.62 (m, 0.72H), 3.37-3.78 (m, 5H), 2.72-3.16 (m, 4H), 2.00-2.30 (m, 2H), 1.70 (m, 4H), 1.57 (m, 2H), 1.35 (t, 2.16H), 1.33 (m, 0.84H).
    • EXAMPLE 178 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzohydrazide
  • The desired product was prepared by substituting benzoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0690]
  • MS(ESI) m/e 312 (M+H)[0691] +;
  • [0692] 1H NMR (300 MHz, CD3OD) δ 7.89 (m, 2H), 7.61 (m, 1H), 7.50 (m, 2H), 4.49 (d, 0.24H), 4.44 (d, 0.76H), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (q, 2H), 2.17 (m, 1H), 1.99 (m, 1H), 1.27 (t, 3H.)
    • EXAMPLE 179 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hdroxy-N′-(4-iodophenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(4-iodophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0693]
  • MS(ESI) m/e 410 (M+H)[0694] +;
  • [0695] 1H NMR (300 MHz, CD3OD) δ 7.48 (m, 2H), 6.67 (m, 2H), 4.43 (d, 0.38H), 4.36 (d, 0.62H), 3.74 (m, 1H), 2.72 (m, 2H), 2.57 (q, 0.76H), 2.51 (q, 1.24H), 2.11 (m, 0.76H), 1.93 (m, 1.24H), 1.26 (t, 1.86H), 1.22 (t, 1.14H).
    • EXAMPLE 180 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-cyclopentylpentanohvdrazide
  • The desired product was prepared by substituting 1-(cyclopentyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0696]
  • MS(ESI) m/e 276 (M+H)[0697] +;
  • [0698] 1H NMR (300 MHz, CD3OD) δ 4.36 (d, 0.23H), 4.27 (d, 0.77H), 3.67 (td, 1H), 3.53 (m, 1H), 2.68 (m, 2H), 2.57 (q, 1.54H), 2.54 (q, 0.46H), 2.07 (m, 0.46H), 1.91 (m, 1.54H), 1.76 (m, 4H), 1.44-1.67 (m, 4H), 1.26 (t, 2.31H), 1.24 (t, 0.69H).
    • EXAMPLE 181 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-chlorophenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(3-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0699]
  • MS(ESI) m/e 318 (M+H)[0700] +;
  • [0701] 1H NMR (300 MHz, CD3OD) δ 7.15 (m, 1H), 6.85 (m, 1H), 6.77 (m, 2H), 5.98 (d, 0.32H), 5.85 (d, 0.68H), 3.71 (m, 1H), 3.43 (q, 1.36H), 3.36 (q, 0.64H), 2.70 (m, 2H), 2.11 (m, 0.64H), 1.95 (m, 1.36H), 1.67 (t, 2.04H), 1.63 (t, 0.96H).
    • EXAMPLE 182 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3 methoxyphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(3-methoxyphenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0702]
  • MS(ESI) m/e 314 (M+H)[0703] +;
  • [0704] 1H NMR (300 MHz, CD3OD) δ 7.09 (m, 1H), 6.44 (m, 3H), 4.43 (d, 0.37H), 4.36 (d, 0.63H), 3.75 (s, 3H), 3.69 (m, 1H), 2.71 (m, 2H), 2.57 (q, 1.26H), 2.50 (q, 0.74H), 2.12 (m, 0.74H), 1.82-2.04 (m, 1.26H), 1.25 (t, 1.89H), 1.21 (t, 1.11H).
    • EXAMPLE 183 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(2-chlorophenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(2-chlorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0705]
  • MS(ESI) m/e 318 (M+H)[0706] +;
  • [0707] 1H NMR (300 MHz, CD3OD) δ 7.29 (m, 1H), 7.17 (m, 1H), 6.93 (m, 1H), 6.83 (m, 1H), 4.47 (d, 0.23H), 4.41 (d, 0.77H), 3.76 (m, 1H), 2.71 (m, 2H), 2.58 (q, 1.54H), 2.52 (q, 0.46H), 2.13 (td, 0.46H), 1.95 (m, 1.54H), 1.26 (t, 2.31H), 1.22 (t, 0.69H).
    • EXAMPLE 184 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-trifluoromethylphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(3-(trifluoromethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0708]
  • MS(ESI) m/e 352 (M+H)[0709] +;
  • [0710] 1H NMR (300 MHz, CD3OD) δ 7.37 (m, 1H), 7.08 (m, 3H), 4.48 (d, 0.39H), 4.40 (d, 0.61H), 3.69 (m, 1H), 2.71 (m, 2H), 2.57 (q, 1.22H), 2.51 (q, 0.78H), 2.13 (m, 0.78H), 1.84-2.05 (m, 1.22H), 1.25 (t, 1.83H), 1.21 (t, 1.17H).
    • EXAMPLE 185 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0711]
  • MS(ESI) m/e 346 (M+H)[0712] +;
  • [0713] 1H NMR (300 MHz, CD3OD) δ 7.89 (m, 1H), 7.81 (m, 1H), 7.61 (m, 1H), 7.50 (m, 1H), 4.49 (d, 0.14H), 4.44 (d, 0.86H), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.27 (t, 3H).
    • EXAMPLE 186 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-chlorobenzohydrazide
  • The desired product was prepared by substituting 2-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0714]
  • MS(ESI) mle 346 (M+H)[0715] +;
  • [0716] 1H NMR (300 MHz, CD3OD) δ 7.62 (m, 1H), 7.46 (m, 3H), 4.49 (d, 0.26H), 4.43 (d, 0.74H), 3.80 (m, 1H), 2.71 (t, 2H), 2.60 (q, 0.52H), 2.57 (q, 1.48H), 2.16 (m, 0.52H), 1.99 (m, 1.48H), 1.27 (t, 2.22H), 1.24 (t, 0.78H).
    • EXAMPLE 187 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-isopropyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(4-(2-methylethyl)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0717]
  • MS(ESI) m/e 326 (M+H)[0718] +;
  • [0719] 1H NMR (300 MHz, CD3OD) δ 7.02 (d, 2H), 6.77 (d, 2H), 4.42 (d, 0.41H), 4.35 (d, 0.59H), 3.74 (m, 1H), 2.61-2.81 (m, 2H), 2.55 (m, 3H), 2.02-2.24 (m, 0.82H), 1.81-2.02 (m, 1.18H), 1.26 (t, 1.77H), 1.22 (t, 1.23H) 1.17 (d, 6H).
    • EXAMPLE 188 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-chloro-4-methylphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(3-chloro-4-methylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0720]
  • MS(ESI) m/e 332 (M+H)[0721] +;
  • [0722] 1H NMR (300 MHz, CD3OD) δ 7.09 (m, 1H), 6.86 (m, 1H), 6.71 (m, 1H), 4.43 (d, 0.33H), 4.36 (d, 0.67H), 3.73 (m, 1H), 2.71 (m, 2H), 2.57 (q, 1.34H), 2.50 (q, 0.66H), 2.25 (m, 3H), 2.12 (m, 0.66H), 1.82-2.04 (m, 1.34H), 1.25 (t, 2.01H), 1.21 (t, 1H).
    • EXAMPLE 189 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-fluorophenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(3-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0723]
  • MS(ESI) m/e 302 (M+H)[0724] +;
  • [0725] 1H NMR (400 MHz, CD3OD) δ 7.15 (m, 1H), 6.64 (m, 1H), 6.52 (m, 2H), 4.48 (d, 0.37H), 4.38 (d, 0.63H), 3.80 (m, 0.37H), 3.70 (m, 0.63H), 2.70 (m, 2H), 2.57 (q, 1.23H), 2.52 (q, 0.74H), 2.12 (m, 0.74H), 1.95 (m, 1.23H), 1.25 (t, 1.89H), 1.22 (t, 1.11H).
    • EXAMPLE 190 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′ (2-ethylphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(2-ethylphenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0726]
  • MS(ESI) m/e 312 (M+H)[0727] +;
  • [0728] 1H NMR (300 MHz, CD3OD) δ 7.07 (m, 111), 6.90 (m, 1H), 6.86 (m, 1H), 6.73 (m, 1H), 4.44 (d, 0.26H), 4.37 (d, 0.74H), 3.80 (m, 1H), 2.45-2.71 (m, 6H), 2.02 (m, 2H), 1.15-1.27 (m, 6H).
    • EXAMPLE 191 (2RS,3R)-3-amino-5-(ethylsulfanyl)2-hydroxy-N′-(4-fluorophenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(4-fluorophenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example 1C in Example 1D. [0729]
  • MS(ESI) mn/e 302 (M+H)[0730] +;
  • [0731] 1H NMR (300 MHz, CD3OD) δ 6.96 (m, 2H), 6.84 (m, 2H), 4.42 (d, 0.41H), 4.35 (d, 0.59H), 3.74 (m, 1H), 2.61-2.81 (m, 2H), 2.57 (q, 1.18H), 2.51 (q, 0.82H), 2.02-2.24 (m, 0.82H), 1.81-2.02 (m, 1.18H), 1.26 (t, 1.77H), 1.22 (t, 1.23H).
    • EXAMPLE 192 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxv-N′-(4-trifluoromethoxyphenyl)pentanohydrazide
  • The desired product was prepared by substituting 1-(4-(trifluoromethoxy)phenyl)hydrazine for 1-benzylhydrazine dihydrochloride and Example 98A for Example IC in Example ID. [0732]
  • MS(ESI) m/e 368 (M+H)[0733] +;
  • [0734] 1H NMR (300 MHz, CD3OD) δ 7.00-7.20 (m, 2H), 6.87 (m, 2H), 4.44 (d, 0.42H), 4.37 (d, 0.58H), 3.63-3.83 (m, 1H), 2.71 (m, 2H), 2.57 (q, 1.16H), 2.51 (q, 0.84H), 2.11 (m, 0.84H), 1.82-2.03 (m, 1.16H), 1.25 (t, 1.74H), 1.22 (t, 1.26H).
    • EXAMPLE 193 (2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N′-(4-methylphenyl)butanohydrazide
  • To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt (0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL of a 0.3M solution of Example 97A (0.15 mmol) in dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of 4-methylphenylhydrazine (0.225 mmol) in dimethylacetamide/dichloromethane (1:1) was added. The mixture was agitated for 18 hours and quenched with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture was filtered and the resins washed with lx3 niL of dichloromethane, the solvent was removed in vacuo, and the crude material purified by reverse phase preparative BPLC. The resulting material was treated with 1 mL of 50% trifluoroacetic acid/dichloromethane and agitated at ambient temperature for 18 hours. The solvent was removed in vacuo to give the desired product. [0735]
  • MS(ESI) m/e 284 (M+H)[0736] +;
  • [0737] 1H NMR (500 MHz, CD3OD) δ 7.02 (m, 2H), 6.77 (m, 2H), 4.51 (d, 0.65H), 4.39 (d, 0.35H), 3.77 (m, 1H), 2.96 (dd, 1H), 2.76 (dd, 1H), 2.63 (dd, 1.3H), 2.57 (dd, 0.7H), 2.23 (s, 3H), 1.28 (t, 1.95H), 1.23 (t, 1.05H).
    • EXAMPLE 194 (2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)propanohydrazide
  • The desired product was prepared by substituting Example 122A for Example 97A in Example 193. [0738]
  • MS(ESI) m/e 292 (M+H)[0739] +;
  • [0740] 1H NMR (500 MHz, CD3OD) δ 7.02 (m, 2H), 6.77 (m, 2H), 4.45 (d, 0.65H), 4.43 (d, 0.35H), 3.27 (m, 1H), 2.23 (s, 3H), 1.87-1.72 (m, 6H), 1.36-1.12 (m, 5H).
    • EXAMPLE 195 (2RS,3S)-3-amino-2-hydroxy-N′-(4-methylphenyl)-4-(propylsulfanyl)butanohydrazide EXAMPLE 195A (2S)-2-((tert-butoxycarbonyl)amino)-3-(propylsulfanyl)propanoic acid
  • The desired product was prepared by substituting 1-bromopropane for 2-brompropane and D-cystine for D-homocystine in Example 123A. [0741]
    • EXAMPLE 195B (2RS,3S)-2-hydroxy-3-((tert-butoxycarbonyl)amino)-3-(propylsulfanyl)propanoic acid
  • The desired product was prepared by substituting Example 195A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0742]
  • MS(ESI) m/e 294 (M+H)[0743] +.
    • EXAMPLE 195C (2RS,3S)-3-amino-2-hydroxy-N′-(4-methylphenyl)-4-(propylsulfanyl)butanohydrazide
  • The desired product was prepared by substituting Example 195B for Example 97A in Example 193. [0744]
  • MS(ESI) m/e 298 (M+H)[0745] +;
  • [0746] 1H NMR (500 MHz, CD3OD) δ 7.02 (dd, 2H), 6.77 (dd, 2H), 4.50 (d, 0.65H), 4.48 (d, 0.35H), 3.76 (m, 0.65H), 3.67-3.58 (m, 0.35H), 2.93 (dd, 0.65H), 2.84 (dd, 0.35H), 2.75 (m, 1H), 2.58 (dd, 1H), 2.51 (m, 1H), 2.23 (s, 3H), 1.65 (dd, 1H), 1.57 (dd, 1H), 1.02 (t, 1.95 H), 0.98 (t, 1.05H).
    • EXAMPLE 196 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(4-methylphenyl)pentanohydrazide
  • The desired product was prepared by substituting Example 123B for Example 97A in Example 193. [0747]
  • MS(ESI) m/e 312 (M+H)[0748] +;
  • [0749] 1H NMR (500 MHz, CD3OD) δ 7.01 (dd, 2H), 6.77 (d, 2H), 4.40 (d, 0.35H), 4.33 (d, 0.65H), 3.66 (m, 1H), 2.96 (dd, 0.65H), 2.89 (dd, 0.35H), 2.69 (m, 1.65H), 2.58 (m, 0.35H), 2.23 (s, 3H), 2.09 (dd, 0.65H), 1.96 (dd, 0.35H), 1.89 (dd, 1H), 1.27 (d, 3 H), 1.26 (d, 3H).
    • EXAMPLE 197 (2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N′-(4-methylphenyl)butanohydrazide
  • The desired product was prepared by substituting Example 124B for Example 97A in Example 193. [0750]
  • MS(ESI) m/e 312 (M+H)[0751] +;
  • [0752] 1H NMR (500 MHz, CD3OD) δ 7.02 (d, 2H), 6.77 (d, 2H), 4.52 (d,1H), 3.65 (ddd, 1H), 2.94 (dd, 1H), 2.75 (dd, 1H), 2.51 (d, 2H), 2.23 (s, 3H), 1.82 (ddd, 1H), 1.02 (d, 6H).
    • EXAMPLE 198 (2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(4-methylphenyl)pentanohydrazide
  • The desired product was prepared by substituting Example 125A for Example 97A in Example 193. [0753]
  • MS(ESI) m/e 314 (M+H)[0754] +;
  • [0755] 1H NMR (500 MHz, CD3OD) δ 7.30 (m, 2H), 7.25-7.18 (m, 3H), 6.97 (m, 2H), 6.74 (m, 2H), 4.43 (d, 0.5H), 4.40 (d, 0.5H), 3.57 (m, 1H), 2.78 (m, 1.5H), 2.67 (m, 0.5H), 2.27 (m, 0.5H), 2.23 (s, 1.5H), 2.21 (s, 1.5H), 2.14 (m, 0.5H), 2.00 (m, 0.5H), 1.93 (m, 0.5H).
    • EXAMPLE 199 (2S ,3R)-3-amino-3-cyclooctyl-2-hvdroxy-N′-(4-methylphenyl)propanohydrazide EXAMPLE 199A (2S,3R)-3-(tertbutoxycarbonyl)amino-3-cyclooctyl-2-hydroxy-propanoic acid
  • The desired product was prepared by substituting cyclooctyl aldehyde for 2-ethylhexanal in Examples 236A-236C. [0756]
    • EXAMPLE 199B (2S,3R)-3-amino-3-cyclooctyl-2-hydroxy-N′-(4-methylphenyl)propanohydrazide
  • The desired product was prepared by substituting Example 199A for Example 97A in Example 193. [0757]
  • MS(ESI) m/e 320 (M+H)[0758] +;
  • [0759] 1H NMR (500 MHz, CD3OD) δ 7.02 (d, 2H), 6.77 (m, 2H), 4.46 (d, 0.35H), 4.38 (d, 0.65H), 3.85 (m, 1H), 3.78 (m, 1H), 2.25 (s, 1.05H), 2.23 (s, 2.95H), 1.80-1.50 (m, 14H).
    • EXAMPLE 200 (2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N′-(4-methylphenyl)butanohydrazide EXAMPLE 200A (2S)-2-((tert-butoxycarbonyl)amino)-3-(cyclohexylmethylsulfanyl)propanoic acid
  • The desired product was prepared by substituting cyclohexylmethyl bromide for 2-brompropane and D-cystine for D-homocystine in Example 123A. [0760]
    • EXAMPLE 200B (2RS,3S)-2-((tert-butoxycarbonyl)amino)-3-(cyclohexylmethylsulfanyl)propanoic acid
  • The desired product was prepared by substituting Example 200A for (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid in Examples 1A-C. [0761]
    • EXAMPLE 200C (2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-(4 methylphenyl)butanohydrazide
  • The desired product was prepared by substituting Example 200B for Example 97A in Example 193. [0762]
  • MS(ESI) m/e 298 (M+H)[0763] +;
  • [0764] 1H NMR (500 MHz, CD3OD) δ 7.02 (dd, 2H), 6.77 (d, 2H), 4.52 (d, 0.65H), 4.50 (d, 0.35H), 3.76 (m, 0.35H), 3.67-3.58 (m, 0.65H), 2.93 (dd, 0.65H), 2.82 (dd, 0.35H), 2.75 (m, 1H), 2.48 (m, 1H), 2.41 (m, 1H), 2.23 (s, 3H), 1.86 (m, 2H), 1.75-1.66 (m, 3H), 1.47 (m, 1H), 1.32-1.15 (m, 3H), 1.00 (m, 2H).
    • EXAMPLE 201 (2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N′-(1-naphthyl)butanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine in Example 193. [0765]
  • MS(ESI) m/e 320 (M+H)[0766] +;
  • [0767] 1H NMR (500 MHz, CD3OD) δ 8.07 (m, 1H), 7.81 (ddd, 1H), 7.47 (ddd, 2H), 7.39 (dd, 1H), 7.33 (ddd, 1H), 6.91 (dd, 1H), 4.62 (d, 0.65H), 4.60 (d, 0.3511), 4.51 (m, 0.5H), 3.71 (m, 1H), 3.00 (dd, 0.5H), 2.81 (m, 1H), 2.65 (dd, 1.3H), 2.60 (dd, 0.7H), 1.30 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 202 (2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N′-(1-naphthyl)propanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine and Example 122A for Example 97A in Example 193. [0768]
  • MS(ESI) m/e 328 (M+H)[0769] +;
  • [0770] 1H NMR (500 MHz, CD3OD) δ 8.08 (m, 1H), 7.82 (ddd, 1H), 7.47 (ddd, 2H), 7.39 (d, 1H), 7.33 (m, 1H), 6.91 (dd, 1H), 4.56 (d, 0.65H), 4.53 (d, 0.35H), 3.37 (dd, 1H), 1.99-1.72 (m, 6H), 1.39-1.12 (m, 5H).
    • EXAMPLE 203 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(1-naphthyl)pentanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine and Example 123B for Example 97A in Example 193. [0771]
  • MS(ESI) m/e 348 (M+H)[0772] +;
  • [0773] 1H NMR (500 MHz, CD3OD) δ 8.07 (m, 1H), 7.81 (ddd, 1H), 7.47 (ddd, 2H), 7.39 (m, 1H), 7.34 (m, 1H), 6.90 (dd, 1H), 4.51 (d, 0.35H), 4.46 (d, 0.65H), 3.76 (m, 1H), 2.99 (dd, 0.65H), 2.93 (dd, 0.35H), 2.74 (m, 1.65H), 2.69 (m, 0.35H), 2.17 (dd, 0.65H), 2.05 (dd, 0.35H), 1.95 (dd, 1H), 1.29 (d, 3 H), 1.27 (d, 3H).
    • EXAMPLE 204 (2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N′-(1-naphthyl)butanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193. [0774]
  • MS(ESI) m/e 347 (M+H)[0775] +;
  • [0776] 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 1H), 7.82 (ddd, 1H), 7.48 (ddd, 2H), 7.41 (m, 1H), 7.33 (t, 1H), 6.92 (d, 1H), 4.63 (d, 1H), 3.70 (ddd, 1H), 2.99 (dd, 1H), 2.80 (dd, 1H), 2.53 (d, 2H), 1.84 (ddd, 1H), 1.03 (d, 6H).
    • EXAMPLE 205 (2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(1-naphthyl)pentanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine and Example 125A for Example 97A in Example 193. [0777]
  • MS(ESI) m/e 350 (M+H)[0778] +;
  • [0779] 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 1H), 7.80 (m, 1H), 7.46 (rn, 2H), 7.37 (m, 1H), 7.31 (dd, 1H), 7.25 (m, 5H), 6.86 (dd, 1H), 4.53 (d, 0.5H), 4.51 (d, 0.5H), 3.65 (m, 0.5H), 3.60 (m, 0.5H), 2.82 (m, 1.5H), 2.72 (m, 0.5H), 2.20 (m, 0.5H), 2.08 (m, 1H), 1.98 (m, 0.5H).
    • EXAMPLE 206 (2RS,3R)-3-amino-3-cvclooctyl-2-hydroxy-N′-(1-naphthyl)propanohydrazide
  • The desired product was prepared by substituting 1-napthylhydrazine for 4-methylphenylhydrazine and Example 199A for Example 97A in Example 193. [0780]
  • MS(ESI) m/e 356 (M+H)[0781] +;
  • [0782] 1H NMR (500 MHz, CD3OD) δ 8.08 (m, 1H), 7.84 (m, 1H), 7.49 (m, 2H), 7.41 (m, 1H), 7.32 (t, 1H), 6.97 (ddd, 1H), 4.49 (d, 0.5H), 3.99 (d, 0.5H), 3.85 (m, 1H), 1.80-1.52 (m, 15H).
    • EXAMPLE 207 N′-((2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine in Example 193. [0783]
  • MS(ESI) m/e 332 (M+H)[0784] +;
  • [0785] 1H NMR (500 MHz, CD3OD) δ 7.91 (m, 1H), 7.81 (m, 1H), 7.62 (m, 1H), 7.51 (m, 1H), 4.63 (d, 0.65H), 4.58 (d, 0.35H), 3.70 (m, 1H), 3.00 (dd, 1H), 2.84 (m, 1H), 2.66 (dd, 1.3H), 2.62 (dd, 0.7H), 1.31 (t, 1.95H), 1.29 (t, 1.05H).
    • EXAMPLE 208 N′-((2RS,3R)-3-amino-3-cyclohexvl-2-hydroxypropanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 122A for Example 97A in Example 193. [0786]
  • MS(ESI) m/e 340 (M+H)[0787] +;
  • [0788] 1H NMR (500 MHz, CD3OD) δ 7.91 (m, 1H), 7.82 (m, 1H), 7.62 (m, 1H), 7.50 (m, 1H), 4.56 (d, 0.65H), 4.52 (d, 0.35H), 3.33 (m, 1H), 1.95 (m, 1H), 1.86 (m, 4H), 1.74 (m, 1H), 1.35 (m, 2H), 1.24 (m, 1H), 1.16 (m, 2H).
    • EXAMPLE 209 N′-((2RS,3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 195B for Example 97A in Example 193. [0789]
  • MS(ESI) m/e 346 (M+H)[0790] +;
  • [0791] 1H NMR (500 MHz, CD3OD) δ 7.91 (ddd, 1H), 7.81 (ddd, 1H), 7.62 (ddd, 1H), 7.50 (m, 1H), 4.63 (d, 0.65H), 4.58 (d, 0.35H), 3.70 (m, 1H), 3.17 (dd, 0.35H), 2.98 (dd, 0.65H), 2.84 (dd, 0.65H), 2.80 (dd, 0.35H), 2.60 (m, 2H), 1.66 (m, 2H), 1.03 (t, 1.95 H), 1.01 (t, 1.05H).
    • EXAMPLE 210 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 123B for Example 97A in Example 193. [0792]
  • MS(ESI) m/e 360 (M+H)[0793] +;
  • [0794] 1H NMR (500 MHz, CD3OD) δ 7.90 (dt, 1H), 7.81 (m, 1H), 7.62 (m, 1H), 7.50 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 211 N′-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 124B for Example 97A in Example 193. [0795]
  • MS(ESI) m/e 360 (M+H)[0796] +;
  • [0797] 1H NMR (500 MHz, CD3OD) δ 7.91 (dd, 1H), 7.82 (ddd, 1H), 7.63 (ddd, 1H), 7.51 (t, 1H), 4.64 (d, 1H), 3.70 (ddd, 1H), 2.97 (dd, 1H), 2.83 (dd, 1H), 2.53 (d, 2H), 1.85 (ddd, 1H), 1.04 (d, 6H).
    • EXAMPLE 212 N′-((2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 125A for Example 97A in Example 193. [0798]
  • MS(ESI) m/e 362 (M+H)[0799] +;
  • [0800] 1H NMR (500 MHz, CD3OD) δ 7.91 (m, 1H), 7.81 (ddd, 1H), 7.61 (ddd, 1H), 7.50 (m, 1H), 7.29 (m, 4H), 7.20 (m, 1H), 4.50 (m, 1H), 3.62 (m, 1H), 2.80 (m, 2H), 2.20 (m, 1H), 2.02 (m, 1H).
    • EXAMPLE 213 N′-((2RS,3R)-3-amino-3-cyclooctyl-2-hydroxypropanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 199A for Example 97A in Example 193. [0801]
  • MS(ESI) m/e 368 (M+H)[0802] +;
  • [0803] 1H NMR (500 MHz, CD3OD) δ 7.90 (m, 1H), 7.82 (m, 1H), 7.62 (ddd, 1H), 7.50 (t, 1H), 3.95 (d, 1H), 3.82 (t, 1H), 1.81 (m, 4H), 1.68 (m, 4H), 1.55 (m, 7H).
    • EXAMPLE 214 N′-((2RS,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 238A for Example 97A in Example 193. [0804]
  • MS(ESI) m/e 367 (M+H)[0805] +;
  • [0806] 1H NMR (500 MHz, CD3OD) δ 7.89 (dd, 1H), 7.80 (d, 111), 7.62 (ddd, 1H), 7.50 (t, 1H), 3.90 (m, 1H), 3.78 (d, 1H), 1.81-1.72 (m, 5H), 1.68 (m, 1H), 1.54 (m, 2H), 1.29 (m, 4H), 1.21 (m, 1H), 0.96 (m, 2H).
    • EXAMPLE 215 (2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)pentanohydrazide
  • The desired product was prepared by substituting Example 238A for Example 97A in Example 193. [0807]
  • MS(ESI) m/e 320 (M+H)[0808] +;
  • [0809] 1H NMR (500 MHz, CD3OD) δ 7.07 (d, 0.5H), 7.00 (d, 1.5H), 6.77 (m, 2H), 3.81 (m, 1H), 3.62 (d, 1H), 2.22 (s, 3H), 1.77-1.60 (m, 6H), 1.50 (m, 2H), 1.29-1.17 (m, 6H), 0.97-0.91 (m, 1H).
    • EXAMPLE 216 (2RS,3S)-3-amino-2-hydroxy-N′-(1-naphthyl)-4-(propylsulfanyl)butanohydrazide
  • The desired product was prepared by substituting 1-naphthylhydrazine for 4-methylphenylhydrazine and Example 195B for Example 97A in Example 193. [0810]
  • MS(ESI) m/e 334 (M+H)[0811] +;
  • [0812] 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 1H), 7.81 (ddd, 1H), 7.47 (ddd, 2H), 7.39 (d, 1H), 7.34 (m, 1H), 6.90 (dd, 1H), 4.62 (d, 0.65H), 4.59 (d, 0.35H), 3.71 (m, 1H), 2.99 (dd, 0.65H), 2.92 (dd, 0.35H), 2.81 (m, 1H), 2.60 (dd, 1H), 2.54 (m, 1H), 1.66 (dd, 1H), 1.59 (dd, 1H), 1.02 (t, 1.95 H), 0.98 (t, 1.05H).
    • EXAMPLE 217 (2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N′-(1-naphthyl)pentanohydrazide
  • The desired product was prepared by substituting 1-naphthylhydrazine for 4-methylphenylhydrazine and Example 238A for Example 97A in Example 193. [0813]
  • MS(ESI) m/e 356 (M+H)[0814] +;
  • [0815] 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 1H), 7.81 (m, 1H), 7.47 (m, 2H), 7.41 (m, 1H), 7.31 (t, 1H), 6.95 (dd, 1H), 3.91 (m, 1H), 3.78 (d, 1H), 1.74 (m, 5H), 1.55 (m, 2H), 1.28 (m, 4H), 1.20 (m, 2H), 0.97 (m, 2H).
    • EXAMPLE 218 (2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-(1-naphthyl)butanohydrazide
  • The desired product was prepared by substituting 1-naphthylhydrazine for 4-methylphenylhydrazine and Example 200B for Example 97A in Example 193. [0816]
  • MS(ESI) m/e 388 (M+H)[0817] +;
  • [0818] 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 1H), 7.81 (ddd, 1H), 7.47 (ddd, 2H), 7.39 (dd, 1H), 7.32 (m, 1H), 6.90 (dd, 1H), 4.62 (d, 0.65H), 4.58 (d, 0.35H), 3.68 (m, 1H), 2.96 (dd, 1H), 2.83 (dd, 0.35H), 2.77 (dd, 0.65H), 2.51 (d, 1.5H), 2.44 (d, 0.5H), 1.88 (m, 2H), 1.75-1.66 (m, 3H), 1.50 (m, 1H), 1.22, (m, 3H), 0.98 (m, 2H).
    • EXAMPLE 219 N′-((2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazide for 4-methylphenylhydrazine and Example 200B for Example 97A in Example 193. [0819]
  • MS(ESI) m/e 401 (M+H)[0820] +;
  • [0821] 1H NMR (500 MHz, CD3OD) δ 7.91 (m, 1H), 7.81 (dd, 1H), 7.61 (ddd, 1H), 7.50 (t, 1H), 4.63 (d, 0.65H), 4.56 (d, 0.35H), 3.68 (m, 1H), 2.95 (dd, 1H), 2.81 (dd, 1H), 2.78 (dd, 0.35H), 2.52 (d, 1H), 2.46 (m, 0.65H), 1.88 (m, 2H), 1.76-1.64 (m, 3H), 1.51 (m, 1H), 1.32-1.16 (m, 3H), 0.99 (m, 2H).
    • EXAMPLE 220 (2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(1-naphthyl)pentanohydrazide
  • The desired product was prepared by substituting 2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 125A for Example 98A in Example 98B. [0822]
  • MS(ESI) m/e 378 (M+H)[0823] +;
  • [0824] 1H NMR (300 MHz, DMSO-d6) δ10.73 (br s, 1H), 10.32 (br s, 1H), 8.52 (s, 1H), 8.04 (m, 6H), 7.65 (m, 2H), 7.30 (m, 5H), 6.69 (m, 1H), 4.32 (m, 1H), 2.74 (m, 2H), 2.06 (m, 1H), 1.89 (m, 1H).
    • EXAMPLE 221 N′-((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-2-naphthohydrazide
  • The desired product was prepared by substituting 2-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and Example 122A for Example 98A in Example 98B. [0825]
  • MS(ESI) m/e 356 (M+H)[0826] +;
  • [0827] 1H NMR (300 MHz, DMSO-d6) δ 10.60 (s, 1H), 10.29 (s, 1H), 8.51 (s, 1H), 8.07 (m, 4H), 7.80 (br s, 2H), 7.64 (m, 2H), 6.54 (m, 1H), 4.41 (m, 1H), 1.77-1.44 (m, 6H), 1.20-0.94 (m, 5H).
    • EXAMPLE 222 N′-((2RS,3R)-3-amino-2-hydroxy-5-isopropylsulfanylpentanovl)-2-naphthohydrazide
  • The desired product was prepared by substituting 2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [0828]
  • MS(ESI) mle 376 (M+H)[0829] +;
  • [0830] 1H NMR (300 MHz, DMSO-d6) δ 10.56 (br s, 0.7H), 10.47 (br s, 0.3H), 9.90 (br s, 0.3H), 9.83 (br s, 0.7H), 8.75 (s, 0.3H), 8.51 (s, 0.7H), 8.00 (m, 3H), 7.63 (m, 2H), 7.38 (m, 1H), 7.22 (m, 1H), 6.89 (m, 1H), 6.18 (m, 1H), 4.21 (m, 0.7H), 4.13 (m, 0.3H), 2.96 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.91 (m, 111), 1.73 (m, 1H), 1.21 (d, 6H).
    • EXAMPLE 223 N′-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-2-naphthohydrazide
  • The desired product was prepared by substituting 2-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and Example 124B for Example 98A in Example 98B. [0831]
  • MS(ESI) m/e 376 (M+H)[0832] +;
  • [0833] 1H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.04 (m, 6H), 7.65 (m, 2H), 6.74 (m, 1H), 4.40 (m, 1H), 2.94 (dd. 1H), 2.72 (dd, 1H), 2.48 (d, 2H), 1.80 (m, 1H), 0.98 (d, 6H).
    • EXAMPLE 224 N′-((2S,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide EXAMPLE 224A N′-((2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide
  • A solution of Example 123B (0.20 g, 0.65 mmol), 3-chlorobenzoyl hydrazine (0.17 g, 1.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.13 g, 0.68 mmol), 1-hydroxybenzotriazole (0.11 g, 0.81 mmol), and N-methylmorpholine (0.070 mL, 0.64 mmol) in dichloromethane (6 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO[0834] 3, brine, 10% KHSO4, and brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by HPLC on silica gel with 4:1/hexanes:acetone to provide the desired product.
  • MS(ESI) m/e 460 (M+H)+. [0835]
    • EXAMPLE 224B N′-((2S ,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting Example 224A for Example 118A in Example 118B. [0836]
  • MS(ESI) m/e 360 (M+H)[0837] +;
  • [0838] 1H NMR (300 MHz, DMSO-d6) δ 11.60 (br s, 1H), 10.30 (br s, 1H), 8.01 (br s, 2H), 7.92 (m, 1H), 7.85 (d, 1H), 7.69 (m, 1H), 7.57 (t, 1H), 6.67 (d, 1H), 4.26 (m, 1H), 2.97 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.97 (m, 1H), 1.85 (m, 1H), 1.21 (d, 6H).
    • EXAMPLE 225 N′-((2S ,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzohydrazide EXAMPLE 225A N′-((2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting Example 98A for Example 123B in Example 224A. [0839]
  • MS(ESI) m/e 446 (M+H)[0840] +.
    • EXAMPLE 225B N′-((2S ,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting Example 225A for Example 118A in Example 118B. [0841]
  • MS(ESI) m/e 346 (M+H)[0842] +;
  • [0843] 1H NMR (300 MHz, DMSO-d6) δ10.68 (br s, 1H), 10.29 (br s, 1H), 7.99 (br s, 2H), 7.91 (m, 1H), 7.84 (m, 1H), 7.69 (m, 1H), 7.57 (t, 1H), 6.67 (d, 1H), 4.25 (m, 1H), 3.40 (m, 1H), 2.67 (m, 2H), 2.50 (m, 2H), 1.99 (m, 1H), 1.85 (m, 1H), 1.19 (t, 3H).
    • EXAMPLE 226 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide
  • The desired product was prepared by substituting 1-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and Example 1C for Example 98A in Example 98B. [0844]
  • MS(ESI) m/e 370 (M+H)[0845] +;
  • [0846] 1H NMR (300 MHz, DMSO-d6) δ 10.53 (br s, 1H), 10.34 (br s, 1H), 8.34 (dd, 1H), 8.08 (d, 1H), 8.01 (m, 1H), 7.85 (br s, 2H), 7.66 (m, 1H), 7.59 (m, 3H), 6.61 (d, 1H), 4.20 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 227 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxy-2-naphthohydrazide
  • The desired product was prepared by substituting 3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example iC for Example 98A in Example 98B. [0847]
  • MS(ESI) m/e 386 (M+H)[0848] +;
  • [0849] 1H NMR (300 MHz, DMSO-d6) δ 11.44 (br s, 1H), 10.70 (br s, 1H), 10.58 (br s, 1H), 8.52 (s, 1H), 7.93 (d, 1H), 7.79 (m, 3H), 7.53 (t, 1H), 7.38 (d, 1H), 7.43 (s, 1H), 6.61 (d, 1H), 4.22 (m, 1H), 1.74-1.60 (m, 6H), 1.50-1.40 (m, 1H), 1.33-1.15 (m, 4H), 0.96-0.80 (m, 2H).
    • EXAMPLE 228 N′-((2RS 3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthohydrazide
  • The desired product was prepared by substituting 1-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0850]
  • MS(ESI) m/e 362 (M+H)[0851] +;
  • [0852] 1H NMR (300 MHz, DMSO-d6) δ 10.54 (br s, 1H), 10.37 (br s, 1H), 8.34 (br s, 1H), 8.01 (m, 3H), 7.59 (m, 4H), 6.68 (d, 0.7H), 6.60 (d, 0.3H), 4.40 (m, 0.3H), 4.26 (m, 0.7H), 3.39 (m, 1H), 2.70 (m, 2H), 2.54 (m, 2H), 2.06 (m, 1H), 1.87 (m, 1H), 1.19 (t, 3H).
    • EXAMPLE 229 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-hydroxy-2-naphthohydrazide
  • The desired product was prepared by substituting 3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [0853]
  • MS(ESI) m/e 378 (M+H)[0854] +;
  • [0855] 1H NMR (300 MHz, DMSO-d6) δ11.45 (br s, 1H), 10.69 (br s, 1H), 10.58 (br s, 1H), 8.52 (br s, 1H), 8.03 (br s, 2H), 7.90 (m, 2H), 7.77 (m, 1H), 7.53 (t, 1H), 7.38 (d, 1H), 7.33 (m, 1H), 6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.40 (m, 0.4H), 4.29 (m, 0.6H), 3.39 (m, 1H), 2.66 (m, 2H), 2.54 (m, 2H), 1.97 (m, 1H), 1.87 (m, 1H), 1.20 (t, 3H).
    • EXAMPLE 230 N′-((2S,3R)-3-amino-2-hydroxv-5-phenylpentanoyl)-1-naphthohydrazide
  • The desired product was prepared by substituting 1-naphthoylhydrazine for 0-phenyl hydroxylamine hydrochloride and Example 125A for Example 98A in Example 98B. [0856]
  • MS(ESI) m/e 378 (M+H)[0857] +;
  • [0858] 1H NMR (300 MHz, DMSO-d6) δ 10.54 (br s, 1H), 10.38 (br s, 1H), 8.35 (m, 1H), 8.08 (m, 1H), 8.00 (br s, 2H), 7.59 (m, 4H), 7.29 (m, 5H), 7.18 (m, 1H), 6.68 (m, 1H), 4.31 (m, 1H), 2.74 (m, 2H), 2.06 (m, 1H), 1.89 (m, 1H).
    • EXAMPLE 231 N′-((2S ,3R)-3-amino-2-hvdroxv-5-phenylpentanoyl)-3-hydroxv-2-naphthohydrazide
  • The desired product was prepared by substituting 3-hydroxy-2-naphthoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 125A for Example 98A in Example 98B. [0859]
  • MS(ESI) m/e 394 (M+H)[0860] +;
  • [0861] 1H NMR (300 MHz, DMSO-d6) δ 11.43 (br s, 1H), 10.70 (br s, 1H), 10.58 (br s, 1H), 8.52 (s, 1H), 7.94 (m, 3H), 7.77 (d, 1H), 7.53 (t, 1H), 7.30 (m, 7H), 6.69 (d, 1H), 4.35 (m, 1H), 2.72 (m, 2H), 1.99 (m, 1H), 1.91 (m, 1H).
    • EXAMPLE 232 (2S ,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide EXAMPLE 232A (2S,3R)-3-((tert-butoxycarbonyl)amino)-4-cyclohexyl-2-hydroxybutanoic acid pentafluorophenyl ester
  • The title compound was prepared by substituting Example 1C for Example 124A in Example 126B. [0862]
  • MS(ESI) m/e 466 (M-H)+. [0863]
    • EXAMPLE 232B (2S ,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide
  • The title compound was prepared by substituting Example 232A for Example 126B and anhydrous hydrazine for Example 126A in Example 126C. [0864]
  • MS(ESI) m/e 216 (M+H)[0865] +.
  • [0866] 1H NMR (300 MHz, DMSO-d6) δ 11.05 (br s, 1H), 7.97 (br s, 2H), 6.75 (br s, 1H), 4.22 (d, 2H), 1.74-1.60 (m 6H), 1.42 (d, 2H), 1.28-1.10 (m, 3H), 0.92-0.74 (m, 2H).
    • EXAMPLE 233 N′-((2R,3R)-3-amino-2-hydroxv-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide EXAMPLE 233A N-((2R,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide
  • The desired product was prepared by substituting Example 98A for Example 123B in Example 224A. [0867]
  • MS(ESI) m/e 446 (M+H)+. [0868]
    • EXAMPLE 233B N′-((2R,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide
  • The desired product was prepared by substituting Example 233A for Example 118A in Example 118B. [0869]
  • MS(ESI) m/e 346 (M+H)[0870] +;
  • [0871] 1H NMR (300 MHz, DMSO-d6) δ 10.52 (br s, 1H), 10.20 (br s, 1H), 8.07 (br s, 2H), 7.90 (m, 1H), 7.83 (m, 1H), 7.67 (m, 1H), 7.56 (t, 1H), 6.60 (d, 1H), 4.39 (m, 1H), 3.57 (m, 1H), 2.69 (m, 2H), 2.53 (m, 2H), 1.95 (m, 1H), 1.86 (m, 1H), 1.18 (t, 3H).
    • EXAMPLE 234 N′-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide EXAMPLE 234A N′-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide
  • The desired product was prepared as described in Example 224A. [0872]
  • MS(ESI) m/e 460 (M+H)[0873] +.
    • EXAMPLE 234B N′-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide
  • The desired product was prepared by substituting Example 234A for Example 118A in Example 118B. [0874]
  • MS(ESI) m/e 360 (M+H)[0875] +;
  • [0876] 1H NMR (300 MHz, DMSO-d6) δ10.52 (br s, 1H), 10.18 (br s, 1H), 8.11 (br s, 2H), 7.90 (m, 1H), 7.84 (d, 1H), 7.64 (m, 1H), 7.56 (t, 1H), 6.59 (d, 1H), 4.42 (m, 1H), 2.97 (m, 1H), 2.69 (m, 1H), 2.62 (m, 1H), 1.89 (m, 2H), 1.20 (d, 6H).
    • EXAMPLE 235 3-(2-aminoethyl)-N′-((2S,3S)-3-amino-2-hydroxy-4-(isobutvlsulfanyl)butanoyl)benzohvdrazide EXAMPLE 235A methyl 3-(cyanomethyl)benzoate
  • A solution of methyl 3-(bromomethyl)benzoate (2.29 g, 0.01 mol) and potassium cyanide (3.26 g, 0.05 mol) in DMSO (20 mL) was heated to 100° C. for 1 h. The reaction mixture was cooled, partitioned between ether and water, washed with brine, dried (Na[0877] 2SO4) and concentrated to give the title compound.
  • MS(ESI) m/e 193 (M+NH4)+. [0878]
    • EXAMPLE 235B 3-(2-(tertbutoxvcarbonylamino)ethyl)benzoyl hydrazide
  • A solution of Example 235A (1.23 g, 7 mmol) in methanol (15 mL) was hydrogenated in the presence of RaNi (2.5 g) for 18h. After filtration and evaporation of the solvent, the resulting oil (0.1 g, 0.6 mmol) was dissolved in dichloromethane (5 mL), treated with di-tert-butyl dicarbonate (0.13 g, 0.6 mmol) for 16 h at room temperature. The solvent was evaporated and the residue treated with hydrazine hydrate (0.2 mL, 6.0 mmol) in ethanol at reflux for 48h. After the solvent was evaporated, and the residue purified by silica gel chromatography (10:90/methanol:dichloromethane) to give the title compound. [0879]
  • MS(ESI) m/e 280 (M+H)[0880] +.
    • EXAMPLE 235C 3-(2-aminoethyl)-N′-((2S,3S)-3-amino-2-hydroxy4-(isobutylsulfanyl)butanoyl)benzohydrazide
  • The title compound was prepared by substituting Example 235B for Example 126A in Example 126C. [0881]
  • MS(ESI) m/e 367 (M-H)[0882] +.
  • [0883] 1H NMR (300 MHz, DMSO-d6) δ 10.62 (s, 1H), 10.27 (s, 1H), 8.12 (br s, 2H), 8.0 (br s, 2H), 7.78 (m, 2H), 7.5 (m, 2H), 6.74 (d, 1H), 4.4 (t, 1H), 3.7 (m, 2H), 2.92 (m, 3H), 2.75 (m, 1H), 2.48 (d, 2H), 1.84-1.7 (m, 1H), 0.97 (d, 6H).
    • EXAMPLE 236 N′-((2S,3R,4RS)-3-amino-4-ethvl-2-hydroxyoctanoyl)-3-chlorobenzohydrazide EXAMPLE 236A Ethyl 4-ethyl-oct-2-enoate
  • A solution of 2-ethyl-hexanal (5.0 g, 39 mmol), triethyl phosphonoacetate (8.0 mL, 40 mmol), lithium bromide (3.65 g, 42 mmol), and triethylamine (5.6 mL, 40 mmol) in tetrahydrofuran (160 niL) at room temperature was stirred for 16 hours, quenched with water, stirred for 15 minutes, diluted with ethyl acetate, washed sequentially with pH 7 buffer and brine, dried (MgSO[0884] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 1:1/dichloromethane:hexanes to provide the desired product.
  • MS(ESI) rn/e 199 (M+H)+. [0885]
    • EXAMPLE 236B ethyl (2S ,3R,4RS)-3-(tert-butoxycarbonyl)amino-4-ethyl-2-hydroxyoctanoate
  • A solution of tert-butylcarbamate (2.85 g, 24 mmol), tert-butylhypochlorite (2.7 mL, 24 mmol), and 0.5 M NaOH (50 mL, 25 mmol) in 1-propanol (75 mL) at room temperature was stirred for 15 minutes. Example 236A (1.70 g, 8.6 mmol), potassium osmate dihydrate (0.27 g, 0.73 mmol) and hydroquinidine 1,4-phthalazinediyl diether (0.62 g, 0.80 mmol) were added, and the mixture stirred in an ice bath for 2 hours, diluted with ethyl acetate, washed sequentially with water, 1 M HCl, aqueous NaHCO[0886] 3, and brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 1:4/ethyl acetate:hexanes to provide the desired product.
  • MS(ESI) m/e 331 (M+H)[0887] +.
    • EXAMPLE 236C (2S,3R,4RS)-3-(tert-butoxycarbonvl)amino-4-ethyl-2-hydroxyoctanoic acid
  • A solution of Example 236B (0.168 g, 0.51 mmol), 30% hydrogen peroxide (0.25 mL, 2.2 mmol), and lithium hydroxide monohydrate (0.042 g, 1.0 mmol) in 3:1 tetrahydrofuran/water (7 mL) was stirred in an ice bath for 3 hours, then concentrated. The residues were taken up in water and the pH adjusted to 10 with NaOH. The solution was washed twice with ether, adjusted to pH 2 with HCl, then extracted twice with ethyl acetate. The ethyl acetate extracts were dried (MgSO[0888] 4), filtered, then concentrated to provide the desired product.
  • MS(ESI) m/e 304 (M+H)[0889] +.
    • EXAMPLE 236D N′-((2S,3R,4RS)-3-amino-4-ethyl-2-hydroxyoctanoyl)-3-chlorobenzohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 236C for Example 98A in Example 98B. [0890]
  • MS(ESI) m/e 356 (M+H)[0891] +;
  • [0892] 1H NMR (300 MHz, DMSO-d6) δ 8.17 (br s, 2H), 7.96 (m, 1H), 7.87 (d, 1H), 7.58 (m, 1H), 7.52 (t, 1H), 5.79 (m, 1H), 3.70 (m, 1H), 1.58 (m, 2H), 1.40-0.80 (m, 5H), 0.70 (t, 3H), 0.64 (m, 2H), 0.42 (t, 3H).
    • EXAMPLE 237 N′-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzohydrazide EXAMPLE 237A methyl 3-propoxybenzoate
  • The title compound was prepared by substituting 1-bromopropane for Example 364A in Example 364B. [0893]
  • [0894] 1H NMR (300 MHz, DMSO-d6) δ 7.54 (m, 1H), 7.43 (m, 2H), 7.23 (m, 1H), 3.98 (t, 2H), 3.84 (s, 3H), 1.8-1.66 (m, 2H), 0.99 (t, 3H).
    • EXAMPLE 237B N′-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzohydrazide
  • The title compound was prepared by substituting Example 237B for Example 126A in Example 126C. [0895]
  • MS(ESI) m/e 382 (M-H)+. [0896]
  • [0897] 1H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H), 10.24 (s, 1H), 8.07 (br s, 2H), 7.44 (m, 3H), 7.16 (m, 1H), 6.24 (d, 1H), 4.4 (t, 1H), 3.98 (t, 2H), 3.4 (m, 1H), 2.92 (dd, 1H), 2.73 (dd, 1H), 2.46 (d, 2H), 1.84-1.7 (m, 3H), 1.0 (t, 3H), 0.97 (d, 6H).
    • EXAMPLE 238 N′-((2S,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazide EXAMPLE 238A (2S 3R)-3-(tert-butoxycarbonyl)amino-5-cyclohexyl-2-hydroxypentanoic acid
  • The desired product was prepared by substituting 3-cyclohexylpropanal for 2-ethylhexanal in Examples 236A-236C. [0898]
  • MS(ESI) m/e 316 (M+H)[0899] +.
    • EXAMPLE 238B N′-((2S,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohYdrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 238A for Example 98A in Example 98B. [0900]
  • MS(ESI) m/e 368 (M+H)[0901] +;
  • [0902] 1H NMR (300 MHz, DMSO-d6) δ10.67 (br s, 1H), 10.27 (br s, 1H), 7.91 (m, 1H), 7.85 (m, 3H), 7.69 (d, 1H), 7.57 (t, 1H), 6.58 (m, 1H), 4.18 (m, 1H), 1.80-1.50 (m, 7H), 1.35-1.10 (m, 6H), 0.89 (m, 2H).
    • EXAMPLE 239 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-trifluoromethylsulfanylbenzohydrazide EXAMPLE 239A N′-((2RS,3R)-3-(tert-butoxycarbonyl)amino-5-(ethylsulfanYl)-2-hydroxypentanoyl)hydrazide
  • To a solution of Example 97A (2.00 g, 6.5 mmol) in acetonitrile (120 niL) was added HOAt (0.443 g, 3.3 mmol) and the mixture stirred for 5 min until homogeneous. To this solution was added DCC (2.00 g, 9.75 mmol) in acetonitrile (20 mL) and the mixture was stirred for 2 minutes. Hydrazine monohydrate (0.306 mL, 9.76 mmol) was added and the reaction stirred fo 16 hours. The solvent was removed in vacuo and the crude material filtered, the solid washed with dichloromethane, and the resulting oil was purified by column chromatography using ethyl acetate to give the desired product 1.2 g (60%). [0903]
    • EXAMPLE 239B N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxypentanoyl)-3-trifluoromethylsulfanylbenzohydrazide
  • To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt (0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL of a 0.3M solution of 3-(ethylsulfanyl)benzoic acid (0.15 mmol) in dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of Example 239A (0.225 mmol) in dimethylacetamide/dichloromethane (1:1) was added. The mixture was agitated for 18 hours and quenched with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture was filtered and the resins washed with 1×3 mL of dichloromethane, the solvent was removed in vacuo, and the crude material purified by reverse phase preparative HPLC. The resulting material was treated with 1 mL of 50% trifluoroacetic acid/dichloromethane and agitated at ambient temperature for 18 hours. The solvent was removed in vacuo to give the desired product. [0904]
  • MS(ESI) m/e 412 (M+H)[0905] +;
  • [0906] 1H NMR (500 MHz, CD3OD) δ 8.22 (d, 1H), 8.07 (dd, 1H), 7.93 (t, 1H), 7.65 (m, 1H), 4.49 (d, 0.35), 4.45 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 240 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-methylbenzohydrazide
  • The desired product was prepared by substituting 2-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0907]
  • MS(ESI) m/e 326 (M+H)[0908] +;
  • [0909] 1H NMR (500 MHz, CD3OD) δ7.49 (m, 1H), 7.40 (dd, 1H), 7.28 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.80 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.47 (s, 1.95H), 2.46 (s, 1.05H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.245 (t, 1.05H).
    • EXAMPLE 241 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methylbenzohydrazide
  • The desired product was prepared by substituting 3-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0910]
  • MS(ESI) m/e 326 (M+H)[0911] +;
  • [0912] 1H NMR (500 MHz, CD3OD) δ 7.72 (d, 1H), 7.67 (dd, 1H), 7.42 (t, 1H), 7.38 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 242 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzohydrazide
  • The desired product was prepared by substituting 4-methylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0913]
  • MS(ESI) m/e 326 (M+H)[0914] +;
  • [0915] 1H NMR (500 MHz, CD3OD) δ 7.79 (m, 211), 7.32 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 243 N′-((2RS,3R)-3-amino-5-(ethvlsulfanyl)-2-hvdroxypentanoyl)-2-aminobenzohydrazide
  • The desired product was prepared by substituting 2-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0916]
  • MS(ESI) m/e 327 (M+H)[0917] +;
  • [0918] 1H NMR (500 MHz, CD3OD) δ 7.56 (dd, 1H), 7.24 (m, 1H), 6.78 (d, 1H), 6.65 (ddd, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 244 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-aminobenzohydrazide
  • The desired product was prepared by substituting 3-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0919]
  • MS(ESI) m/e 327 (M+H)[0920] +;
  • [0921] 1H NMR (500 MHz, CD3OD) δ 7.26 (m, 3H), 6.99 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 245 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-aminobenzohydrazide
  • The desired product was prepared by substituting 4-aminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0922]
  • MS(ESI) m/e 327 (M+H)[0923] +;
  • [0924] 1H NMR (500 MHz, CD3OD) δ 7.66 (dd, 2H), 6.67 (dd, 2H), 4.46 (d, 0.35), 4.42 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 246 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxvpentanoyl)-2-hydroxybenzohydrazide
  • The desired product was prepared by substituting 2-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0925]
  • MS(ESI) m/e 328 (M+H)[0926] +;
  • [0927] 1H NMR (500 MHz, CD3OD) δ 7.86 (ddd, 1H), 7.44 (m, 1H), 6.96 (m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 111), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 247 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxypentanoyl)-3-hydroxybenzohydrazide
  • The desired product was prepared by substituting 3-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0928]
  • MS(ESI) m/e 328 (M+H)[0929] +;
  • [0930] 1H NMR (500 MHz, CD3OD) δ 7.30 (m, 3H), 7.00 (ddd, 1H), 4.46 (d, 0.35), 4.42 (d, 0.65), 3.75 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 248 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-hydroxybenzohydrazide
  • The desired product was prepared by substituting 4-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0931]
  • MS(ESI) m/e 328 (M+H)[0932] +;
  • [0933] 1H NMR (500 MHz, CD3OD) δ 7.77 (m, 2H), 6.85 (m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 249 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methoxybenzohydrazide
  • The desired product was prepared by substituting 3-methoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0934]
  • MS(ESI) m/e 342 (M+H)[0935] +;
  • [0936] 1H NMR (500 MHz, CD3OD) δ 7.44 (m, 3H), 7.16 (ddd, 1H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.85 (s, 3H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 250 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxygentanoyl)-4-methoxybenzohydrazide
  • The desired product was prepared by substituting 4-hydroxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0937]
  • MS(ESI) m/e 342 (M+H)[0938] +;
  • [0939] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 2H), 7.02 (m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.87 (s, 3H), 3.76 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 251 N-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-fluorobenzohydrazide
  • The desired product was prepared by substituting 2-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0940]
  • MS(ESI) m/e 330 (M+H)[0941] +;
  • [0942] 1H NMR (500 MHz, CD3OD) δ7.82 (m, 1H), 7.60 (m, 1H), 7.73 (t, 1H), 7.26 (m, 1B), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1B), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 252 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-fluorobenzohydrazide
  • The desired product was prepared by substituting 3-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0943]
  • MS(ESI) m/e 330 (M+H)[0944] +;
  • [0945] 1H NMR (500 MHz, CD3OD) δ 7.71 (dd, 1H), 7.62 (m, 1H), 7.53 (t, 1H), 7.36 (m, 1B), 4.49 (d, 0.35), 4.45 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1B), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 253 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-fluorobenzohydrazide
  • The desired product was prepared by substituting 4-fluorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0946]
  • MS(ESI) m/e 330 (M+H)[0947] +;
  • [0948] 1H NMR (500 MHz, CD3OD) δ 7.95 (m, 2H), 7.24 (m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 254 (2RS,3R)-N′-acetyl-3-amino-5-(ethylsulfanyl)-2-hydroxypentanohydrazide
  • The desired product was prepared by substituting acetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0949]
  • MS(ESI) m/e 250 (M+H)[0950] +;
  • [0951] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 1H), 2.68 (ddd, 2H), 2.58 (dd, 1.3H), 2.55 (dd, 0.7H), 2.10 (m, 1H), 2.03 (s, 1.95H), 2.01 (s, 1.05H),1.95 (m, 1H), 1.23-1.28 (m, 3H).
    • EXAMPLE 255 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-isobutylpentanohydrazide
  • The desired product was prepared by substituting 2-methylpropionic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0952]
  • MS(ESI) m/e 278 (M+H)[0953] +;
  • [0954] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.35), 4.37 (d, 0.65), 3.73 (m, 1H), 2.73-2.51 (m, 5H), 2.10 (m, 1H), 1.95 (dt, 1H), 1.26 (t, 1.95H), 1.24 (t, 1.05H), 1.17 (m, 6H).
    • EXAMPLE 256 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-methylbutanoyl)pentanohydrazide
  • The desired product was prepared by substituting 3-methylbutyric acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0955]
  • MS(ESI) m/e 292 (M+H)[0956] +;
  • [0957] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.35), 4.37 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55 (dd, 0.7H), 2.07-2.16 (m, 4H), 1.95 (dt, 1H), 1.26 (t, 1.95H), 1.24 (t, 1.05H), 1.10 (t, 6H).
    • EXAMPLE 257 (2RS,3R)-3-amino-5-(ethylsulfanyl)-N′-heptanoyl-2-hydroxypentanohydrazide
  • The desired product was prepared by substituting heptanoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0958]
  • MS(ESI) m/e 320 (M+H)[0959] +;
  • [0960] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.35), 4.37 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 211), 2.59 (dd, 1.3H), 2.55 (dd, 0.7H), 2.28 (dd, 2H), 2.12 (ddd, 1H), (1.95 (dt, 1H), 1.64 (dd, 211), 1.31-1.40 (m, 6H), 1.26 (t, 1.95H), 1.24 (t, 1.05H), 0.91 (t, 3H).
    • EXAMPLE 258 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(tetrahydro-2-furanylcarbonyl)pentanohydrazide
  • The desired product was prepared by substituting 2-tetrahydrofuroic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0961]
  • MS(ESI) m/e 306 (M+H)[0962] +;
  • [0963] 1H NMR (500 MHz, CD3OD) δ 4.48-4.41 (m, 1.35), 4.37 (d, 0.65), 4.01 (m, 1H), 3.88 (m, 1H), 3.73 (m, 1H), 2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55 (dd, 0.7H), 2.29 (m. 1H), 2.08 (m, 2H), 1.96 (m, 3H), 1.26 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 259 (2RS,3R)-3-amino-N′-(cyclohexylacetyl)-5-(ethylsulfanyl)-2-hydroxyheptanohydrazide
  • The desired product was prepared by substituting cyclohexylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0964]
  • MS(ESI) m/e 332 (M+H)[0965] +;
  • [0966] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.35), 4.36 (d, 0.65), 3.73 (m, 1H), 2.67 (dd, 2H), 2.59 (dd, 1.3H), 2.55 (dd, 0.7H), 2.16-2.07 (m, 31H), 1.95 (dt, 1H), 1.65-1.81 (m, 9H), 1.26 (t, 1.95H), 1.24 (t, 1.05H) 1.02 (dd, 2H).
    • EXAMPLE 261 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-bromobenzohydrazide
  • The desired product was prepared by substituting 4-bromobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0967]
  • MS(ESI) m/e 391 (M+H)[0968] +;
  • [0969] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.68 (m, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 262 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(phenylacetyl)pentanohydrazide
  • The desired product was prepared by substituting phenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0970]
  • MS(ESI) m/e 326 (M+H)[0971] +;
  • [0972] 1H NMR (500 MHz, CD3OD) δ 7.35-7.23 (m, 5H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 1H), 3.61 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 263 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hvdroxy-N′-((2-methoxyphenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 2-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0973]
  • MS(ESI) m/e 356 (M+H)[0974] +;
  • [0975] 1H NMR (500 MHz, CD3OD) δ 7.21 (dt, 1H), 6.94 (d, 1H), 6.90 (d, 1H), 6.81 (m, 1H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.78 (s, 3H), 3.72 (m, 11H), 3.58 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 264 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((3-methoxyphenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 3-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0976]
  • MS(ESI) m/e 356 (M+H)[0977] +;
  • [0978] 1H NMR (500 MHz, CD3OD) δ 7.25 (m, 2H), 6.95 (d, 1H), 6.90 (d, 1H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.83 (s, 3H), 3.72 (m, 1H), 3.61 (dd, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 265 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((4-methoxyphenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 4-methoxyphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0979]
  • MS(ESI) m/e 356 (M+H)[0980] +;
  • [0981] 1H NMR (500 MHz, CD3OD) δ 7.25 (d, 2H), 6.87 (dd, 2H), 4.41 (d, 0.35), 4.37 (d, 0.65), 3.77 (s, 3H), 3.72 (m, 1H), 3.53 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 266 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxv-N′-((2-chlorophenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 2-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0982]
  • MS(ESI) m/e 360 (M+H)[0983] +;
  • [0984] 1H NMR (500 MHz, CD3OD) δ 7.43 (m, 2H), 7.27 (m, 2H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.80 (d, 1H), 3.78 (s, 1H), 3.73 (m, 1H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 267 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((3-chlorophenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 3-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0985]
  • MS(ESI) m/e 360 (M+H)[0986] +;
  • [0987] 1H NMR (500 MHz, CD3OD) δ 7.39 (m, 1H), 7.25-7.31 (m, 3H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.72 (m, 1H), 3.61 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 268 (2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((4-chlorophenyl)acetyl)pentanohydrazide
  • The desired product was prepared by substituting 4-chlorophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0988]
  • MS(ESI) m/e 360 (M+H)[0989] +;
  • [0990] 1H NMR (500 MHz, CD3OD) δ 7.32 (m, 4H), 4.42 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 1H), 3.61 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 269 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1,1 ′-biphenyl)-4-ylacetohydrazide
  • The desired product was prepared by substituting 4-phenylphenylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0991]
  • MS(ESI) m/e 402 (M+H)[0992] +;
  • [0993] 1H NMR (500 MHz, CD3OD) δ 7.58 (m, 4H), 7.42 (m, 4H), 7.32 (m, 1H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.72 (m, 1H), 3.65 (d, 2H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 270 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-dimethylaminophenyl)acetohydrazide
  • The desired product was prepared by substituting 4-dimethylaminophenylacetic acid for 3-(ethylsulfanyl)benzoic acid in [0994]
  • [0995] 1H NMR (500 MHz, CD3OD) δ 7.36 (m, 2H), 7.13 (m, 2H), 4.42 (d, 0.35), 4.37 (d, 0.65), 3.72 (m, 11H), 3.59 (d, 2H), 3.09 (s, 3H), 3.07 (s, 3H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.53 (dd, 0.7H), 2.11 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.21 (t, 1.05H).
    • EXAMPLE 271 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1-naphthyl)acetohydrazide
  • The desired product was prepared by substituting 1-naphthylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0996]
  • MS(ESI) m/e 369 (M+H)[0997] +;
  • [0998] 1H NMR (500 MHz, CD3OD) δ 8.10 (d, 1H), 7.88 (d, 1H), 7.81 (d, 1H), 7.51 (m, 3H) 7.45 (t, 1H), 4.42 (d, 0.35), 4.37 (d, 0.65), 4.10 (d, 2H), 3.70 (m, 1H), 2.65 (t, 2H), 2.56 (dd, 1.3H), 2.47 (dd, 0.7H), 2.09 (dd, 1H), 1.92 (dt, 1H), 1.24 (t, 1.95H), 1.15 (t, 1.05H).
    • EXAMPLE 272 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-naphthyl)acetohydrazide
  • The desired product was prepared by substituting 2-naphthylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [0999]
  • MS(ESI) m/e 376 (M+H)[1000] +;
  • [1001] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 4H), 7.46 (m, 3H), 4.42 (d, 0.35), 4.38 (d, 0.65), 3.78 (d, 2H), 3.73 (m, 1H), 2.66 (t, 2H), 2.57 (dd, 1.3H), 2.52 (dd, 0.7H), 2.09 (dd, 1H), 1.94 (dt, 1H), 1.25 (t, 1.95H), 1.19 (t, 1.05H).
    • EXAMPLE 273 N′-((2RS,3R)-3-amino-5-(ethyl sulfanyl)-2-hydroxypentanoyl)-2-furohydrazide
  • The desired product was prepared by substituting 2-furoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1002]
  • MS(ESI) m/e 302 (M+H)[1003] +;
  • [1004] 1H NMR (500 MHz, CD3OD) δ 7.73 (dd, 0.65H), 7.72 (dd, 0.35H), 7.24 (dd, 0.65H), 7.22 (dd, 0.35H), 6.64 (dd, 0.65H), 6.63 (dd, 0.35H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 274 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-furohydrazide
  • The desired product was prepared by substituting 3-furoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1005]
  • MS(ESI) m/e 302 (M+H)[1006] +;
  • [1007] 1H NMR (500 MHz, CD3OD) δ 8.16 (m, 0.65H), 8.14 (m, 0.35H), 7.62 (dd, 0.65H), 7.61 (dd, 0.35H), 6.83 (m, 1H), 4.47 (d, 0.35), 4.42 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 275 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-thiophenecarbohydrazide
  • The desired product was prepared by substituting 2-thiophene carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1008]
  • MS(ESI) m/e 318 (M+H)[1009] +;
  • [1010] 1H NMR (500 MHz, CD3OD) δ 7.79 (dd, 0.65H), 7.78 (dd, 0.35H), 7.77 (dd, 0.65H), 7.75 (dd, 0.35H), 7.17 (m, 1H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 276 N′-((2RS,3R)-3-amino-5-(ethvlsulfanyl)-2-hydroxypentanoyl)-3-thiophenecarbohydrazide
  • The desired product was prepared by substituting 3-thiophene carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1011]
  • MS(ESI) m/e 318 (M+H)[1012] +; 1H NMR (500 MHz, CD3OD) δ 8.18 (dd, 0.65H), 8.16 (dd, 0.35H), 7.53 (m, 2H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.71H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 277 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrrole-2-carbohydrazide
  • The desired product was prepared by substituting 2-pyrrole carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1013]
  • MS(ESI) m/e 301 (M+H)[1014] +;
  • [1015] 1H NMR (500 MHz, CD3OD) δ 6.99 (dd, 0.65H), 6.98 (dd, 0.35H), 6.91 (dd, 0.65H, 6.89 (dd, 0.35H), 6.21 (m, 1H), 4.46 (d, 0.35), 4.42 (d, 0.65), 3.77 (m, 1H), 2.71 (m, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 278 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-2-carbohydrazide
  • The desired product was prepared by substituting 2-thiazole carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1016]
  • MS(ESI) m/e 319 (M+H)[1017] +;
  • [1018] 1H NMR (500 MHz, CD3OD) δ 8.02 (d, 0.65H), 8.00 (d, 0.35H), 7.94 (d, 0.65H, 7.91 (d, 0.35H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (m, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 279 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-4-carbohydrazide
  • The desired product was prepared by substituting 4-thiazole carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1019]
  • MS(ESI) m/e 319 (M+H)[1020] +;
  • [1021] 1H NMR (500 MHz, CD3OD) δ9.06 (d, 0.65H), 9.04 (d, 0.35H), 8.40 (d, 0.65H, 8.37 (d, 0.35H), 4.48 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 280 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-5-carbohydrazide
  • The desired product was prepared by substituting 5-thiazole carboxyl acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1022]
  • MS(ESI) m/e 319 (M+H)[1023] +;
  • [1024] 1H NMR (500 MHz, CD3OD) δ9.21 (s, 0.65H), 9.19 (s, 0.35H), 8.49 (s, 0.65H, 8.47 (s, 0.35H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 281 N′-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-5-carbohydrazide
  • The desired product was prepared by substituting 1H-pyrazole-5-carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1025]
  • MS(ESI) m/e 302 (M+H)[1026] +;
  • [1027] 1H NMR (500 MHz, CD3OD) δ 7.74 (d, 0.65H), 7.73 (d, 0.35H), 8.83 (m, 1H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.98 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 282 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-4-carbohydrazide
  • The desired product was prepared by substituting 1-H-pyrazole-4-carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1028]
  • MS(ESI) m/e 302 (M+H)[1029] +;
  • [1030] 1H NMR (500 MHz, CD3OD) δ 8.11 (s, 1H), 8.10 (s, 1H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.76 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.15 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 283 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-5-isoxazolecarbohydrazide
  • The desired product was prepared by substituting 5-isoxazole caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1031]
  • MS(ESI) m/e 303 (M+H)[1032] +;
  • [1033] 1H NMR (500 MHz, CD3OD) δ 8.58 (d, 0.65H), 8.56 (d, 0.35H), 7.09 (d, 0.65H), 7.06 (d, 0.35H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.97 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 284 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyridinecarbohydrazide
  • The desired product was prepared by substituting 2-pyridine caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1034]
  • MS(ESI) m/e 313 (M+H)[1035] +;
  • [1036] 1H NMR (500 MHz, CD3OD) δ 8.67 (t, 1H), 8.11 (t, 1H), 7.99 (m, 1H), 7.60 (m, 1H), 4.49 (d, 0.35), 4.45 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 1.3H), 2.58 (dd, 0.7H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 285 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-pyridnyl)acetohydrazide
  • The desired product was prepared by substituting 2-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1037]
  • MS(ESI) m/e 327 (M+H)[1038] +;
  • [1039] 1H NMR (500 MHz, CD3OD) δ 8.63 (d, 0.35H), 8.59 (d, 0.65H), 8.11 (dt, 0.35H), 8.04 (dt, 0.65H), 7.71 (d, 0.35H), 7.66 (d, 0.65H), 7.59 (ddd, 0.35H), 7.53 (ddd, 0.65H), 4.44 (d, 0.35), 4.38 (d, 0.65), 3.73 (m, 1H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.52 (dd, 0.7H), 2.10 (dd, 1H), 1.93 (dt, 1H), 1.25 (t, 1.95H), 1.20 (t, 1.05H).
    • EXAMPLE 286 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyrndinecarbohydrazide
  • The desired product was prepared by substituting 3-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1040]
  • MS(ESI) m/e 313 (M+H)[1041] +;
  • [1042] 1H NMR (500 MHz, CD3OD) δ9.04 (m, 1H), 8.77 (d, 1H), 8.32 (dd, 0.35H), 8.30 (dd, 0.65H), 7.61 (d, 0.35H), 7.60 (d, 0.65H), 4.51 (d, 0.35), 4.46 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 1.3H), 2.58 (dd, 0.7H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 287 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(3-pyridinyl)acetohydrazide
  • The desired product was prepared by substituting 3-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1043]
  • MS(ESI) m/e 327 (M+H)[1044] +;
  • [1045] 1H NMR (500 MHz, CD3OD) δ 8.69 (d, 1H), 8.61 (m, 1H), 8.24 (d, 0.35H), 8.19 (dd, 0.65H), 7.75 (dd, 0.35H), 7.71 (dd, 0.65H), 4.44 (d, 0.35), 4.38 (d, 0.65), 3.81 (m, 2H), 3.73 (m, 1H), 2.67 (t, 2H), 2.57 (dd, 1.3H), 2.52 (dd, 0.7H), 2.10 (dd, 1H), 1.93 (dt, 1H), 1.25 (t, 1.95H), 1.20 (t, 1.05H).
    • EXAMPLE 288 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pyridinecarbohydrazide
  • The desired product was prepared by substituting 4-pyridine caboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1046]
  • MS(ESI) m/e 313 (M+H)[1047] +;
  • [1048] 1H NMR (500 MHz, CD3OD) δ 8.76 (m, 2H), 7.86 (m, 2H), 4.51 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 1.3H), 2.58 (dd, 0.7H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 289 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-pyridinyl)acetohydrazide
  • The desired product was prepared by substituting 4-pyridylacetic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1049]
  • MS(ESI) m/e 327 (M+H)[1050] +;
  • [1051] 1H NMR (500 MHz, CD3OD) δ 8.68 (t, 2H), 7.87 (d, 0.711), 7.83 (d, 1.3H), 4.45 (d, 0.35), 4.38 (d, 0.65), 3.73 (m, 1H), 2.67 (t, 2H), 2.58 (dd, 1.3H), 2.52 (dd, 0.7H), 2.10 (dd, 1H), 1.93 (dt, 1H), 1.25 (t, 1.95H), 1.20 (t, 1.05H).
    • EXAMPLE 290 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyridazinecarbohydrazide
  • The desired product was prepared by substituting 3-pyridazine carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1052]
  • MS(ESI) m/e 314 (M+H1)+; [1053]
  • [1054] 1H NMR (500 MHz, CD3OD) δ 9.37 (ddd, 1H), 8.31 (ddd, 1H), 7.92 (dd, 1H), 4.51 (d, 0.35), 4.47 (d, 0.65), 3.81 (m, 1H), 2.72 (t, 2H), 2.61 (dd, 2H), 2.18 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 291 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pynmidinecarbohydrazide
  • The desired product was prepared by substituting 4-pyrimidine carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1055]
  • MS(ESI) m/e 314 (M+H)[1056] +;
  • [1057] 1H NMR (500 MHz, CD3OD) δ9.31 (d, 0.65H), 9.30 (d, 0.35H), 9.07 (d, 0.65H), 9.06 (0.35H), 8.11 (dd, 0.65H), 8.09 (dd, 0.35H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 292 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyrazinecarbohydrazide
  • The desired product was prepared by substituting 2-pyrazine carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1058]
  • MS(ESI) m/e 314 (M+H)[1059] +;
  • [1060] 1H NMR (500 MHz, CD3OD) δ9.25 (d, 0.65H), 9.24 (d, 0.35H), 8.85 (d, 0.65H), 8.83 (0.35H), 8.72 (dd, 0.65H), 8.71 (dd, 0.35H), 4.50 (d, 0.35), 4.46 (d, 0.65), 3.80 (m, 1H), 2.71 (t, 2H), 2.60 (t, 2H), 2.18 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 293 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropylbenzohydrazide
  • The desired product was prepared by substituting 4-(2-methylethyl)phenylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1061]
  • MS(ESI) m/e 355 (M+H)[1062] +;
  • [1063] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 2H), 7.37 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.24-1.29 (m, 10H)
    • EXAMPLE 294 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-propoxybenzohydrazide
  • The desired product was prepared by substituting 4-propoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1064]
  • MS(ESI) m/e 370 (M+H)[1065] +;
  • [1066] 1H NMR (500 MHz, CD3OD) δ 7.86 (m, 2H), 7.01 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.01 (dt, 2H), 3.77 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 211), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.82 (ddd, 2H), 1.28 (t, 1.95H), 1.25 (t, 1.05H) 1.05 (t, 3H).
    • EXAMPLE 295 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(methylsulfanyl)benzohydrazide
  • The desired product was prepared by substituting 4-methylsulfanylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1067]
  • MS(ESI) m/e 358 (M+H)[1068] +;
  • [1069] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 2H), 7.35(m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.53 (s, 3H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 296 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropoxybenzohydrazide
  • The desired product was prepared by substituting 4-(2-methylethoxy)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1070]
  • MS(ESI) m/e 370 (M+H)[1071] +;
  • [1072] 1H NMR (500 MHz, CD3OD) δ 7.84 (m, 2H), 6.99 (m, 2H), 4.71 (ddd, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, o 1H), 1.34 (d, 6H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 297 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(diethylamino)benzohydrazide
  • The desired product was prepared by substituting 4-(diethylamino)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1073]
  • MS(ESI) m/e 383 (M+H)[1074] +;
  • [1075] 1H NMR (500 MHz, CD3OD) δ 7.76 (dd, 2H), 6.73 (m, 2H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 3.46 (q, 4H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H), 1.19 (t, 6H).
    • EXAMPLE 298 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-butoxybenzohydrazide
  • The desired product was prepared by substituting 4-butoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1076]
  • MS(ESI) m/e 384 (M+H)[1077] +;
  • [1078] 1H NMR (500 MHz, CD3OD) δ 7.85 (m, 2H), 6.99 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.06 (dt, 2H), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.78 (ddd, 2H), 1.53 (ddd, 2H), 1.28 (t, 1.95H), 1.26 (t, 1.05H), 0.99 (t, 3H).
    • EXAMPLE 299 N′-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-diethoxybenzohydrazide
  • The desired product was prepared by substituting 2,3-diethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1079]
  • MS(ESI) rn/e 400 (M+H)[1080] +;
  • [1081] 1H NMR (500 MHz, CD3OD) δ 7.52 (dd, 1H), 7.48 (d, 1H), 7.03 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 4.13 (m, 4H), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.43 (m, 6H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 300 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-chlorobenzohydrazide
  • The desired product was prepared by substituting 4-chlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1082]
  • MS(ESI) m/e 346 (M+H)[1083] +;
  • [1084] 1H NMR (500 MHz, CD3OD) δ 7.87 (dd, 2H), 7.52 (dd, 2H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 301 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-bromobenzohydrazide
  • The desired product was prepared by substituting 2-bromobenzoic acid for 3(ethylsulfanyl)benzoic acid in Example 239B. [1085]
  • MS(ESI) m/e 391 (M+H)[1086] +;
  • [1087] 1H NMR (500 MHz, CD3OD) δ 7.69 (dd, 1H), 7.59 (ddd, 1H), 7.47 (m, 1H), 7.41 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 302 (2RS,3R)-3-amino-N′-((2RS,3S)-3-amino-2-hvdroxy-5-(isopropylsulfanYl)pentanoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide
  • The title compound is obtained by substituting hydrazine hydrate for O-phenylhydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [1088]
  • MS(ESI) m/e 409 (M-H)+. [1089]
  • [1090] 1H NMR (300 MHz, DMSO-d6) δ10.94 (br s, 1H), 10.11 & 9.93 (s, 1H), 8.2 & 8.02 (m, 4H), 6.8 & 6.65(br s, 2H), 4.44 & 4.28 (m, 1H), 4.2 (m, 1H), 3.0-2.9 (m, 2H), 2.75-2.55 (m, 4H), 1.95-1.75 (m, 4H), 1.2 (d, 12H).
    • EXAMPLE 304 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(dimethylamino)benzohydrazide
  • The desired product was prepared by substituting 3-dimethylaminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1091]
  • MS(ESI) m/e 355 (M+H)[1092] +;
  • [1093] 1H NMR (500 MHz, CD3OD) δ 7.32 (dd, 1H), 7.28 (m, 1H), 7.21 (d, 1H), 7.01 (dd, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.79 (m, 1H), 3.00 (s, 6H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 305 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(dimethylamino)benzohydrazide
  • The desired product was prepared by substituting 4-dimethylaminobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1094]
  • MS(ESI) m/e 355 (M+H)[1095] +;
  • [1096] 1H NMR (500 MHz, CD3OD) δ 7.78 (dd, 2H), 6.75 (d, 2H), 4.46 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 3.04 (s, 6H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 306 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromethyl)benzohydrazide
  • The desired product was prepared by substituting 3-(trifluoromethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1097]
  • MS(ESI) m/e 380 (M+H)[1098] +;
  • [1099] 1H NMR (500 MHz, CD3OD) δ 8.21 (d, 1H), 8.14 (t, 1H), 7.92 (t, 1H), 7.73 (dd, 1H), 4.50 (d, 0.35), 4.46 (d, 0.65), 3.79 (m, 1H), 2.72 (t, 2H), 2.61 (dd, 2H), 2.18 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 307 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(trifluoromethyl)benzohydrazide
  • The desired product was prepared by substituting 4-(trifluoromethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1100]
  • MS(ESI) mle 380 (M+H)[1101] +;
  • [1102] 1H NMR (500 MHz, CD3OD) δ 8.05 (dd, 2H), 7.82 (dd, 2H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H)
    • EXAMPLE 308 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromethoxy)benzohydrazide
  • The desired product was prepared by substituting 3-(trifluoromethoxy)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1103]
  • MS(ESI) m/e 396 (M+H)[1104] +;
  • [1105] 1H NMR (500 MHz, CD3OD) δ 7.89 (dd, 1H), 7.80 (d, 1H), 7.62 (dd, 1H), 7.53 (dd, 1H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 309 N′-((2RS.3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-phenoxybenzohydrazide
  • The desired product was prepared by substituting 4-phenoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1106]
  • MS(ESI) m/e 404 (M+H)[1107] +;
  • [1108] 1H NMR (500 MHz, CD3OD) δ 7.89 (m, 2H), 7.42 (m, 2H), 7.22 (m, 1H), 7.08 (m, 2H), 7.04 (m, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 310 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(phenoxymethyl)benzohydrazide
  • The desired product was prepared by substituting 4-(phenoxymethyl)benzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1109]
  • MS(ESI) m/e 418 (M+H)[1110] +;
  • [1111] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 2H), 7.44 (d, 2H), 7.38 (t, 2H), 7.32 (t, 1H), 7.11 (m, 2H), 5.17 (s, 2H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.77 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 311 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethylbenzohydrazide
  • The desired product was prepared by substituting 2,3-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1112]
  • MS(ESI) m/e 340 (M+H)[1113] +;
  • [1114] 1H NMR (500 MHz, CD3OD) δ 7.29 (m, 2H), 7.16 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65),3.80 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.36 (s, 3H), 2.32 (s, 3H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 312 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethylbenzohydrazide
  • The desired product was prepared by substituting 2,4-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1115]
  • MS(ESI) m/e 340 (M+H)[1116] +;
  • [1117] 1H NMR (500 MHz, CD3OD) δ 7.40 (m, 1H), 7.12 (d, 1H), 7.08 (dd, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.43 (s, 3H), 2.34 (s, 3H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 313 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2.5-dimethylbenzohydrazide
  • The desired product was prepared by substituting 2,5-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1118]
  • MS(ESI) m/e 340 (M+H)[1119] +;
  • [1120] 1H NMR (500 MHz, CD3OD) δ 7.33 (m, 1H), 7.21 (dd, 1H), 7.17 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 314 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4,5-dimethylbenzohydrazide
  • The desired product was prepared by substituting 3,4-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1121]
  • MS(ESI) m/e 340 (M+H)[1122] +;
  • [1123] 1H NMR (500 MHz, CD3OD) δ 7.68 (d, 1H), 7.61 (dd, 1H), 7.25 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.33 (s, 6H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 315 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dimethylbenzohydrazide
  • The desired product was prepared by substituting 3,5-dimethylbenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1124]
  • MS(ESI) m/e 340 (M+H)[1125] +;
  • [1126] 1H NMR (500 MHz, CD30D) δ7.50 (d, 2H), 7.25 (d, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.37 (s, 6H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 316 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 2,3-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1127]
  • MS(ESI) m/e 372 (M+H)[1128] +;
  • [1129] 1H NMR (500 MHz, CD3OD) δ 7.42 (dd, 0.65H), 7.40 (dd, 0.35H), 7.24 (ddd, 1H), 7.19 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.95 (s, 1.95H), 3.94 (s, 1.05H), 3.91 (s, 1.95H), 3.90 (s, 1.05H), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 317 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 2,4-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1130]
  • MS(ESI) m/e 372 (M+H)[1131] +;
  • [1132] 1H NMR (500 MHz, CD3OD) δ 7.98 (m, 1H), 6.68 (m, 2H), 4.47 (d, 0.35), 4.44 (d, 0.65), 4.00 (s, 1.95H), 3.99 (s, 1.05H), 3.88 (s, 3H), 3.78 (m, 1H), 2.70 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 318 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 2,5-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1133]
  • MS(ESI) m/e 372 (M+H)[1134] +;
  • [1135] 1H NMR (500 MHz, CD3OD) δ 7.54 (dd, 0.65H), 7.53 (dd, 0.35H), 7.14 (m, 2H), 4.48 (d, 0.35), 4.45 (d, 0.65), 3.96 (s, 1.95H), 3.95 (s, 1.05H), 3.79 (s, 3H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 319 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 3,4-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1136]
  • MS(ESI) m/e 372 (M+H)[1137] +;
  • [1138] 1H NMR (500 MHz, CD3OD) δ 7.55 (ddd, 1H), 7.49 (dd, 1H), 7.05 (m, 1H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.90 (s, 1.95H), 3.89 (s, 1.05H), 3.88 (s, 3H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 320 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dimethoxybenzohydrazide
  • The desired product was prepared by substituting 3,5-dimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1139]
  • MS(ESI) m/e 372 (M+H)[1140] +;
  • [1141] 1H NMR (500 MHz, CD3OD) δ 7.04 (m, 2H), 6.71 (dd, 0.65H), 6.99 (dd, 0.35H), 4.48 (d, 0.35), 4.44 (d, 0.65), 3.83 (s, 6H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 321 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-benzodioxole-5-carbohydrazide
  • The desired product was prepared by substituting 1,3-benzodioxole carboxylic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1142]
  • MS(ESI) mle 356 (M+H)[1143] +;
  • [1144] 1H NMR (500 MHz, CD3OD) δ 7.49 (m, 1H), 7.35 (d, 0.65H), 7.34 (d, 0.35H), 6.92 (m, 1H), 6.06 (s, 1.3H), 6.05 (s, 0.7H), 4.47 (d, 0.35), 4.43 (d, 0.65), 3.77 (m, 1H), 2.70 (t, 2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 322 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4,5-trimethoxybenzohydrazide
  • The desired product was prepared by substituting 3,4,5-trimethoxybenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1145]
  • MS(ESI) m/e 402 (M+H)[1146] +;
  • [1147] 1H NMR (500 MHz, CD3OD) δ 7.25 (s, 1.3H), 7.24 (s, 0.7H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.89 (s, 6H), 3.83 (s, 1.95H), 3.82 (s, 1.05H), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.26 (t, 1.05H).
    • EXAMPLE 323 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dichlorobenzohydrazide
  • The desired product was prepared by substituting 2,3-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1148]
  • MS(ESI) m/e 381 (M+H)[1149] +;
  • [1150] 1H NMR (500 MHz, CD3OD) δ 7.68 (ddd, 1H), 7.54 (m, 1H), 7.41 m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.80 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 324 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dichlorobenzohydrazide
  • The desired product was prepared by substituting 2,4-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1151]
  • MS(ESI) m/e 381 (M+H)[1152] +;
  • [1153] 1H NMR (500 MHz, CD3OD) δ 7.60 (m, 2H), 7.46 (m, 1H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 325 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dichlorobenzohydrazide
  • The desired product was prepared by substituting 2,5-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1154]
  • MS(ESI) m/e 381 (M+H)[1155] +;
  • [1156] 1H NMR (500 MHz, CD3OD) δ 7.65 (m, 1H), 7.52 (m, 2H), 4.48 (d, 0.35), 4.43 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.60 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.24 (t, 1.05H).
    • EXAMPLE 326 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-dichlorobenzohydrazide
  • The desired product was prepared by substituting 3,4-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1157]
  • MS(ESI) m/e 381 (M+H)[1158] +;
  • [1159] 1H NMR (500 MHz, CD3OD) δ 8.05 (d, 0.65H), 8.04 (d, 0.35H), 7.80 (m, 1H), 7.68 (m, 1H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 327 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dichlorobenzohydrazide
  • The desired product was prepared by substituting 3,5-dichlorobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1160]
  • MS(ESI) m/e 381 (M+H)[1161] +;
  • [1162] 1H NMR (500 MHz, CD3OD) δ 7.85 (d, 1.3H), 7.83 (d, 0.7H), 7.72 (t, 0.65H), 7.70 (t, 0.35H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.16 (dd, 1H), 1.99 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 328 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanovl)-2-hydroxybenzohydrazide
  • The desired compound was prepared by substituting salicylic acid for o-toluic acid in Example 329B. [1163]
  • MS(ESI) mle 336 (M+H)[1164] +;
  • [1165] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 1H), 7.44 (m, 1H), 6.95 (m, 2H), 4.45 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m, 1H), 1.76 (m, 6H), 1.58 (m, 1H), 1.47 (m, 1H), 1.32 (m, 1H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 329 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methylbenzohydrazide EXAMPLE 329A N′-((2RS,3R)-3-(tert-butoxycarbonyl)amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazide
  • The desired compound was prepared by substituting Example 1C for Example 97A acid in Example 239A. [1166]
    • EXAMPLE 329B N′- ((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methylbenzohydrazide
  • To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt (0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL of a 0.3M solution of o-toluic acid (0.15 mmol) in dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of Example 329A (0.225 mmol) in dimethylacetamide/dichloromethane (1:1) was added. The mixture was agitated for 18 hours and quenched with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture was filtered and the resins washed with 1×3 mL of dichloromethane, the solvent was removed in vacuo, and the crude material purified by reverse phase preparative HPLC. The resulting material was treated with 1 mL of 50% trifluoroacetic acid/dichloromethane and agitated at ambient temperature for 18 hours. The solvent was removed in vacuo to give the desired product. [1167]
  • MS(ESI) m/e 334 (M+H)[1168] +;
  • [1169] 1H NMR (500 MHz, CD3OD) δ 7.50 (m, 1H), 7.39 (ddd, 1H), 7.28 (m, 2H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.71 (mn, 0.7H), 3.67 (m 0.3H), 2.46 (s, 3H), 1.73 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.28 (m, 3H), 1.02 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 330 2-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
  • The desired compound was prepared by substituting o-aminobenzoic acid for o-toluic acid in Example 329B. [1170]
  • MS(ESI) m/e 335 (M+H)[1171] +;
  • [1172] 1H NMR (500 MHz, CD3OD) δ 7.57 (m, 1H), 7.25 (m, 1H), 6.80 (m, 1H), 6.67 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.69 (m, 0.7H), 3.65 (m 0.3H), 1.76 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.37-1.20 (m, 3H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 331 4-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
  • The desired compound was prepared by substituting p-aminobenzoic acid for o-toluic acid in Example 329B. [1173]
  • MS(ESI) m/e 335 (M+H)[1174] +;
  • [1175] 1H NMR (500 MHz, CD3OD) δ 7.67 (m, 2H), 6.69 (m, 2H), 4.42 (d, 0.4H), 4.35 (d, 0.6H), 3.69-3.62 (m, 1H), 1.85-1.61 (m, 6H), 1.56 (m, 1H), 1.46 (m, 1H), 1.37-1.20 (m, 3H), 1.03 (m, 1.2H), 0.91 (m, 0.8H).
    • EXAMPLE 332 3-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide
  • The desired compound was prepared by substituting m-amninobenzoic acid for o-toluic acid in Example 329B. [1176]
  • MS(ESI) m/e 335 (M+H)[1177] +;
  • [1178] 1H NMR (500 MHz, CD3OD) δ 7.36 (m, 3H), 7.09 (m, 1H), 4.45 (d, 0.25H), 4.36 (d, 0.75H), 3.69 (m, 1H), 1.85-1.64 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.22 (m, 1H), 1.02 (m, 1.5 H), 0.92 (m, 0.5H).
    • EXAMPLE 333 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxybenzohydrazide
  • The desired compound was prepared by substituting 3-hydroxybenzoic acid for o-toluic acid in Example 329B. [1179]
  • MS(ESI) m/e 336 (M+H)[1180] +;
  • [1181] 1H NMR (500 MHz, CD3OD) δ 7.31 (m, 3H), 7.01 (m, 1H), 6.80 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.69 (m, 0.7H), 3.65 (m 0.3H), 1.85-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 334 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-hydroxybenzohydrazide
  • The desired compound was prepared by substituting 4-hydroxybenzoic acid for o-toluic acid in Example 329B. [1182]
  • MS(ESI) m/e 336 (M+H)[1183] +;
  • [1184] 1H NMR (500 MHz, CD3OD) δ 7.78 (m, 2H), 6.85 (m, 2H), 4.43 (d, 0.3H), 4.36 (d, 0.7H), 3.71-3.62 (m, 1H), 1.75 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.38-1.20 (m, 3H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 335 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methoxybenzohydrazide
  • The desired compound was prepared by substituting p-anisic acid for o-toluic acid in Example 329B. [1185]
  • MS(ESI) m/e 350 (M+H)[1186] +;
  • [1187] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 2H), 7.02 (m, 2H), 6.80 (m, 1H), 6.67 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.70-3.64 (m, 1H), 1.84-1.62 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.39-1.20 (m, 3H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 336 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-fluorobenzohydrazide
  • The desired compound was prepared by substituting 2-fluorobenzoic acid for o-toluic acid in Example 329B. [1188]
  • MS(ESI) m/e 338 (M+H)[1189] +;
  • [1190] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 1H), 7.61 (m, 1H), 7.34-7.23 (m, 2H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.69 (m, 1H), 1.75 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.38-1.20 (m, 3H), 1.03 (m, 1.4H), 0.93 (m, 0.6H).
    • EXAMPLE 337 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-fluorobenzohydrazide
  • The desired compound was prepared by substituting 3-fluorobenzoic acid for o-toluic acid in Example 329B. [1191]
  • MS(ESI) m/e 338 (M+H)[1192] +;
  • [1193] 1H NMR (500 MHz, CD3OD) δ 7.72 (m, 1H), 7.63 (m, 1H), 6.53 (m, 1H), 7.35 (m, 1H), 4.45 (d, 0.25H), 4.37 (d, 0.75H), 3.68 (m, 1H), 1.83-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, IH), 1.02 (m, 1.5H), 0.92 (m, 0.5H).
    • EXAMPLE 338 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-fluorobenzohydrazide
  • The desired compound was prepared by substituting 4-fluorobenzoic acid for o-toluic acid in Example 329B. [1194]
  • MS(ESI) m/e 338 (M+H)[1195] +;
  • [1196] 1H NMR (500 MHz, CD3OD) δ 7.95 (m, 2H), 7.24 (m, 2H), 6.53 (m, 1H), 7.35 (m, 1H), 4.45 (d, 0.3H), 4.37 (d, 0.7H), 3.68 (m, 1H), 1.85-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 339 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-bromobenzohydrazide
  • The desired compound was prepared by substituting 2-bromobenzoic acid for o-toluic acid in Example 329B. [1197]
  • MS(ESI) m/e 399 (M+H)[1198] +;
  • [1199] 1H NMR (500 MHz, CD3OD) δ 7.72 (m, 1H), 7.69 (m, 1H), 7.46 (m, 1H), 7.41 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.38-1.18 (m, 3H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 340 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-cyanobenzohydrazide
  • The desired compound was prepared by substituting 3-cyanobenzoic acid for o-toluic acid in Example 329B. [1200]
  • MS(ESI) m/e 345 (M+H)[1201] +;
  • [1202] 1H NMR (500 MHz, CD3OD) δ 8.23 (m, 1H), 8.17 (m, 1H), 7.96 (m, 1H), 7.71 (m, 1H), 4.46 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.58 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.5H), 0.92 (m, 0.5H).
    • EXAMPLE 341 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-cyanobenzohydrazide
  • The desired compound was prepared by substituting 4-cyanobenzoic acid for o-toluic acid in Example 329B. [1203]
  • MS(ESI) m/e 345 (M+H)[1204] +;
  • [1205] 1H NMR (500 MHz, CD3OD) δ 8.02 (m, 2H), 7.88 (m, 2H), 4.46 (d, 0.3H), 4.37 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 111), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 342 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(dimethylamino)benzohydrazide
  • The desired compound was prepared by substituting 3-dimethylaminobenzoic acid for o-toluic acid in Example 329B. [1206]
  • MS(ESI) m/e 363 (M+H)[1207] +;
  • [1208] 1H NMR (500 MHz, CD3OD) δ 7.32 (t, 1H), 7.28 (m, 1H), 7.21 (m, 1H), 7.01 (dd, 1H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.68 (m, 1H), 3.01-3.00 (2S, 6H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.32 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 343 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(dimethylamino)benzohydrazide
  • The desired compound was prepared by substituting 4-dimethylaminobenzoic acid for o-toluic acid in Example 329B. [1209]
  • MS(ESI) m/e 363 (M+H)[1210] +; 1H NMR (500 MHz, CD3OD) δ 7.78 (d, 2H), 7.65 (d, 2H), 6.53 (m, 1H), 4.42 (d, 0.3H), 4.35 (d, 0.7H), 3.68 (m, 1H), 3.04 (2S, 6H), 1.85-1.63 (m, 6H), 1.57 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 344 N′-((2RS,3R)-3-amino-4-cyclohexvl-2-hydroxybutanoyl)-3-(trifluoromethyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(trifluoromethyl)benzoic acid for o-toluic acid in Example 329B. [1211]
  • MS(ESI) m/e 388 (M+H)[1212] +;
  • [1213] 1H NMR (500 MHz, CD3OD) δ 8.21 (s, 1H), 8.14 (m, 1H), 7.93 (m, 1H), 7.73 (m, 1H), 4.45 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 345 N′-((2RS.3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(trifluoromethyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(trifluoromethyl)benzoic acid for o-toluic acid in Example 329B. [1214]
  • MS(ESI) m/e 388 (M+H)[1215] +; 1H NMR (500 MHz, CD3OD) δ 8.06 (m, 2H), 7.82 (m, 2H), 4.46 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 346 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(trifluoromethoxy)benzohydrazide
  • The desired compound was prepared by substituting 3-(trifluoromethoxy)benzoic acid for o-toluic acid in Example 329B. [1216]
  • MS(ESI) m/e 404 (M+H)[1217] +;
  • [1218] 1H NMR (500 MHz, CD3OD) δ 7.89 (m, 1H), 7.80 (s, 1H), 7,62 (m, 1H), 7.53 (m, 1H), 4.46 (d, 0.3H), 4.38 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 347 N′-((2RS 3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-phenoxybenzohydrazide
  • The desired compound was prepared by substituting 4-phenoxybenzoic acid for o-toluic acid in Example 329B. [1219]
  • MS(ESI) m/e 412 (M+H)[1220] +;
  • [1221] 1H NMR (500 MHz, CD3OD) δ 7.89 (m, 2H), 7.42 (m, 2H), 7.21 (m, 1H), 7.07 (m, 2H), 7.03 (m, 2H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.69 (m, 1H), 1.85-1.64 (m, 6H), 1.56 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 348 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dimethylbenzohydrazide
  • The desired compound was prepared by substituting 2, 4-dimethylbenzoic acid for o-toluic acid in Example 329B. [1222]
  • MS(ESI) m/e 348 (M+H)[1223] +;
  • [1224] 1H NMR (500 MHz, CD3OD) δ 7.41 (dd, 1H), 7.12 (s, 1H), 7.09 (m, 1H), 4.43 (d, 0.25H), 4.36 (d, 0.75H), 3.70 (m, 0.75H), 3.66 (m, 0.25H), 2.43 (s, 3H), 2.34 (s, 3H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.46 (m, 1H), 1.32 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.5H), 0.92 (m, 0.5H).
    • EXAMPLE 349 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethylbenzohydrazide
  • The desired compound was prepared by substituting 2, 5-dimethylbenzoic acid for o-toluic acid in Example 329B. [1225]
  • MS(ESI) m/e 348 (M+H)[1226] +;
  • [1227] 1H NMR (500 MHz, CD3OD) δ 7.33 (s, 1H), 7.21 (m, 1H), 7.17 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.70 (m, 0.7H), 3.66 (m, 0.3H), 2.41 (s, 3H), 2.34 (s, 3H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 350 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3 ,4-dimethylbenzohydrazide
  • The desired compound was prepared by substituting 3,4-dimethylbenzoic acid for o-toluic acid in Example 329B. [1228]
  • MS(ESI) m/e 348 (M+H)[1229] +;
  • [1230] 1H NMR (500 MHz, CD3OD) δ 7.66 (s, 1H), 7.62 (dd, 1H), 7.26 (dd, 1H), 4.44 (d, 0.3B), 4.36 (d, 0.7H), 3.68 (m, 1H), 2.07 (s, 6H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 351 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethylbenzohydrazide
  • The desired compound was prepared by substituting 3,5-dimethylbenzoic acid for o-toluic acid in Example 329B. [1231]
  • MS(ESI) m/e 348 (M+H)[1232] +;
  • [1233] 1H NMR (500 MHz, CD3OD) δ 7.50 (s, 2H), 7.26 (s, 0.75H), 7.24 (s, 0.25H), 4.44 (d, 0.25H), 4.36 (d, 0.75H), 3.68 (m, 1H), 2.37 (s, 6H), 1.85-1.65 (m, 6H), 1.55 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.03 (m, 1.5H), 0.92 (m, 0.5H).
    • EXAMPLE 352 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethoxybenzohydrazide
  • The desired compound was prepared by substituting 2, 3-dimethoxybenzoic acid for o-toluic acid in Example 329B. [1234]
  • MS(ESI) m/e 380 (M+H)[1235] +;
  • [1236] 1H NMR (500 MHz, CD3OD) δ 7.41 (m, 1H), 7.24 (td, 2H), 7.19 (td, 1H), 4.43 (d, 0.3H), 4.37 (d, 0.7H), 3.95 (s, 2.1H), 3.95 (s, 0.9H), 3.91 (s, 2.1H), 3.90 (s, 0.9H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 353 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4-dimethoxybenzohydrazide
  • The desired compound was prepared by substituting 3,4-dimethoxybenzoic acid for o-toluic acid in Example 329B. [1237]
  • MS(ESI) m/e 380 (M+H)[1238] +;
  • [1239] 1H NMR (500 MHz, CD3OD) δ 7.55 (m, 1H), 7.50 (d, 1H), 7.05 (dd, 1H), 4.44 (d, 0.3H), 4.37 (d, 0.7H), 3.90 (s, 3H), 3.88 (s, 3H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 354 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4,5-trimethoxybenzohydrazide
  • The desired compound was prepared by substituting 3,4,5-trimethoxybenzoic acid for o-toluic acid in Example 329B. [1240]
  • MS(ESI) m/e 410 (M+H)[1241] +;
  • [1242] 1H NMR (500 MHz, CD3OD) δ 7.25 (s, 2H), 4.46 (d, 0.3H), 4.37 (d, 0.7H), 3.89 (s, 6H), 3.83 (s, 3H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 355 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dichlorobenzohydrazide
  • The desired compound was prepared by substituting 2, 3-dichlorobenzoic acid for o-toluic acid in Example 329B. [1243]
  • MS(ESI) m/e 389 (M+H)[1244] +;
  • [1245] 1H NMR (500 MHz, CD3OD) δ 7.68 (td, 1H), 7.54 (dt, 1H), 6.42 (td, 111), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.69 (m, 1H), 1.85-1.65 (m, 6H), 1.55 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 356 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dichlorobenzohydrazide
  • The desired compound was prepared by substituting 2, 4-dichlorobenzoic acid for o-toluic acid in Example 329B. [1246]
  • MS(ESI) m/e 389 (M+H)[1247] +;
  • [1248] 1H NMR (500 MHz, CD3OD) δ 7.60 (m, 2H), 7.46 (m, 1H), 4.44 (d, 0.311), 4.35 (d, 0.7H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.55 (m, 1H), 1.46 (m, 1H), 1.33 (m, 2H), 1.23 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 357 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4-dichlorobenzohydrazide
  • The desired compound was prepared by substituting 3,4-dichlorobenzoic acid for o-toluic acid in Example 329B. [1249]
  • MS(ESI) m/e 389 (M+H)[1250] +;
  • [1251] 1H NMR (500 MHz, CD3OD) δ 8.05 (m, 1H), 7.80 (m, 1H), 7.68 (m, 1H), 4.45 (d, 0.3H), 4.37 (d, 0.7H), 3.67 (m, 1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 358 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dichlorobenzohydrazide
  • The desired compound was prepared by substituting 3,5-dichlorobenzoic acid for o-toluic acid in Example 329B. [1252]
  • MS(ESI) m/e 389 (M+H)[1253] +;
  • [1254] 1H NMR (500 MHz, CD3OD) δ 7.97-7.69 (m, 3H), 4.45 (d, 0.3H), 4.37 (d, 0.7H), 3.68 (m, 1H), 1.85-1.65 (m, 6H), 1.56 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 359 N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethylbenzohydrazide
  • The desired compound was prepared by substituting 2, 3-dimethylbenzoic acid for o-toluic acid in Example 329B. [1255]
  • MS(ESI) m/e 348 (M+H)[1256] +;
  • [1257] 1H NMR (500 MHz, CD3OD) δ 7.29 (m, 2H), 7.16 (m, 1H), 4.44 (d, 0.3H), 4.36 (d, 0.7H), 3.68 (m, 1H), 1.85-1.64 (m, 6H), 1.57 (m, 1H), 1.47 (m, 1H), 1.33 (m, 2H), 1.24 (m, 1H), 1.02 (m, 1.4H), 0.92 (m, 0.6H).
    • EXAMPLE 360 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzenesulfonohydrazide
  • The desired product was prepared by substituting benzenesulfonylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [1258]
  • MS(ESI) m/e 348 (M+H)[1259] +;
  • [1260] 1H NMR (300 M1z, DMSO-d6) δ 7.38 (m, 5H), 6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.30 (m, 0.4H), 4.14 (m, 0.6H), 3.87 (m, 1H), 2.60 (m, 2H), 2.45 (m, 2H), 1.64 (m, 1H), 1.36 (m, 1H), 1.16 (t, 3H).
    • EXAMPLE 361 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxvpentanoyl)-3-chlorobenzenesulfonohydrazide
  • The desired product was prepared by substituting 3-chlorophenylsulfonylhydrazine for O-phenyl hydroxylamine hydrochloride in [1261]
    • EXAMPLE 362 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthalenesulfonohydrazide
  • The desired product was prepared by substituting 1-naphthylsulfonylhydrazine for O-phenyl hydroxylamine hydrochloride in Example 98B. [1262]
  • MS(ESI) m/e 398 (M+H)[1263] +;
  • [1264] 1H NMR (300 MHz, DMSO-d6) δ10.25 (m, 1H), 10.14 (m, 1H), 8.70 (br s, 2H), 8.27 (m, 1H), 8.17 (m, 1H), 8.13 (m, 1H), 7.68 (m, 4H), 6.68 (d, 0.6H), 6.62 (d, 0.4H), 4.30 (m, 0.4H), 4.14 (m, 0.6H), 3.87 (m, 1H), 2.60 (m, 2H), 2.45 (m, 2H), 1.64 (m, 1H), 1.36 (m, 1H), 1.16 (t, 3H).
    • EXAMPLE 363 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzenesulfonohydrazide
  • The desired product was prepared by substituting 4-methylphenylsulfonylhydrazine for O-phenyl hydroxylamine hydrochloride in [1265]
    • EXAMPLE 364 (2RS,3R)-3-amino-N′-(3-(2-aminoethoxy)phenyl)-2-hydroxy-5-(isopropylsulfanvl)pentanohydrazide EXAMPLE 364A N-(tert-butoxycarbonyl)-2-bromoethylamine
  • A solution of 2-bromoethylamine hydrobromide (1.0 g, 4.9 mmol), di-tert-butyl dicarbonate (1.06 g, 4.9 mmol) and triethylamine (0.7 mL, 4.9 mmol) in dichloromethane (40 mL) was stirred at room temperature for 18h. The reaction mixture was diluted with ether, washed with brine, dried (Na[1266] 2SO4), and concentrated to give the title compound.
    • EXAMPLE 364B 3-(2-(tertbutoxycarbonylamino)ethoxy)benzoyl hydrazide
  • Example 364A, methyl-3-hydroxy-benzoate (1.09 g, 4.9 mmol) and potassium tert-butoxide (6.5 g, 5.8 mmol) in DMSO were stirred at room temperature for 16 hours. The reaction was poured into ice water and extracted with ether, washed with brine, dried over Na2SO4, evaporated, and treated with hydrazine hydrate in ethanol at reflux for 48h. The reaction mixture was evaporated to dryness to give the title compound. [1267]
    • EXAMPLE 364C (2RS,3R)-3-amino-N′-(3-(2-aminoethoxy)phenyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide
  • The desired product was prepared by substituting Example 364A for O-phenyl hydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [1268]
  • MS(ESI) m/e 383 (M-H)+. [1269]
  • [1270] 1H NMR (300 MHz, DMSO-d6) δ10.6 & 10.42 (s, 1H), 10.25 & 10.12 (s, 1H), 8.15 & 8.04 (br s, 2H), 7.56-7.33 (m, 3H), 7.2 (m, 1H), 6.67 & 6.59 (br s, 1H), 4.45 & 4.24 (m, 3H), 3.25 (m, 2H), 3.0-2.9 (m, 1H), 2.75-2.55 (m, 2H), 2.0-1.80 (m, 2H), 1.2 (m,6H).
    • EXAMPLE 365 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-bromobenzohydrazide
  • The desired product was prepared by substituting 3-bromobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1271]
  • MS(ESI) m/e 391 (M+H)[1272] +;
  • [1273] 1H NMR (500 MHz, CD3OD) δ 8.06 (ddd, 1H), 7.85 (ddd, 1H), 7.77 (ddd, 1H), 7.44 (m, 1H), 4.49 (d, 0.35), 4.44 (d, 0.65), 3.78 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 1.99 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 366 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-cyanobenzohydrazide
  • The desired product was prepared by substituting 2-cyanobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1274]
  • MS(ESI) m/e 337 (M+H)[1275] +;
  • [1276] 1H NMR (500 MHz, CD3OD) δ 8.23 (ddd, 1H), 8.16 (ddd, 1H), 7.96 (ddd, 1H), 7.71 (m, 1H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.28 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 367 N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-cyanobenzohydrazide
  • The desired product was prepared by substituting 4-cyanobenzoic acid for 3-(ethylsulfanyl)benzoic acid in Example 239B. [1277]
  • MS(ESI) m/e 337 (M+H); [1278]
  • [1279] 1H NMR (500 MHz, CD3OD) δ 8.02 (m, 2H), 7.88 (m, 2H), 4.50 (d, 0.35), 4.45 (d, 0.65), 3.79 (m, 1H), 2.71 (t, 2H), 2.61 (dd, 2H), 2.17 (dd, 1H), 2.00 (dt, 1H), 1.27 (t, 1.95H), 1.25 (t, 1.05H).
    • EXAMPLE 368 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropvlsulfanvl)pentanoyl)-3-hydroxybenzohydrazide
  • The title compound is obtained by substituting 3-hydroxybenzoyl hydrazide for O-phenylhydroxylamine hydrochloride and Example 123B for Example 98A in Example 98B. [1280]
  • MS(ESI) m/e 340 (M-H)+. [1281]
  • [1282] 1H NMR (300 MHz, DMSO-d6) δ10.44 & 10.26 (s, 1H), 10.17 & 10.06 (s, 1H), 9.78 & 9.74 (s, 1H), 8.05 & 8.7.97 (br s, 2H), 7.26 (m, 3H), 6.97 (m, 1H), 6.63 & 6.595(bd, 1H), 4.38 & 4.22 (m, 1H), 3.7 & 3.6 (m, 1H), 3.0-2.9 (m, 1H), 2.75-2.55 (m, 2H), 2.05-1.77 (m, 2H), 1.2 (m, 6H).
    • EXAMPLE 369 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methylbenzohydrazide EXAMPLE 369A N′-((2RS,3R)-3-(tert-butoxycarbonyl)amino-5-(isopropylsulfanyl)-2-hydroxypentanoyl)hydrazide
  • The desired compound was prepared by substituting Example 123B for Example 97A acid in Example 239A. [1283]
    • EXAMPLE 369B N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methylbenzohydrazide
  • To DCC resin (148 mg, 0.225 mmol) in 1.0 mL of dichloromethane was added 0.5 mL of a 0.45 M solution of HOBt (0.225 mmol) in dimethylacetamide/dichloromethane (1:6), and 0.5 mL of a 0.3M solution of o-toluic acid (0.15 mmol) in dimethylacetamide. After 5 minutes, 1.0 mL of a 0.225 M solution of Example 369A (0.225 mmol) in dimethylacetamide/dichloromethane (1:1) was added. The mixture was agitated for 18 hours and quenched with 0.19 g of trisamine resin (0.75 mmol) followed by 0.13 g of isocyanate resin (0.225 mmol) and agitated for 4 hours. The mixture was filtered and the resins washed with lx3 niL of dichioromethane, the solvent was removed in vacuo, and the crude material purified by reverse phase preparative HPLC. The resulting material was treated with 1 mL of 50% trifluoroacetic acid/dichloromethane and agitated at ambient temperature for 18 hours. The solvent was removed in vacuo to give the desired product. [1284]
  • MS(ESI) m/e 340 (M+H)[1285] +;
  • [1286] 1H NMR (500 MHz, CD3OD) δ 7.50 (m, 1H), 7.40 (ddd, 1H), 7.28 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.79 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.47 (2s, 3H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 370 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methylbenzohydrazide
  • The desired compound was prepared by substituting m-toluic acid for o-toluic acid in Example 369. [1287]
  • MS(ESI) m/e 340 (M+H)[1288] +;
  • [1289] 1H NMR (500 MHz, CD3OD) δ 7.69 (m, 2H), 7.40 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.41 (s, 3H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 371 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-4-methylbenzohydrazide
  • The desired compound was prepared by substituting p-toluic acid for o-toluic acid in Example 369. [1290]
  • MS(ESI) m/e 340 (M+H)[1291] +;
  • [1292] 1H NMR (500 MHz, CD3OD) δ 7.78 (m, 2H), 7.31 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.41 (s, 3H), 2.15 (m, 1H), 1.99 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 372 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methoxybenzohydrazide
  • The desired compound was prepared by substituting o-anisic acid for o-toluic acid in Example 369. [1293]
  • MS(ESI) m/e 356 (M+H)[1294] +;
  • [1295] 1H NMR (500 MHz, CD3OD) δ 7.99 (dd, 1H), 7.57 (m, 1H), 7.19 (m, 1H), 7.09 (m, 1H), 4.48 (d, 0.3H), 4.45 (d, 0.7H), 4.00 (s, 2.1H), 3.99 (s, 0.9H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 373 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methoxybenzohydrazide
  • The desired compound was prepared by substituting m-anisic acid for o-toluic acid in Example 369. [1296]
  • MS(ESI) m/e 356 (M+H)[1297] +;
  • [1298] 1H NMR (500 MHz, CD3OD) δ 7.43 (m, 3H), 7.16 (m, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.85 (s, 3H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 374 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-methoxybenzohvdrazide
  • The desired compound was prepared by substituting p-anisic acid for o-toluic acid in Example 369. [1299]
  • MS(ESI) m/e 356 (M+H)[1300] +;
  • [1301] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 2H), 7.02 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.87 (s, 2,1H), 3.86 (s, 0.9H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 375 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-fluorobenzohydrazide
  • The desired compound was prepared by substituting o-fluorobenzoic acid for o-toluic acid in Example 369. [1302]
  • MS(ESI) mle 344 (M+H)[1303] +;
  • [1304] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 1H), 7.60 (m, 1H), 7.33 (m, 1H), 7.27 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 376 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-fluorobenzohydrazide
  • The desired compound was prepared by substituting m-fluorobenzoic acid for o-toluic acid in Example 369. [1305]
  • MS(ESI) m/e 344 (M+H)[1306] +; 1H NMR (500 MHz, CD3OD) δ 7.72 (t, 1H), 7.62 (m, 1H), 7.53 (ddd, 1H), 7.36 (ddd, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 377 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-fluorobenzohydrazide
  • The desired compound was prepared by substituting p-fluorobenzoic acid for o-toluic acid in Example 369. [1307]
  • MS(ESI) m/e 344 (M+H)[1308] +;
  • [1309] 1H NMR (500 MHz, CD3OD) δ 7.95 (m, 2H), 7.24 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 378 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chlorobenzohydrazide
  • The desired compound was prepared by substituting o-chlorobenzoic acid for o-toluic acid in Example 369. [1310]
  • MS(ESI) m/e 360 (M+H)[1311] +;
  • [1312] 1H NMR (500 MHz, CD3OD) δ 7.61 (m, 1H), 7.50 (m, 2H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • (399005) EXAMPLE 379 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-chlorobenzohydrazide
  • The desired compound was prepared by substituting p-chlorobenzoic acid for o-toluic acid in Example 369. [1313]
  • MS(ESI) m/e 360 (M+H)[1314] +;
  • [1315] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 2H), 7.52 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 380 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropvlsulfanyl)pentanoyl)-2-bromobenzohydrazide
  • The desired compound was prepared by substituting o-bromobenzoic acid for o-toluic acid in Example 369. [1316]
  • MS(ESI) m/e 405 (M+H)[1317] +;
  • [1318] 1H NMR (500 MHz, CD3OD) δ 7.69 (m, 1H), 7.59 (m, 1H), 7.46 (m, 1H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 381 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-bromobenzohydrazide
  • The desired compound was prepared by substituting 3-bromobenzoic acid for o-toluic acid in Example 369. [1319]
  • MS(ESI) m/e 405 (M+H)[1320] +;
  • [1321] 1H NMR (500 MHz, CD3OD) δ 8.06 (dt, 1H), 7.85 (m, 1H), 7.77 (m, 1H), 7.44 (m, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 382 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-bromobenzohydrazide
  • The desired compound was prepared by substituting 4-bromobenzoic acid for o-toluic acid in Example 369. [1322]
  • MS(ESI) m/e 405 (M+H)[1323] +;
  • [1324] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.68 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 383 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-dichlorobenzohydrazide
  • The desired compound was prepared by substituting 2, 3-dichlorobenzoic acid for o-toluic acid in Example 369. [1325]
  • MS(ESI) m/e 395 (M+H)[1326] +;
  • [1327] 1H NMR (500 MHz, CD3OD) δ 7.69 (td, 1H), 7.53 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 384 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(tetrahydro-2-furanylcarbonyl)pentanohvdrazide
  • The desired compound was prepared by substituting tetrahydrofuran-2-carboxylic acid for o-toluic acid in Example 369. [1328]
  • MS(ESI) m/e 320 (M+H)[1329] +;
  • [1330] 1H NMR (500 MHz, CD3OD) δ 4.45 (m, 1.3H), 4.38 (d, 0.7H), 4.02 (m, 1H), 3.87 (m, 1H), 3.73 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.29 (m, 1H), 2.10 (m, 2H), 1.94 (m, 3H), 1.28-1.23 (m, 6H).
    • EXAMPLE 385 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(tetrahydro-3-furanylcarbonyl)pentanohydrazide
  • The desired compound was prepared by substituting tetrahydro-3-furic acid for o-toluic acid in Example 369. [1331]
  • MS(ESI) m/e 320 (M+H)[1332] +;
  • [1333] 1H NMR (500 MHz, CD3OD) δ 4.42 (d, 0.3H), 4.38 (d, 0.7H), 3.96 (m, 1H), 3.88 (m, 2H), 3.79 (m, 1H), 3.72 (m, 1H), 3.10 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.13 (m, 3H), 1.94 (m, 1H), 1.28-1.23 (m, 6H).
    • EXAMPLE 386 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-cyclopentylpentanohydrazide
  • The desired compound was prepared by substituting cyclopentanecarboxylic acid for o-toluic acid in Example 369. [1334]
  • MS(ESI) m/e 318 (M+H)[1335] +;
  • [1336] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.3H), 4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.70 (m, 2H), 2.11(m, 1H), 2.10 (m, 1H), 1.91 (m, 3H), 1.77 (m, 5H), 1.62 (m, 1H), 1.28-1.23 (m, 6H).
    • EXAMPLE 387 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclopentylacetohydrazide
  • The desired compound was prepared by substituting cyclopentylacetic acid for o-toluic acid in Example 369. [1337]
  • MS(ESI) m/e 332 (M+H)[1338] +;
  • [1339] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.3H), 4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.27 (m, 3H), 2.10 (m, 1H), 1.94 (m, 1H), 1.85 (m, 2H), 1.67 (m, 2H), 1.58 (m, 2H), 1.28-1.23 (m, 8H).
    • EXAMPLE 388 (2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-cyclohexylpentanohydrazide
  • The desired compound was prepared by substituting cyclohexanecarboxylic acid for o-toluic acid in Example 369. [1340]
  • MS(ESI) m/e 332 (M+H)[1341] +;
  • [1342] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.3H), 4.37 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.30 (m, 1H), 2.10 (m, 1H), 1.94 (m, 1H), 1.82 (m, 4H), 1.71 (m, 1H), 1.48 (m, 2H), 1.37-1.23 (m, 9H).
    • EXAMPLE 389 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclohexylacetohydrazide
  • The desired compound was prepared by substituting cyclohexylacetic acid for o-toluic acid in Example 369. [1343]
  • MS(ESI) m/e 346 (M+H)[1344] +;
  • [1345] 1H NMR (500 MHz, CD3OD) δ 4.41 (d, 0.3H), 4.36 (d, 0.7H), 3.72 (m, 1H), 2.98 (m, 1H), 2.69 (t, 2H), 2.12 (m, 3H), 1.94 (m, 1H), 1.74 (m, 6H), 1.26 (m, 9H), 1.02 (m, 2H).
    • EXAMPLE 390 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-2-furohydrazide
  • The desired compound was prepared by substituting furan-2-carboxylic acid for o-toluic acid in Example 369. [1346]
  • MS(ESI) m/e 316(M+H)[1347] +;
  • [1348] 1H NMR (500 MHz, CD3OD) δ 7.74 (d, 0.7H), 7.72 (d, 0.3H), 7.24 (d, 0.7H), 7.21 (d, 0.3H), 6.64 (m, 1H), 4.47 (d, 0.3H), 4.43 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.28-1.23 (m, 6H).
    • EXAMPLE 391 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-furohydrazide
  • The desired compound was prepared by substituting furan-3-carboxylic acid for o-toluic acid in Example 369. [1349]
  • MS(ESI) m/e 316 (M+H)[1350] +;
  • [1351] 1H NMR (500 MHz, CD3OD) δ 8.17 (d, 0.7H), 8.14 (d, 0.3H), 7.62 (m, 1H), 6.83 (m, 1H), 4.47 (d, 0.3H), 4.43 (d, 0.7H), 3.75 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.28-1.23 (m, 6H).
    • EXAMPLE 392 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,5-dimethyl-3-furohydrazide
  • The desired compound was prepared by substituting 2,5-dimethyl-3-furoic acid for o-toluic acid in Example 369. [1352]
  • MS(ESI) m/e 344 (M+H)[1353] +;
  • [1354] 1H NMR (500 MHz, CD3OD) δ 6.32 (s, 0.7H), 6.31 (d, 0.3H), 4.46 (d, 0.3H), 4.41 (d, 0.7H), 3.75 (m, 1H), 3.00 (m, 1H), 2.70 (t, 2H), 2.50 (s, 3H), 2.25 (s, 3H), 2.14 (m, 1H), 1.97 (m, 1H), 1.28-1.23 (m, 6H).
    • EXAMPLE 393 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-2-thiophenecarbohydrazide
  • The desired compound was prepared by substituting thiophene-2-carboxylic acid for o-toluic acid in Example 369. [1355]
  • MS(ESI) m/e 332 (M+H)[1356] +;
  • [1357] 1H NMR (500 MHz, CD3OD) δ 7.77 (m, 2H), 7.17 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 394 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-thiophenecarbohydrazide
  • The desired compound was prepared by substituting thiophene-3-carboxylic acid for o-toluic acid in Example 369. [1358]
  • MS(ESI) m/e 332 (M+H)[1359] +;
  • [1360] 1H NMR (500 MHz, CD3OD) δ 8.19 (m, 0.7H), 8.16 (m, 0.3H), 7.54 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 395 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methyl-2-thiophenecarbohydrazide
  • The desired compound was prepared by substituting 3-methylthiophene-2-carboxylic acid for o-toluic acid in Example 369. [1361]
  • MS(ESI) m/e 346 (M+H)[1362] +;
  • [1363] 1H NMR (500 MHz, CD3OD) δ 7.56 (d, 0.7H), 7.53 (d, 0.3H), 6.99 (m, 1H), 4.47 (d, 0.3H), 4.43 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.51 (s, 2.1H), 2.50 (s, 0.9H), 2.14 (m, 1H), 1.97 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 396 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-methyl-2-thiophenecarbohydrazide
  • The desired compound was prepared by substituting 5-methylthiophene-2-carboxylic acid for o-toluic acid in Example 369. [1364]
  • MS(ESI) m/e 346 (M+H)[1365] +;
  • [1366] 1H NMR (500 MHz, CD3OD) δ 7.61 (d, 0.7H), 7.58 (d, 0.3H), 6.86 (m, 1H), 4.46 (d, 0.3H), 4.42 (d, 0.7H), 3.76 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.53(s, 3H), 2.14 (m, 1H), 1.97 (m, 1H), 1.28-1.24 (m, 6H).
    • EXAMPLE 397 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-IH-pyrrole-2-carbohydrazide
  • The desired compound was prepared by substituting pyrrole-2-carboxylic acid for o-toluic acid in Example 369. [1367]
  • MS(ES1) m/e 315 (M+H)[1368] +;
  • [1369] 1H NMR (500 MHz, CD3OD) δ 6.99 (m, 1H), 6.90 (m, 1H), 6.21 (m, 1H), 4.45 (d, 0.3H), 4.42 (d, 0.7H), 3.76 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.13 (m, 1H), 1.97 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 398 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanYl)pentanoyl)-1-methyl-1H-pyrrole-2-carbohydrazide
  • The desired compound was prepared by substituting 1-methylpyrrole-2-carboxylic acid for o-toluic acid in Example 369. [1370]
  • MS(ESI) m/e 329 (M+H)[1371] +;
  • [1372] 1H NMR (500 MHz, CD3OD) δ 6.90 (m, 2H), 6.10 (m, 1H), 4.45 (d, 0.3H), 4.42(d, 0.7H), 3.89 (s, 3H), 3.76 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 399 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazole-2-carbohydrazide
  • The desired compound was prepared by substituting thiazole-2-carboxylic acid for o-toluic acid in Example 369. [1373]
  • MS(ESI) m/e 333 (M+H)[1374] +;
  • [1375] 1 H NMR (500 MHz, CD3OD) δ 8.02 (d, 0.6H), 8.00 (d, 0.4H), 7.94 (d, 0.6H), 7.92 (d, 0.4H), 4.49 (d, 0.4H), 4.44 (d, 0.6H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.29-1.26 (m, 6H).
    • EXAMPLE 400 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazole-4-carbohydrazide
  • The desired compound was prepared by substituting thiazole-4-carboxylic acid for o-toluic acid in Example 369. [1376]
  • MS(ESI) m/e 333 (M+H)[1377] +;
  • [1378] 1H NMR (500 MHz, CD3OD) δ 90.6 (d, 0.7H), 9.04 (d, 0.3H), 8.41 (d, 0.7H), 8.37 (d, 0.3H), 4.48 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 111), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 401 N′-((2RS,3R)-3-amino-2-hydroxy-5-isopropylpentanoyl)-2-pyridinecarbohydrazide
  • The desired compound was prepared by substituting pyridine-2-carboxylic acid for o-toluic acid in Example 369. [1379]
  • MS(ESI) m/e 327 (M+H)[1380] +;
  • [1381] 1H NMR (500 MHz, CD3OD) δ 8.67 (t, 1H), 8.11 (t, 1H), 7.99 (m, 1H), 7.61 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.79 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 402 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-6-chloro-2H-chromene-3-carbohydrazide
  • The desired compound was prepared by substituting 6-chloro(2H)-1-benzopyran-3-carboxylic acid for o-toluic acid in Example 369. [1382]
  • MS(ESI) m/e 414 (M+H)[1383] +;
  • [1384] 1H NMR (500 MHz, CD3OD) δ 7.28 (s, 1H), 7.23 (m, 2H), 6.84 (m, 1H), 4.97 (s, 2H), 4.47 (d, 0.3H), 4.42 (d, 0.7H), 3.75 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.13 (m, 1H), 1.96 (m, 1H), 1.28-1.24 (m, 6H).
    • EXAMPLE 403 N′-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-2-(4-morpholinyl)acetohydrazide
  • The desired compound was prepared by substituting 1-morpholineacetic acid for o-toluic acid in Example 369. [1385]
  • MS(ESI) m/e 349 (M+H)[1386] +;
  • [1387] 1H NMR (500 MHz, CD3OD) δ 4.48 (d, 0.3H), 4.39 (d, 0.7H), 3.91 (m, 6H), 3.73 (m, 1H), 3.27 (m, 4H), 2.98 (m, 1H), 2.70 (t, 2H), 2.11 (m, 1H), 1.94 (m, 1H), 1.27-1.23 (m, 6H).
    • EXAMPLE 404 N′-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-2-(4-methyl-1-piperazinyl)acetohydrazide
  • The desired compound was prepared by substituting 4-N-methylpiperazine-1-acetic acid for o-toluic acid in Example 369. [1388]
  • MS(ESI) m/e 362 (M+H)[1389] +;
  • [1390] 1H NMR (500 MHz, CD3OD) δ 4.47-4.30 (m, 1H), 3.73 (m, 2H), 3.48 (m, 2H), 3.31 (m, 3H), 3.16 (m, 2H), 3.00 (m, 1H), 2.90 (s, 2H), 2.69 (m, 4H), 2.09 (m, 1H), 1.93 (m, 2H), 1.28-1.22 (m, 6H).
    • EXAMPLE 405 1-acetyl-N′-((2RS,3R)-3-amino-2-hydroxy-7-(isopropylsulfanyl)pentanoyl)-4-piperidinecarbohydrazide
  • The desired compound was prepared by substituting 1-acetylpiperidine-4-carboxylic acid for o-toluic acid in Example 369. [1391]
  • MS(ESI) m/e 375 (M+H)[1392] +;
  • [1393] 1H NMR (500 MHz, CD3OD) δ 4.49 (m, 1H), 4.42(d, 0.3H), 4.37 (d, 0.7H), 3.96 (m, 1H), 3.72 (m, 1H), 3.19 (m, 1H), 2.98 (m, 1H), 2.70 (m, 2H), 2.59 (m, 1H), 2.10 (m, 4H), 1.91 (m, 3H), 1.66 (m, 2H), 1.28-1.23 (m, 6H).
    • EXAMPLE 406 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethylbenzohydrazide
  • The desired compound was prepared by substituting 4-ethylbenzoic acid for o-toluic acid in Example 369. [1394]
  • MS(ESI) m/e 354 (M+H)[1395] +;
  • [1396] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 2H), 7.34 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 4H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 9H).
    • EXAMPLE 407 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanvl)pentanovl)-3-fluoro-2-methylbenzohydrazide
  • The desired compound was prepared by substituting 3-fluoro-2-methyl-benzoic acid for o-toluic acid in Example 369. [1397]
  • MS(ESI) m/e 358 (M+H)[1398] +;
  • [1399] 1H NMR (500 MHz, CD3OD) δ 7.32 (m, 2H), 7.21 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.79 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.36 (m, 3H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 408 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-difluorobenzohydrazide
  • The desired compound was prepared by substituting 2, 3-difluorobenzoic acid for o-toluic acid in Example 369. [1400]
  • MS(ESI) m/e 362 (M+H)[1401] +;
  • [1402] 1H NMR (500 MHz, CD3OD) δ 7.55 (m, 1H), 7.49 (m, 1H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 409 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propylbenzohydrazide
  • The desired compound was prepared by substituting 4-N-propylbenzoic acid for o-toluic acid in Example 369. [1403]
  • MS(ESI) m/e 368 (M+H)[1404] +;
  • [1405] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 1H), 7.32 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.70 (t, 4H), 2.15 (m, 1H), 1.98 (m, 1H), 1.68 (m, 2H), 1.29-1.24 (m, 6H), 0.95 (t, 1H).
    • EXAMPLE 410 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropylbenzohydrazide
  • The desired compound was prepared by substituting 4-isopropylbenzoic acid for o-toluic acid in Example 369. [1406]
  • MS(ESI) m/e 368 (M+H)[1407] +;
  • [1408] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 2H), 7.38 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 12H).
    • EXAMPLE 411 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-2-ethoxybenzohydrazide
  • The desired compound was prepared by substituting 2-ethoxybenzoic acid for o-toluic acid in Example 369. [1409]
  • MS(ESI) m/e 370 (M+H)[1410] +;
  • [1411] 1H NMR (500 MHz, CD3OD) δ 7.97 (m, 1H), 7.54 (m, 1H), 7.18 (m, 1H), 7.09 (t, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 4.29 (q, 2H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.51 (t, 3H), 1.29-1.24 (m, 6H).
    • EXAMPLE 412 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethoxybenzohydrazide
  • The desired compound was prepared by substituting 4-ethoxybenzoic acid for o-toluic acid in Example 369. [1412]
  • MS(ESI) m/e 370 (M+H)[1413] +;
  • [1414] 1H NMR (500 MHz, CD3OD) δ 7.85 (m, 1H), 6.99 (m, 1H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 4.12 (q, 2H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.41 (t, 3H), 1.29-1.24 (m, 6H).
    • EXAMPLE 413 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanovl)-1-naphthohydrazide
  • The desired compound was prepared by substituting 1-naphthoic acid for o-toluic acid in Example 369. [1415]
  • MS(ESI) m/e 376 (M+H)[1416] +;
  • [1417] 1H NMR (500 MHz, CD3OD) δ 7.38 (m, 1H), 8.04 (t, 1H), 7.95 (m, 1H), 7.77 (t, 1H), 7.56 (m, 3H), 4.53 (d, 0.3H), 4.49 (d, 0.7H), 3.84 (m, 1H), 3.02 (m, 1H), 2.74 (t, 2H), 2.19 (m, 1H), 2.01 (m, 1H), 1.31-1.24 (m, 6H).
    • EXAMPLE 414 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-tert-butylbenzohydrazide
  • The desired compound was prepared by substituting 4-tert-butylbenzoic acid for o-toluic acid in Example 369. [1418]
  • MS(ESI) m/e 382 (M+H)[1419] +;
  • [1420] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 2H), 7.55 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.99 (m, 1H), 1.35 (s, 9H), 1.29-1.24 (m, 6H).
    • EXAMPLE 415 N-(4-((2-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)hydrazino)carbonyl)phenyl)acetamide
  • The desired compound was prepared by substituting 4-acetamidobenzoic acid for o-toluic acid in Example 369. [1421]
  • MS(ESI) m/e 383 (M+H)[1422] +;
  • [1423] 1H NMR (500 MHz, CD3OD) δ 7.86 (m, 2H), 7.71 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 4H), 1.97 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 416 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propoxybenzohydrazide
  • The desired compound was prepared by substituting p-propoxybenzoic acid for o-toluic acid in Example 369. [1424]
  • MS(ESI) m/e 384 (M+H)[1425] +;
  • [1426] 1H NMR (500 MHz, CD3OD) δ 7.85 (m, 2H), 7.00 (m, 2H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 4.01 (m,2H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.82 (m, 2H), 1.29-1.24 (m, 6H), 1.05 (t, 3H).
    • EXAMPLE 417 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropoxybenzohydrazide
  • The desired compound was prepared by substituting 4-isopropoxybenzoic acid for o-toluic acid in Example 369. [1427]
  • MS(ESI) m/e 384 (M+H)[1428] +;
  • [1429] 1H NMR (500 MHz, CD3OD) δ 7.84 (m, 2H), 6.98 (m, 2H), 4.71 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.34 (d, 6H), 1.29-1.24 (m, 6H).
    • EXAMPLE 418 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-chloro-2-methoxybenzohydrazide
  • The desired compound was prepared by substituting 5-chloro-2-methoxybenzoic acid for o-toluic acid in Example 369. [1430]
  • MS(ESI) m/e 390 (M+H)[1431] +;
  • [1432] 1H NMR (500 MHz, CD3OD) δ 7.92 (d, 0.7H), 7.89 (d, 0.3H), 7.55 (td, 1H), 7.20 (m, 1H), 4.47 (d, 0.3H), 4.44 (d, 0.7H), 4.00 (s, 2.1H), 3.98 (s, 0.9H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 419 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4 (methylsulfonyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(methylsulfonyl)benzoic acid for o-toluic acid in Example 369. [1433]
  • MS(ESI) m/e 404 (M+H)[1434] +;
  • [1435] 1H NMR (500 MHz, CD3OD) δ 8.10 (s, 2.8H), 8.09 (s, 1.2H), 4.51 (d, 0.3H), 4.46 (d, 0.7H), 3.78 (m, 1H), 3.17 (s, 2.8H), 3.17 (s, 1.2H), 3.01 (m, 1H), 2.72 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 420 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chloro-5-(methylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 2-chloro-5-(methylthio)benzoic acid for o-toluic acid in Example 369. [1436]
  • MS(ESI) m/e 406 (M+H)[1437] +;
  • [1438] 1H NMR (500 MHz, CD3OD) δ 7.49 (d, 1H), 7.43-7.35 (m, 2H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.52 (s, 1H), 2.15 (m, 1H), 1.97 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 421 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3,4-diethoxybenzohydrazide
  • The desired compound was prepared by substituting 3,4-diethoxybenzoic acid for o-toluic acid in Example 369. [1439]
  • MS(ESI) m/e 414 (M+H)[1440] +;
  • [1441] 1H NMR (500 MHz, CD3OD) δ 7.51 (m, 1H), 7.48 (m, 1H), 7.02 (m, 1H), 4.47 (d, 0.3H), 4.44 (d, 0.7H), 4.12 (m, 4H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.43 (m, 6H), 1.29-1.24 (m, 6H).
    • EXAMPLE 422 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-benzylbenzohydrazide
  • The desired compound was prepared by substituting alpha-phenyl-o-toluic acid for o-toluic acid in Example 369. [1442]
  • MS(ESI) m/e 416 (M+H)[1443] +;
  • [1444] 1H NMR (500 MHz, CD3OD) δ 7.54 (t, 1H), 7.40 (m, 1H), 7.29 (t, 1H), 7.23 (m, 5H), 7.16 (m, 1H), 4.49 (d, 0.3H), 4.43 (d, 0.7H), 4.19 (m, 1H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.97 (m, 1H), 1.29-1.19 (m, 6H).
    • EXAMPLE 423 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-anilinobenzohydrazide
  • The desired compound was prepared by substituting N-phenylanthranilic acid for o-toluic acid in Example 369. [1445]
  • MS(ESI) m/e 417 (M+H)[1446] +;
  • [1447] 1H NMR (500 MHz, CD3OD) δ 7.68 (m, 1H), 7.32 (m, 4H), 7.16 (d, 2H), 7.02 (m, 1H), 6.83 (m, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.16 (m, 1H), 1.98 (m, 1H), 1.28-1.19 (m, 6H).
    • EXAMPLE 424 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(2-phenylethyl)benzohydrazide
  • The desired compound was prepared by substituting 2-bibenzylcarboxylic acid for o-toluic acid in Example 369. [1448]
  • MS(ESI) m/e 430 (M+H)[1449] +;
  • [1450] 1H NMR (500 MHz, CD3OD) δ 7.53 (m, 1H), 7.40 (m, 1H), 7.28 (m, 2H), 7.23 (d, 4H), 7.15 (m, 1H), 4.50 (d, 0.3H), 4.45 (d, 0.7H), 3.81 (m, 1H), 3.10 (m, 2H), 3.01 (m, 1H), 2.93 (m, 2H), 2.72 (t, 2H), 2.17 (m, 1H), 1.99 (m, 1H), 1.29-1.20 (m, 6H).
    • EXAMPLE 425 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(methylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(methylthio)benzoic acid for o-toluic acid in Example 369. [1451]
  • MS(ESI) m/e 372 (M+H)[1452] +;
  • [1453] 1H NMR (500 MHz, CD3OD) δ 7.77 (m, 1H), 7.63 (m, 1H), 7.48 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.53 (s, 3H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 426 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(ethylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(ethylthio)benzoic acid for o-toluic acid in Example 369. [1454]
  • MS(ESI) m/e 386 (M+H)[1455] +;
  • [1456] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 1H), 7.67 (m, 1H), 7.54 (m, 1H), 7.43 (m, 1H), 4.49 (d, 0.311), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.33-1.25 (m, 9H).
    • EXAMPLE 427 N′-((2RS,3R)-3-amino-2-hvdroxv-5-(isopropylsulfanyl)pentanoyl)-3-(propylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(propylthio)benzoic acid for o-toluic acid in Example 369. [1457]
  • MS(ES1) m/e 400 (M+H)[1458] +;
  • [1459] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 1H), 7.66 (t, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.68 (m, 2H), 1.29-1.24 (m, 6H), 1.04 (t, 3H).
    • EXAMPLE 428 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(butylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(butylthio)benzoic acid for o-toluic acid in Example 369. [1460]
  • MS(ESI) m/e 414 (M+H)[1461] +;
  • [1462] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 1H), 7.66 (t, 1H), 7.54 (t, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.64 (m, 2H), 1.49 (m, 2H), 1.29-1.24 (m, 6H), 0.94 (t, 3H).
    • EXAMPLE 429 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(hexylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(hexylthio)benzoic acid for o-toluic acid in Example 369. [1463]
  • MS(ESI) m/e 442 (M+H)[1464] +;
  • [1465] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 1H), 7.66 (t, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.65 (m, 2H), 1.46 (m, 2H), 1.32-1.24 (m, lOH), 0.90 (t, 3H).
    • EXAMPLE 430 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isopropylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(isopropylthio)benzoic acid for o-toluic acid in Example 369. [1466]
  • MS(ESI) m/e 400 (M+H)[1467] +;
  • [1468] 1H NMR (500 MHz, CD3OD) δ 7.90 (m, 1H), 7.73 (m, 1H), 7.61 (m, 1H), 7.45 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.51 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.30-1.24 (m, 12H).
    • EXAMPLE 431 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isobutvlsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(2-methylpropylthio)benzoic acid for o-toluic acid in Example 369. [1469]
  • MS(ESI) m/e 414 (M+H)[1470] +;
  • [1471] 1H NMR (500 MHz, CD3OD) δ 7.84 (m, 1H), 7.65 (m, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.90 (d, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.86 (m, 1H), 1.29-1.24 (m, 6H), 1.05 (d, 6H).
    • EXAMPLE 432 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-3-((4-methylpentyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(4-methylpentylthio)benzoic acid for o-toluic acid in Example 369. [1472]
  • MS(ESI) m/e 442 (M+H)[1473] +;
  • [1474] 1H NMR (500 MHz, CD3OD) δ 7.83 (m, 1H), 7.66 (m, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.66 (m, 2H), 1.56 (m, 1H), 1.34 (m, 2H), 1.29-1.24 (m, 6H), 0.89 (d, 6H).
    • EXAMPLE 433 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(sec-butylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(1-methylpropylthio)benzoic acid for o-toluic acid in Example 369. [1475]
  • MS(ESI) m/e 414 (M+H)[1476] +;
  • [1477] 1H NMR (500 MHz, CD3OD) δ 7.90 (m, 1H), 7.72 (m, 1H), 7.61 (m, 1H), 7.44 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.31 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.62 (m, 2H), 1.29-1.24 (m, 9H), 1.03 (t, 3H).
    • EXAMPLE 434 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(neopentylsulfanvl)benzohvdrazide
  • The desired compound was prepared by substituting 3-(2,2-dimethylpropylthio)benzoic acid for o-toluic acid in Example 369. [1478]
  • MS(ESI) m/e 428 (M+H)[1479] +;
  • [1480] 1H NMR (500 MHz, CD3OD) δ 7.86 (m, 1H), 7.65 (m, 1H), 7.57 (m, 1H), 7.40 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H), 1.05 (s, 9H).
    • EXAMPLE 435 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(cyclohexylsulfanvl)benzohydrazide
  • The desired compound was prepared by substituting 3-(cyclohexylthio)benzoic acid for o-toluic acid in Example 369. [1481]
  • MS(ESI) m/e 440 (M+H)[1482] +;
  • [1483] 1H NMR (500 MHz, CD3OD) δ 7.90 (m, 1H), 7.72 (m, 1H), 7.60 (m, 1H), 7.43 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.78 (m, 1H), 3.25 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 3H), 1.78 (m, 2H), 1.65 (m, 2H), 1.38 (m, 4H), 1.29-1.24 (m, 6H).
    • EXAMPLE 436 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((cyclohexylmethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(2-cyclohexylethylthio)benzoic acid for o-toluic acid in Example 369. [1484]
  • MS(ESI) mle 454 (M+H)[1485] +;
  • [1486] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 1H), 7.65 (t, 1H), 7.53 (t, 1H), 7.41 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.90 (d, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.91 (m, 2H), 1.74 (m, 2H), 1.66 (m, 2H), 1.53 (m, 1H), 1.29-1.18 (m, 8H), 1.05 (m, 2H).
    • EXAMPLE 437 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(benzylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(benzylthio)benzoic acid for o-toluic acid in Example 369. [1487]
  • MS(ESI) m/e 448 (M+H)[1488] +;
  • [1489] 1H NMR (500 MHz, CD3OD) δ 7.86 (m, 1H), 7.67 (m, 1H), 7.52 (m, 1H), 7.39 (m, 1H), 7.31 (d, 2H), 7.26 (t, 2H), 7.20 (m, 1H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 4.22 (s, 2H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 438 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((2-phenylethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(2-phenylethylthio)benzoic acid for o-toluic acid in Example 369. [1490]
  • MS(ESI) m/e 462 (M+H)[1491] +;
  • [1492] 1H NMR (500 MHz, CD3OD) δ 7.87 (m, 1H), 7.68 (m, 1H), 7.57 (m, 1H), 7.44 (m, 1H), 7.27 (t, 2H), 7.23-7.17 (m, 3H), 4.49 (d, 0.3H), 4.45 (d, 0.7H), 3.77 (m, 1H), 3.26 (t, 2H), 3.00 (m, 1H), 2.93 (t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 439 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((3-phenylpropyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(3-phenylpropylthio)benzoic acid for o-toluic acid in Example 369. [1493]
  • MS(ESI) m/e 476 (M+H)[1494] +;
  • [1495] 1H NMR (500 MHz, CD3OD) δ 7.84 (m, 1H), 7.67 (m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.25 (t, 2H), 7.15 (m, 3H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 3H), 2.76 (t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.96 (m, 3H), 1.29-1.24 (m, 6H).
    • EXAMPLE 440 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(((1,1 ′-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 3-(biphenylmethylthio)benzoic acid for o-toluic acid in Example 369. [1496]
  • MS(ESI) m/e 524 (M+H)[1497] +;
  • [1498] 1H NMR (500 MHz, CD3OD) δ 7.89 (s, 1H), 7.68 (m, 1H), 7.55 (m, 5H), 7.40 (m, 5H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 4.27 (m, 2H), 3.77 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 441 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(methylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(methylthio)benzoic acid for o-toluic acid in Example 369. [1499]
  • MS(ESI) m/e 372 (M+H)[1500] +;
  • [1501] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 2H), 7.34 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.53 (s, 3H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 442 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(ethylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(ethylthio)benzoic acid for o-toluic acid in Example 369. [1502]
  • MS(ESI) m/e 386 (M+H)[1503] +;
  • [1504] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 2H), 7.38 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.03 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.35 (t, 3H), 1.29-1.25 (m, 6H).
    • EXAMPLE 443 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(propylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(propylthio)benzoic acid for o-toluic acid in Example 369. [1505]
  • MS(ESI) m/e 400 (M+H)[1506] +;
  • [1507] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.38 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.01 (m, 3H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.72 (m, 2H), 1.29-1.24 (m, 6H), 1.06 (t, 3H).
    • EXAMPLE 444 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanoyl)-4-(butylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(butylthio)benzoic acid for o-toluic acid in Example 369. [1508]
  • MS(ESI) m/e 414 (M+H)[1509] +;
  • [1510] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.37 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.02 (m, 3H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.67 (m, 2H), 1.50 (m, 2H), 1.29-1.24 (m, 6H), 0.95 (t, 3H).
    • EXAMPLE 445 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(hexylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(hexylthio)benzoic acid for o-toluic acid in Example 369. [1511]
  • MS(ESI) m/e 442 (M+H)[1512] +;
  • [1513] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.37 (t, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.02 (m, 3H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.68 (m, 2H), 1.47 (m, 2H), 1.33 (m, 4H), 1.29-1.24 (m, 6H), 0.91 (t, 3H).
    • EXAMPLE 446 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isopropylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(isopropylthio)benzoic acid for o-toluic acid in Example 369. [1514]
  • MS(ESI) m/e 400 (M+H)[1515] +;
  • [1516] 1H NMR (500 MHz, CD3OD) δ 7.81 (m, 2H), 7.43 (dd, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.62 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.34 (d, 6H), 1.29-1.24 (m, 6H).
    • EXAMPLE 447 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isobutylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(2-methylpropylthio)benzoic acid for o-toluic acid in Example 369. [1517]
  • MS(ESI) m/e 414 (M+H)[1518] +;
  • [1519] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.38 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.00 (m, 1H), 2.92 (d, 2H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.90 (m, 1H), 1.29-1.24 (m, 6H), 1.06 (d, 6H).
    • EXAMPLE 448 N′-((2RS,3R)-3-arnino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-4-((4-methylpentyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(4-methylpentylthio)benzoic acid for o-toluic acid in Example 369. [1520]
  • MS(ESI) m/e 442 (M+H)[1521] +;
  • [1522] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.38 (m, 2H), 4.45 (d, 0.3H), 4.41 (d, 0.7H), 3.71 (m, 1H), 3.01 (m, 3H), 2.71 (t, 2H), 2.13 (m, 1H), 1.96 (m, 1H), 1.69 (m, 2H), 1.57 (m, 1H), 1.36 (m, 2H), 1.29-1.24 (m, 6H), 0.89 (d, 6H).
    • EXAMPLE 449 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(sec-butylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(1-methylpropylthio)benzoic acid for o-toluic acid in Example 369. [1523]
  • MS(ESI) m/e 414 (M+H)[1524] +;
  • [1525] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.43 (dd, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.65 (m, 2H), 1.33 (d, 3H), 1.29-1.24 (m, 6H), 1.04 (t, 3H).
    • EXAMPLE 450 N′-((2RS,3R)-3-amino-2-hydroxv-5-(isopropylsulfanyl)pentanovl)-4-(neopentylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(2, 2-dimethylpropylthio)benzoic acid for o-toluic acid in Example 369. [1526]
  • MS(ESI) m/e 428 (M+H)[1527] +;
  • [1528] 1H NMR (500 MHz, CD3OD) δ 7.79 (m, 2H), 7.42 (m, 2H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 3H), 2.72 (t, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H), 1.06 (s, 9H).
    • EXAMPLE 451 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(cyclohexylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(cyclohexylthio)benzoic acid for o-toluic acid in Example 369. [1529]
  • MS(ESI) mle 440 (M+H)[1530] +;
  • [1531] 1H NMR (500 MHz, CD3OD) δ 7.80 (m, 2H), 7.41 (m, 2H), 4.49 (d, 0.3H), 4.44 (d, 0.7H), 3.78 (m, 1H), 3.37 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 3H), 1.79 (m, 2H), 1.65 (m, 2H), 1.39 (m, 4H), 1.29-1.24 (m, 6H).
    • EXAMPLE 452 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((cyclohexylmethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(2-cyclohexylethylthio)benzoic acid for o-toluic acid in Example 369. [1532]
  • MS(ESI) m/e 454 (M+H)[1533] +;
  • [1534] 1 H NMR (500 MHz, CD3OD) δ 7.79 (m, 2H), 7.37 (m, 1H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.00 (m, 1H), 2.91 (d, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.92 (m, 2H), 1.75 (m, 2H), 1.67 (m, 2H), 1.56 (m, 1H), 1.29-1.21 (m, 8H), 1.06 (m, 2H).
    • EXAMPLE 453 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(benzylsulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(benzylthio)benzoic acid for o-toluic acid in Example 369. [1535]
  • MS(ESI) m/e 448 (M+H)[1536] +;
  • [1537] 1H NMR (500 MHz, CD3OD) δ 7.77 (m, 2H), 7.39 (m, 4H), 7.28 (t, 2H), 7.22 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 4.27 (s, 0.7H), 4.26 (s, 0.3H), 3.77 (m, 1H), 3.00 (m, 1H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.23 (m, 6H).
    • EXAMPLE 454 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((2-phenylethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(2-phenylethylthio)benzoic acid for o-toluic acid in Example 369. [1538]
  • MS(ESI) m/e 462 (M+H)[1539] +;
  • [1540] 1H NMR (500 MHz, CD3OD) δ 7.82 (m, 2H), 7.41 (m, 2H), 7.28 (m, 2H), 7.21 (m, 3H), 7.27 (t, 2H), 7.23-7.17 (m, 3H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.28 (m, 2H), 3.00 (m, 1H), 2.96 (t, 2H), 2.72 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.24 (m, 6H).
    • EXAMPLE 456 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((3-phenylpropvl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(3-phenylpropylthio)benzoic acid for o-toluic acid in Example 369. [1541]
  • MS(ESI) m/e 476 (M+H)[1542] +;
  • [1543] 1H NMR (500 MHz, CD3OD) δ 7.78 (m, 2H), 7.33 (m, 2H), 7.27 (m, 2H), 7.18 (m, 3H), 4.48 (d, 0.3H), 4.44 (d, 0.7H), 3.77 (m, 1H), 3.01 (m, 3H), 2.77 (t, 2H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 3H), 1.29-1.24 (m, 6H).
    • EXAMPLE 457 N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(((1,1′-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide
  • The desired compound was prepared by substituting 4-(biphenylmethylthio)benzoic acid for o-toluic acid in Example 369. [1544]
  • MS(ESI) m/e 524 (M+H)[1545] +;
  • [1546] 1H NMR (500 MHz, CD3OD) δ 7.78 (m, 2H), 7.58 (d, 2H), 7.55 (d, 2H), 7.43 (m, 6H), 7.31 (m, 1H), 4.48 (d, 0.3H), 4.43 (d, 0.7H), 4.32 (s, 1.4H), 4.31 (s, 0.6H), 3.76 (m, 1H), 3.00 (m, 1H), 2.71 (t, 2H), 2.15 (m, 1H), 1.98 (m, 1H), 1.29-1.25 (m, 6H).
    • EXAMPLE 458 (2S ,3R)-3-arnino-N′-(3-chlorobenzoyl)-2-hydroxy-5-phenylpentanohydrazide Example 458A 4-phenylbutanal
  • A solution of 4-phenylbutyric acid (1.64 g, 10.0 mmol), N,O-dimethyl hydroxylamine hydrochloride (1.58 g, 16 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.06 g, 10.7 mmol), 1-hydroxybenzotriazole (1.56 g, 11.6 mmol), and N-methylmorpholine (2.8 mL, 26 mmol) in dichloromethane (40 mL) at room temperature was stirred for 16 hours, diluted with dichloromethane, washed sequentially with aqueous NaHCO[1547] 3, brine, 10% KHSO4, and brine, dried (MgSO4), filtered, and concentrated. The concentrate and lithium aluminum hydride (9.0 mmol, 1 equivalent) in diethyl ether (49 mL) at room temperature was stirred 90 minutes, treated with IM NaHSO4, diluted with ether, washed sequentially with 10% KHSO4, and brine, dried (MgSO4), filtered then concentrated to provide the desired product.
  • MS(ESI) m/e 148 (M+H)[1548] +.
    • EXAMPLE 458B (2S,3R)-3-(tert-butoxycarbonyl)amino-2-hydroxy-6-phenylhexanoic acid
  • The desired product was prepared by substituting Example 458A for 2-ethylhexanal in Examples 236A-236C. [1549]
  • MS(ESI) m/e 324 (M+H)[1550] +.
    • EXAMPLE 458C (2S ,3R)-3-amino-N′-(3-chlorobenzoyl)-2-hydroxy-5-phenylpentanohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 458B for Example 98A in Example 98B. [1551]
  • MS(ESI) m/e 376 (M+H)[1552] +;
  • [1553] 1H NMR (300 MHz, DMSO-d6) δ 10.69 (br s, 1H), 10.30 (br s, 1H), 8.24 (br s, 2H), 7.92 (m, 1H), 7.86 (d, 1H), 7.69 (d, 1H), 7.57 (t, IH), 7.24 (m, 5H), 6.62 (m, 1H), 4.21 (m, 1H), 2.60 (m, 2H) 1.90-1.55 (m, 4H).
    • EXAMPLE 459 (2S,3R)-3-amino-N′-(3-chlorobenzoyl)-2-hydroxy-5-(1H-indol-3-yl)pentanohydrazide EXAMPLE 459A 3-(3-indolyl)propanal
  • The desired product was prepared by substituting 3-indolylpropionic acid for 4-phenylbutyric acid in Example 458A. [1554]
  • MS(ESI) m/e 174 (M+H)[1555] +.
    • EXAMPLE 459B (2S,3R)-3-(tert-butoxycarbonvl)amino-2-hydroxy-5-(3-indolyl)pentanoic acid The desired product was prepared by substituting Example 459A for 2-ethylhexanal in Examples 236A-236C.
  • MS(ESI) m/e 349 (M+H)+. [1556]
    • EXAMPLE 459C (2S ,3R)-3-amino-N′-(3-chlorobenzoyl)-2-hydroxy-5-(lH-indol-3-yl)pentanohydrazide
  • The desired product was prepared by substituting 3-chlorobenzoylhydrazine for O-phenyl hydroxylamine hydrochloride and Example 459B for Example 98A in Example 98B. [1557]
  • MS(ESI) m/e 400 (M+H)[1558] +;
  • [1559] 1H NMR (300 MHz, DMSO-d6) δ 10.69 (br s, 1H), 10.33 (br s, 1H), 7.98 (br s, 2H), 7.90 (m. 1H), 7.85 (d, 1H), 7.68 (d, 1H), 7.56 (t, 1H), 7.34 (m, 2H), 7.17 (m, 1H), 7.08 (m, 1H), 6.98 (m, 1H), 6.67 (m, 1H), 4.23 (m, 1H), 2.80 (m, 2H), 2.27 (m, 1H), 1.91 (m, 1H).
    • EXAMPLE 460 (2RS,3R)-3-amino-N′-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide Example 460A methyl 3-(prop-2-enyloxy)benzoate
  • Methyl-3-hydroxy-benzoate (1.09 g, 4.9 mmol), allyl bromide (0.73 g, 6.0 mmol) and potassium tert-butoxide (6.5 g, 5.8 mmol) in DMSO (15 mL) was stirred at room temperature for 16 hours. The mixture was poured into ice water, extracted with ether, washed with brine, dried (Na[1560] 2SO4), and evaporated to give the title compound.
  • [1561] 1H NMR (300 MHz, DMSO-d6) δ 7.55 (m, 1H), 7.45 (m, 2H), 7.24 (m, 1H), 6.12-5.98 (m, 1H), 5.44-5.26 (m, 2H), 4.64 (m, 2H), 3.84 (s, 3H).
    • EXAMPLE 460B methyl 3-(2,3-dihydoxypropyloxy)benzoate
  • A solution of Example 460A (0.3 g, 1.5 mmol), 4-methylmorpholine N-oxide (0.55 g, 4.5 mmol) and osmium tetroxide (4 wt % solution in water 0.1 mL, 0.015 mmol) in 9:1/acetone:water was stirred at room temperature for 48h. The reaction was quenched with 10% Na[1562] 2S203 and stirred for 15 minutes, extracted with ethyl acetate, washed with brine, dried (Na2SO4), and concentrated to give the title compound.
  • MS(ESI) m/e 249 (M+Na)[1563] +.
  • [1564] 1H NMR (300 MHz, DMSO-d6) δ 7.54 (m, 1H), 7.44 (m, 2H), 7.23 (m, 1H), 4.98 (d, 1H), 4.68 (t, 1H), 4.05 (dd, 1H), 3.51 (dd, 1H), 3.85 (s, 3H), 3.8 (m, 1H), 3.55 & 3.45 (t, 2H).
    • EXAMPLE 460C Methyl 3-(2,3-di(tertbutyldimethylsilyloxy)propoxv)benzoate
  • A solution of Example 460B (0.26 g, 1.15 mmol), tert-butyldimethylsilyl chloride (0.44 g, 2.87 mmol) and imidazole (0.31 g, 4.6 mmol) in DMF (10 mL) was stirred at room temperature for 18 hours. The mixture was diluted with ether, washed with brine, dried (Na[1565] 2SO4), and concentrated to give the title compound.
  • MS(ESI) m/e 455 (M+H)+. [1566]
  • [1567] 1H NMR (300 MHz, DMSO-d6) δ 7.58 (m, 1H), 7.47 (m, 2H), 7.26 (m, 1H), 4.09 (dd, 1H), 3.98 (dd, 1H), 3.89 (s, 3H), 3.85 (m, 1H), 3.67 (d, 2H), 0.91 (s, 9H), 0.89 (s, 9H), 0.08 (s, 6H), 0.05 (s, 6H).
    • EXAMPLE 460D (2RS 3R)-3-amino-N′-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide
  • Example 460C was treated with hydrazine hydrate in ethanol at reflux for 48h. After evaporation of the reaction mixture to dryness, the resulting hydrazide was reacted with Example 123B as in Example 98B. [1568]
  • MS(ESI) m/e 414 (M−H)[1569] +.
  • [1570] 1H NMR (300 MHz, DMSO-d6) δ 10.57 & 10.38 (s, 1H), 10.23 & 10.12 (s, 1H), 8.05 & 7.97 (br s, 2H), 7.48-7.38(m, 3H), 7.16 (m, 1H), 6.65 & 6.56 (d, 1H), 4.98 & 4.7 (br s, 1H), 4.39 & 4.25 (t, 1H), 4.05 (dd, 1H), 3.92 (m, 1H), 3.81 (m, 1H), 3.46 (d, 2H), 3.02-2.92(m, 1H), 2.75-2.55 (m, 2H), 2.05-1.75 (m, 2H), 1.2 (m,6H).
  • It will be evident to one skilled in the art that the present invention is not limited to the forgoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, and all changes which come within the meaning and range of equivalency of the claims and therefore intended to be embraced therein. [1571]

Claims (40)

What is claimed is:
1. A compound of formula (I),
Figure US20020002152A1-20020103-C00008
or a therapeutically acceptable salt or prodrug thereof, wherein
R1 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, and R5S-(alkylene)-;
wherein each group is drawn with its right-hand end being the end that is attached to the parent molecular moiety;
R3 is selected from the group consisting of hydrogen, alkyl, and arylalkyl;
R4 is selected from the group consisting of —NR6R7, and —OR wherein each group is drawn with its left-hand end being the end that is attached to the parent molecular moiety;
R5 is selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;
R6 and R7 are independently selected from the group consisting of hydrogen, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl, aryl, arylalkanoyl, arylalkoxyalkyl, arylalkoxycarbonyl, arylalkyl, aryloxyalkyl, (aryl)oyl, arylsulfonyl, carboxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (cycloalkyl)alkanoyl, (cycloalkyl)oyl, haloalkanoyl, haloalkyl, heterocycle, (heterocycle)alkanoyl, (heterocycle)oyl, hydroxyalkyl, a nitrogen protecting group, and —C(O)NR9R10; or
R6 and R7 together are arylalkylidene; or
R6 and R7, together with the nitrogen atom to which they are attached, form a heterocycle;
R8 is selected from the group consisting of hydrogen, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, arylalkoxycarbonylalkyl, (aryl)oylalkyl, carboxyalkyl, and (cycloalkyl)alkyl; and
R9 and R10 are independently selected from the group consisting of hydrogen, alkyl and aryl.
2. A compound according to claim 1, wherein R1 is selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, arylalkyl, and (heterocycle)alkyl.
3. A compound according to claim 2, wherein R4 is —OR8.
4. A compound according to claim 3 selected from the group consisting of
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-phenoxybutanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-N-(methoxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-N-(tert-butoxy)-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-N-ethoxy-2-hydroxybutanamide;
(2RS,3R)-N-(allyloxy)-3-amino-4-cyclohexyl-2-hydroxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-isobutoxybutanamide;
(2RS,3R)-3-amino-4-cyclohexyl-N,2-dihydroxybutanamide;
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N-phenoxypropanamide;
(2RS,3R)-3-amino-5-phenyl-2-hydroxy-N-phenoxypentanamide;
(2RS,3R)-3-amino-3-cyclooctyl-2-hydroxy-N-phenoxypropanamide,
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N-phenoxypentanamide;
ethyl ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate;
benzyl ((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetate;
((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetic acid;
ethyl (2S)-2-((((((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)amino)oxy)acetyl)amino)propanoate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(2-oxo-2-((2-phenylethyl)amino)ethoxy)butanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-3-cyclohexyl-2-hydroxypropanamide; and
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-phenylpentanamide.
5. A compound according to claim 2 wherein R4 is —NR6 R7.
6. A compound according to claim 5 wherein one of R6 and R7 is hydrogen and the other is (aryl)oyl.
7. A compound according to claim 6 selected from the group consisting of
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-ethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dihydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-nitrobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-naphthohydrazide;
N′-((2 RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-chlorobenzohydrazide;
(2RS,3R)-3-amino-N′-benzoyl-4-cyclohexyl-2-hydroxybutanohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-tert-butylbenzohydrazide;
N′ ((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-3-cyclooctyl-2-hydroxypropanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(1-naphthyl)pentanohydrazide;
N′-((2RS,3R)-3-amino-3-cyclohexyl-2-hydroxypropanoyl)-2-naphthohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-naphthohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxy-2-naphthohydrazide;
N′-((2S,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-1-naphthohydrazide;
N′-((2S,3R)-3-amino-2-hydroxy-5-phenylpentanoyl)-3-hydroxy-2-naphthohydrazide;
N′-((2S,3R,4RS)-3-amino-4-ethyl-2-hydroxyoctanoyl)-3-chlorobenzohydrazide;
N′-((2S ,3R)-3-amino-5-cyclohexyl-2-hydroxypentanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-methylbenzohydrazide;
2-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide;
4-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide;
3-amino-N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-eyanobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-cyanobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(dimethylamino)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(dimethylamino)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(trifluoromethyl)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-(trifluoromethyl)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-(trifluoromethoxy)benzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-4-phenoxybenzohydrazide;
N′-((2RS,3R)-3-arnino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,5-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3 ,4-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,4,5-trimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4-dichlorobenzohydrazide;
N′-((2RS,3R)-3-arnino-4-cyclohexyl-2-hydroxybutanoyl)-3 ,4-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3,5-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,3-dimethylbenzohydrazide;
(2S,3R)-3-amino-N′-(3-chlorobenzoyl)-2-hydroxy-5-phenylpentanohydrazide; and
(2S,3R)-3-amino-N′-(3-chlorobenzoyl)-2-hydroxy-5-(1H-indol-3-yl)pentanohydrazide.
8. A compound according to claim 5 wherein one of R6and R7 is selected from the group consisting of hydrogen, alkyl, and aryl; and the other is selected from the group consisting of hydrogen, aryl, and arylalkyl.
9. A compound according to claim 8 selected from the group consisting of
(2RS,3R)-3-amino-N′-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-benzyl-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-phenylethyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-methyl-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-methoxyphenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(1-naphthyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2,4-difluorophenyl)-2-hydroxybutanohydrazide;
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)benzenesulfonamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-N′-(4-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-(2-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-(trifluoromethyl)phenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-iodophenyl)butanohydrazide;
(2RS,3R)-3-amino-N′-(3-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-methoxyphenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(3,5-dichlorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-(3-bromophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3,-methoxyphenyl)butanohydrazide;
(2RS,3R)-3-amino-N′-(3-chloro-4-methylphenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-(trifluoromethoxy)phenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(4-fluorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-(4-chlorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2-ethylphenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(3-fluorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-arnino-N′-(4-chloro-2-methylphenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-mesitylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-((E)-2-(2-pyridinyl)ethenyl)phenyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2-fuorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-(trifluoromethyl)phenyl)butanohydrazide;
(2RS,3R)-3-amino-N′-(2-chloro-6-fluorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2,5-difluorophenyl)-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-(3-chloro-4-fluorophenyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-N′-(2-chlorobenzyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(3-phenylpropyl)butanohydrazide;
(2RS,3R)-3-amino4-cyclohexyl-2-hydroxy-N′-isobutyl-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′- entyl-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((2RS)-2-methylbutyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-isopentyl-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-hexyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((2RS)-2-methylpentyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-3-methylpentyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(3 ,3-dimethylbutyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2-ethylbutyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-dodecyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-((3RS)-3,5,5-trimethylhexyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-octyl-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-propylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-heptyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-ethyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-(4-methylphenyl)ethyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-((2RS)-2-ethylhexyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-N′-((2RS)-2-(4-chlorophenyl)-2-cyanoethyl)-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-((2RS)-2-phenylpropyl)butanohydrazide;
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)propanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(4-methylphenyl)pentanohydrazide;
(2S,3R)-3-amino-3-cyclooctyl-2-hydroxy-N′-(4-methylphenyl)propanohydrazide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N′-(4-methylphenyl)butanohydrazide;
(2RS,3R)-3-amino-3-cyclohexyl-2-hydroxy-N′-(1-naphthyl)propanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-phenyl-N′-(1-naphthyl)pentanohydrazide;
(2RS,3R)-3-amino-3-cyclooctyl-2-hydroxy-N′-(1-naphthyl)propanohydrazide;
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N′-(4-methylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-cyclohexyl-2-hydroxy-N′-(1-naphthyl)pentanohydrazide; and (2S,3R)-3-amino-4-cyclohexyl-2-hydroxybutanohydrazide.
10. A compound according to claim 5 wherein one of R6 and R7 is selected from the group consisting of hydrogen, alkyl, and aryl; and the other is selected from the group consisting of alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylsulfanylalkyl, aryloxyalkyl, arylalkoxycarbonyl, arylsulfonyl, carboxyalkyl, —C(O)R9R10, cycloalkyl, (cycloalkyl)alkyl, haloalkanoyl, haloalkyl, heterocycle, (heterocycle)oyl, and hydroxyalkyl.
11. A compound according to claim 10 selected from the group consisting of
(2RS,3R)-3-amino-N′-(7-chloro-4-quinolinyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-iodophenyl)hydrazinecarboxamide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-2,4,6-trimethylbenzenesulfonohydrazide;
ethyl (2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)acetate trifluoroacetate;
benzyl 2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazinecarboxylate;
ethyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-3-oxopropanoate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2,2,2-trifluoroethyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-methyl-N′-(3-nitro-2-pyridinyl)butanohydrazide;
(2RS,3R)-3-amino-N′,4-dicyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-pyridinyl)butanohydrazide;
(2RS,3R)-3-amino-N′-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxy-N′-methylbutanohydrazide;
(2RS,3R)-3-amino-N′-(5-chloro-1-methyl-6-oxo-1 ,6-dihydro-4-pyridazinyl)-4-cyclohexyl-2-hydroxy-N′-methylbutanohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1 ,3-benzodioxole-5-carbohydrazide;
methyl 2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((2RS)-2-hydroxy-3-(3-(trifluoromethyl)phenoxy)propyl)-N′-methylbutanohydrazide;
methyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-2-thiophenecarboxylate;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-pyridinylcarbonyl)butanohydrazide;
ethyl 3-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate;
(2RS,3R)-3-amino-N′-(1 ,3-benzothiazol-2-yl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(trifluoroacetyl)butanohydrazide;
N′-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-3-chloro-1-benzothiophene-2-carbohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-quinoxalinyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-methyl-N′-(5-(trifluoromethyl)-2-pyridinyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(1 ,3-dimethyl-4-nitro-1H-pyrazol-5-yl)-2-hydroxybutanohydrazide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-phenylhydrazinecarboxamide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(4-chloro-2-methoxyphenyl)hydrazinecarboxamide;
2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-N-(3-fluorophenyl)hydrazinecarboxamide;
N-((1R)-1-((2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)carbonyl)-3-(methylsulfanyl)propyl)-4-(trifluoromethyl)benzamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(2-thienylcarbonyl)butanohydrazide;
4-chlorobenzyl 2-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)hydrazino)-4-(trifluoromethyl)-5-pyrimidinecarboxylate;
(2RS,3R)-3-amino-N′-(6-chloro-3-pyridazinyl)-4-cyclohexyl-2-hydroxybutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-3-(methylsulfanyl)butyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclopropylmethyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-N′-(2-(benzyloxy)ethyl)-4-cyclohexy1-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(2,2,5-trichloropentyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(3-(methylsulfanyl)propyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclopentylmethyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(5-hydroxypentyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-((2R)-2,3-dihydroxypropyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2,2-dichlorohexyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-7-methoxy-3,7-dimethyloctyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclooctylmethyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-((11Z)-11-hexadecenyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N phenyl-N′-tridecylbutanohydrazide;
4-(2-((2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoyl)-1-phenylhydrazino)butanoic acid;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((6Z)-6-nonenyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-((4Z)-4-decenyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-(4-pentenyl)-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-((3RS)-3,7-dimethyl-6-octenyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-phenyl-N′-(4,4,4-trifluorobutyl)butanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N′-((3RS)-3-hydroxybutyl)-N′-95 phenylbutanohydrazide;
(2RS,3R)-3-amino4-cyclohexyl-N′-(2-(((3RS)-3 ,7-dimethyl-6-octenyl)oxy)ethyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-4-cyclohexyl-N′-(2-((1RS)-3,3-dimethylcyclohexyl)ethyl)-2-hydroxy-N′-phenylbutanohydrazide;
(2RS,3R)-3-amino-N′-((4S)-6-bromo-4-methylhexyl)-4-cyclohexyl-2-hydroxy-N′-phenylbutanohydrazide; and
(2RS,3R)-3-amino-4-cyclohexyl-N′-(cyclohexylmethyl)-2-hydroxy-N′-phenylbutanohydrazide.
12. A compound according to claim 5 wherein R6and R7together are arylalkylidene.
13. A compound according to claim 12 which is
(2RS,3R)-3-amino-N′-((E)-(4-chlorophenyl)methylidene)-4-cyclohexyl-2-hydroxybutanohydrazide.
14. A compound according to claim 5 wherein R6 and R7, together with the nitrogen atom to which they are attached, form a heterocycle.
15. A compound according to claim 14 selected from the group consisting of
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2S)-2-(methoxymethyl)pyrrolidinyl)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-pyrrolidinyl)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)butanamide;
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(1-piperidinyl)butanamide; and
(2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-((2R)-2-(methoxymethyl)pyrrolidinyl)butanamide.
16. A compound according to claim 1 wherein R1 is R5S-(alkylene)-.
17. A compound according to claim 16 wherein R4 is —OR8.
18. A compound according to claim 17 selected from the group consisting of
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-phenoxypentamide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N-phenoxybutanamide;
(2RS,3S)-3-amino-2-hydroxy-N-phenoxy-4-(propylsulfanyl)butanamide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-phenoxypentanamide;
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-phenoxybutanamide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N-phenoxybutanamide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-benzyloxypentanamide;
(2RS,3R)-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)pentanamide;
(2RS,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide;
(2S,3S)-3-amino-N-(cyclohexylmethoxy)-2-hydroxy-4-(isobutylsulfanyl)butanamide;
(2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N-(mesitylmethoxy)butanamide;
(2RS,3R)-3-amino-2-hydroxy-5-(ethylsulfanyl)-N-((1RS)-1-phenylethoxy)pentanamide;
(2S,3S)-3-amino-N-(benzyloxy)-2-hydroxy-4-(isobutylsulfanyl)-N-methylbutanamide;
(2RS,3S )-3-amino-N-(benzyloxy)-2-hydroxy-5-(isopropylsulfanyl)-N-methylpentanamide; and
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N-((1RS)-1-phenylethoxy)pentanamide.
19. A compound according to claim 18 wherein R4 is —NR6R7.
20. A compound according to claim 19 wherein one of R6 and R7 is hydrogen and the other is (aryl)oyl.
21. A compound according to claim 20 wherein the aryl(oyl) is unsubstituted.
22. A compound according to claim 21 selected from the group consisting of
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-naphthohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-isopropylsulfanylpentanoyl)-2-naphthohydrazide;
N′-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-2-naphthohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthohydrazide; and
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1-naphthohydrazide.
23. A compound according to claim 20 wherein the aryl(oyl) is substituted with one substituent.
24. A compound according to claim 23 wherein the substituent is at the 2-position.
25. A compound according to claim 24 selected from the group consisting of
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-hydroxy-2-naphthohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-aminobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-ethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-benzylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-anilinobenzohydrazide; and
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(2-phenylethyl)benzohydrazide.
26. A compound according to claim 23 wherein the substituent is at the 3-position.
27. A compound according to claim 23 selected from the group consisting of
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-chlorobenzohydrazide;
N′-((2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)-3-chlorobenzohydrazide;
N′-((2S,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl-3-chlorobenzohydrazide;
N′-((2R,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzohydrazide;
N′-((2R,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzohydrazide;
3-(2-aminoethyl)-N′-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)benzohydrazide;
N′-((2S,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)butanoyl)-3-propoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-trifluoromethylsulfanylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-aminobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(dimethylamino)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromethyl)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-(trifluoromethoxy)benzohydrazide;
(2RS,3R)-3-amino-N′-(3-(2-aminoethoxy)phenyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-cyanobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(methylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(ethylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(propylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(butylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(hexylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isopropylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(isobutylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentnoyl)-3-((4-methylpentyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(sec-butylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(neopentylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(cyclohexylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((cyclohexylmethyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(benzylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((2-phenylethyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-((3-phenylpropyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-(((1,1 ′-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide; and
(2RS,3R)-3-amino-N′-(3-(2,3-dihydroxypropoxy)benzoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide.
28. A compound according to claim 23 wherein the substituent is at the 4-position.
29. A compound according to claim 28 selected from the group consisting of
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-aminobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-,hydroxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-bromobenzohydrazide;N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-propoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(methylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-isopropoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(diethylamino)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-butoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-chlorobenzohydrazide;
N′-((2RS,3R)-3-amno-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(dimethylamino)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(trifluoromethyl)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-phenoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-(phenoxymethyl)benzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-cyanobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-methylbenzohydrazide;
N′-((2RS,3R)-3-aniino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-fluorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-chlorobenzohydrazide;
N′-((2RS,3R)-3-aniino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-bromobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-ethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-tert-butylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-propoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-isopropoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(methylsulfonyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(methylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(ethylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(propylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(butylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(hexylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isopropylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(isobutylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((4-methylpentyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(sec-butylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(neopentylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(cyclohexylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((cyclohexylmethyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(benzylsulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((2-phenylethyl)sulfanyl)benzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-((3-phenylpropyl)sulfanyl)benzohydrazide; and
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-(((1,1 ′-biphenyl)-4-ylmethyl)sulfanyl)benzohydrazide.
30. A compound according to claim 20 wherein the aryl(oyl) is substituted with two or three substituents.
31. A compound according to claim 30 selected from the group consisting of
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-diethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4,5-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3 ,5-dimethylbenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-arnino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,4,5-trimethoxybenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,3-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,4-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2,5-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3 ,4-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3,5-dichlorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-dichlorobenzohydrazide;N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-fluoro-2-methylbenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,3-difluorobenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-chloro-2-methoxybenzohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-chloro-5-(methylsulfanyl)benzohydrazide; and
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3,4-diethoxybenzohydrazide.
32. A compound according to claim 19 wherein one of R6 and R7 is hydrogen; and the other is selected from the group consisting of aryl, arylalkanoyl, arylalkoxycarbonyl, and arylsulfonyl.
33. A compound according to claim 32 selected from the group consisting of
benzyl 2-((2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxybutanoyl)hydrazinecarboxylate;
benzyl 2-((2RS,3S)-3-amino-2-hydroxy-4-(propylsulfanyl)butanoyl)hydrazinecarboxylate;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-methylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-methoxyphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(1-naphthyl)pentanohydrazide;
(2RS,3R)-3-arino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-iodophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-chloropheiyl)pentanohydrazide;
(2R S ,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-methoxyphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(2-chlorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-trifluoromethylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-isopropyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-chloro-4-methylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-fluorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(2-ethylphenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-fluorophenyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(4-trifluoromethoxyphenyl)pentanohydrazide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N′-(4-methylphenyl)butanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-N′-(4-methylphenyl)-4-(propylsulfanyl)butanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(4-methylphenyl)pentanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N′-(4-methylphenyl)butanohydrazide;
(2RS,3S)-3-amino-4-(ethylsulfanyl)-2-hydroxy-N′-(1-naphthyl)butanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(1-naphthyl)pentanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-4-(isobutylsulfanyl)-N′-(1-naphthyl)butanohydrazide;
(2RS,3S)-3-amino-2-hydroxy-N′-(1-naphthyl)-4-(propylsulfanyl)butanohydrazide;
(2RS,3S)-3-amino-4-((cyclohexylmethyl)sulfanyl)-2-hydroxy-N′-(1-naphthyl)butanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(phenylacetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((2-methoxyphenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((3-methoxyphenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((4-methoxyphenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((2-chlorophenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((3-chlorophenyl)acetyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-((4-chlorophenyl)acetyl)pentanohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1,1 ′-biphenyl)-4-ylacetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-dimethylaminophenyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(1-naphthyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-naphthyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)benzenesulfonohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-chlorobenzenesulfonohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1-naphthalenesulfonohydrazide; and
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-methylbenzenesulfonohydrazide.
34. A compound according to claim 19 wherein one of R6 and R7 is hydrogen; and the other is selected from the group consisting of alkanoyl, cycloalkyl, cycloalkylalkanoyl, (cycloalkyl)oyl, (heterocycle)alkanoyl, and (heterocycle)oyl.
35. A compound according to claim 34 selected from the group consisting of
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-cyclopentylpentanohydrazide;
(2RS,3R)-N′-acetyl-3-amino-5-(ethylsulfanyl)-2-hydroxypentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-isobutyrylpentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(3-methylbutanoyl)pentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-N′-heptanoyl-2-hydroxypentanohydrazide;
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N′-(tetrahydro-2-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-N′-(cyclohexylacetyl)-5-(ethylsulfanyl)-2-hydroxyheptanohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-furohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-furohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3H-pyrrole-2-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-2-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-4-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-thiazole-5-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-5-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1H-pyrazole-4-carbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-5-isoxazolecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyridinecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(2-pyridinyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyridinecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(3-pyridinyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pyridinecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-(4-pyridinyl)acetohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-3-pyridazinecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-4-pyrimidinecarbohydrazide;
N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-2-pyrazinecarbohydrazide;
(2RS,3R)-3-amino-N′-((2RS,3S)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-hydroxy-5-(isopropylsulfanyl)pentanohydrazide;N′-((2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoyl)-1,3-benzodioxole-5-carbohydrazide;(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(tetrahydro-2-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-(tetrahydro-3-furanylcarbonyl)pentanohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-cyclopentylpentanohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclopentylacetohydrazide;
(2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)-N′-cyclohexylpentanohydrazide;
N′-((2RS,3R)-3-arnino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-cyclohexylacetohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-furohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-furohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2,5-dimethyl-3-furohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-methyl-2-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-5-methyl-2-thiophenecarbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1H-pyrrole-2-carbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1-methyl-1H-pyrrole-2-carbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1 ,3-thiazole-2-carbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-1,3-thiazole-4-carbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-isopropylpentanoyl)-2-pyridinecarbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-6-chloro-2H-chromene-3-carbohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(4-morpholinyl)acetohydrazide;
N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-2-(4-methyl-1-piperazinyl)acetohydrazide; and
1-acetyl-N′-((2RS,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-4-piperidinecarbohydrazide.
36. A compound according to claim 19 wherein R6 and R7, together with the nitrogen atom to which they are attached, form a heterocycle.
37. A compound according to claim 36 which is
(2RS,3R)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-(1-piperidinyl)pentanamide.
38. A pharmaceutical composition comprising a compound of claim 1 or a therapeutically acceptable salt or prodrug thereof, in combination with a therapeutically acceptable carrier.
39. A method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of claim 1.
40. A compound which is
N′-((2S ,3R)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-3-chlorobenzoyl hydrazide.
US09/833,917 2000-04-14 2001-04-12 Hydrazide and alkoxyamide angiogenesis inhibitors Abandoned US20020002152A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/833,917 US20020002152A1 (en) 2000-04-14 2001-04-12 Hydrazide and alkoxyamide angiogenesis inhibitors
US10/782,502 US6887863B2 (en) 2000-04-14 2004-02-19 Hydrazide and alkoxyamide angiogenesis inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19726200P 2000-04-14 2000-04-14
US09/833,917 US20020002152A1 (en) 2000-04-14 2001-04-12 Hydrazide and alkoxyamide angiogenesis inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/782,502 Continuation US6887863B2 (en) 2000-04-14 2004-02-19 Hydrazide and alkoxyamide angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
US20020002152A1 true US20020002152A1 (en) 2002-01-03

Family

ID=26892708

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/833,917 Abandoned US20020002152A1 (en) 2000-04-14 2001-04-12 Hydrazide and alkoxyamide angiogenesis inhibitors
US10/782,502 Expired - Fee Related US6887863B2 (en) 2000-04-14 2004-02-19 Hydrazide and alkoxyamide angiogenesis inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/782,502 Expired - Fee Related US6887863B2 (en) 2000-04-14 2004-02-19 Hydrazide and alkoxyamide angiogenesis inhibitors

Country Status (1)

Country Link
US (2) US20020002152A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122098A1 (en) * 2002-08-06 2004-06-24 Bamaung Nwe Y. 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20090204077A1 (en) * 2008-02-13 2009-08-13 Hasted Soren B Moulded Connection Between Cannula and Delivery Part
US20090252676A1 (en) * 2008-01-08 2009-10-08 Lantheus Medical Imaging, Inc N-alkoxyamide conjugates as imaging agents
US20090284890A1 (en) * 2008-05-16 2009-11-19 Thiel Leroy D Mechanism and Method for Permanent Magnet Degaussing
WO2011005322A3 (en) * 2009-07-08 2011-04-21 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
WO2012087800A2 (en) 2010-12-20 2012-06-28 Apple Inc. Enhancing keycap legend visibility with optical components
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
EP2886534A1 (en) * 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US9067905B2 (en) 2009-10-09 2015-06-30 Zafgen, Inc. Sulphone compounds and methods of making and using same
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
US9266896B2 (en) 2010-07-22 2016-02-23 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
CN106278991A (en) * 2016-08-03 2017-01-04 沅江华龙催化科技有限公司 A kind of by NHPI and the method preparing PINO derivant in nonmetal catalyzed lower direct coupling containing benzyl compounds
CN106349149A (en) * 2016-08-03 2017-01-25 沅江华龙催化科技有限公司 Method for preparing PINO (phthimide-N-oxyl) derivatives by direct coupling of NHPI (N-hydroxyphthalimide) and ketone compounds
US9561209B2 (en) 2012-11-05 2017-02-07 Zafgen, Inc. Methods of treating liver diseases
US9649293B2 (en) 2010-04-07 2017-05-16 Zafgen, Inc. Methods of treating an overweight subject
US20170157111A1 (en) * 2008-12-10 2017-06-08 The General Hospital Corporation Hif inhibitors and use thereof
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
CN114805120A (en) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 Synthesis process of m-cyanomethyl benzoate

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718675B2 (en) * 2004-01-23 2010-05-18 Speedel Experimenta Ag Diamino alcohols and their use as renin inhibitor
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CN107141410B (en) 2010-05-25 2022-12-09 辛德弗雷克斯公司 Polymer-conjugated MetAP2 inhibitors and methods of treatment for their use
ES2749746T3 (en) 2013-04-10 2020-03-23 Syndevrx Inc Polymer conjugated or modified fumagilol metap2 inhibitors for use in the treatment of obesity
US11129586B1 (en) 2015-08-14 2021-09-28 Volumetrics Medical Systems, LLC Devices, methods, systems, and computer program products for 4-dimensional ultrasound imaging
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2020087077A1 (en) 2018-10-26 2020-04-30 Syndevrx,Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
NZ506184A (en) 1998-02-19 2003-05-30 American Cyanamid Co N-hydroxy-2-(alkyl, aryl, or heteroaryl sulphanyl, sulphinyl or sulphonyl)-3-substituted-alkyl, aryl or heteroarylamides useful as matrix metalloproteinase inhibitors
SK16282000A3 (en) 1998-05-01 2001-05-10 Abbott Laboratories Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
DE19831710A1 (en) 1998-07-15 2000-01-20 Merck Patent Gmbh New diacyl-hydrazine derivatives, are integrin inhibitors useful for treating e.g. thrombosis, cardiac infarction, tumors, osteoporosis, inflammation or infection

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122098A1 (en) * 2002-08-06 2004-06-24 Bamaung Nwe Y. 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US20090252676A1 (en) * 2008-01-08 2009-10-08 Lantheus Medical Imaging, Inc N-alkoxyamide conjugates as imaging agents
US9266846B2 (en) 2008-01-08 2016-02-23 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US9732047B2 (en) 2008-01-08 2017-08-15 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US8852553B2 (en) 2008-01-08 2014-10-07 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US8361438B2 (en) 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20090204077A1 (en) * 2008-02-13 2009-08-13 Hasted Soren B Moulded Connection Between Cannula and Delivery Part
US20090284890A1 (en) * 2008-05-16 2009-11-19 Thiel Leroy D Mechanism and Method for Permanent Magnet Degaussing
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EP2886534A1 (en) * 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US20170157111A1 (en) * 2008-12-10 2017-06-08 The General Hospital Corporation Hif inhibitors and use thereof
US10881656B2 (en) * 2008-12-10 2021-01-05 The General Hospital Corporation HIF inhibitors and use thereof
WO2011005322A3 (en) * 2009-07-08 2011-04-21 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US9393329B2 (en) 2009-07-08 2016-07-19 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US9067905B2 (en) 2009-10-09 2015-06-30 Zafgen, Inc. Sulphone compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
US10406134B2 (en) 2010-04-07 2019-09-10 Zafgen, Inc. Methods of treating an overweight subject
US9649293B2 (en) 2010-04-07 2017-05-16 Zafgen, Inc. Methods of treating an overweight subject
US9839623B2 (en) 2010-07-22 2017-12-12 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9266896B2 (en) 2010-07-22 2016-02-23 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
US20130316994A1 (en) * 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
WO2012087800A2 (en) 2010-12-20 2012-06-28 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9617237B2 (en) 2011-05-06 2017-04-11 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9446016B2 (en) 2011-10-03 2016-09-20 Zafgen, Inc. Methods of treating age related disorders
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US10064839B2 (en) 2012-11-05 2018-09-04 Zafgen, Inc. Methods of treating liver diseases
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US9561209B2 (en) 2012-11-05 2017-02-07 Zafgen, Inc. Methods of treating liver diseases
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106278991A (en) * 2016-08-03 2017-01-04 沅江华龙催化科技有限公司 A kind of by NHPI and the method preparing PINO derivant in nonmetal catalyzed lower direct coupling containing benzyl compounds
CN106349149A (en) * 2016-08-03 2017-01-25 沅江华龙催化科技有限公司 Method for preparing PINO (phthimide-N-oxyl) derivatives by direct coupling of NHPI (N-hydroxyphthalimide) and ketone compounds
CN114805120A (en) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 Synthesis process of m-cyanomethyl benzoate

Also Published As

Publication number Publication date
US6887863B2 (en) 2005-05-03
US20040167126A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
US6887863B2 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
US20020103192A1 (en) Inhibitors of histone deacetylase
ES2201480T3 (en) CERTAIN DERIVATIVES OF AMIDA ACILAMINOACIDO REPLACED WITH UNCLE CYCLES
US6242494B1 (en) Substituted β-amino acid inhibitors of methionine aminopeptidase-2
US7030262B2 (en) 3-Amino-2-hydroxyalkanoic acids and their prodrugs
JP2010513326A (en) Inhibitors of histone deacetylase and prodrugs thereof
WO2004004648A2 (en) Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
JP2012236836A (en) Tricyclic aromatic and bis-phenyl sulfinyl derivative
CA2158352A1 (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
WO2014041424A1 (en) Histone deacetylase inhibitors for enhancing activity of antifungal agents
EP1272456B1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
US5179125A (en) N-substituted mercaptopropanamide derivatives
FR2842523A1 (en) ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1908466B1 (en) Substituted propanamide derivative and pharmaceutical composition containing the same
US5917090A (en) Matrix metalloproteinase inhibitors
SK16282000A3 (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
CA2329704A1 (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
US5840974A (en) Metalloproteinase inhibitors
RU2136657C1 (en) Derivatives of hydroxamic or carboxylic acid and pharmaceutical or veterinary composition on said
US7241921B2 (en) Bacterial enzyme inhibitors
MXPA00010791A (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
CA2494632A1 (en) 3-amino-2-hrydroxyalkanoic acids and their prodrugs
CZ20003967A3 (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
EP1589001A1 (en) Tricyclic aromatic and bis-phenyl sulfinyl derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT LABORATORIES, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CRAIG, RICHARD A.;KAWAI, MAGUMI;LYNCH, LINDA M.;AND OTHERS;REEL/FRAME:011713/0590;SIGNING DATES FROM 20010614 TO 20010625

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION